1
|
Feng X, Wu WYY, Onwuka JU, Haider Z, Alcala K, Smith-Byrne K, Zahed H, Guida F, Wang R, Bassett JK, Stevens V, Wang Y, Weinstein S, Freedman ND, Chen C, Tinker L, Nøst TH, Koh WP, Muller D, Colorado-Yohar SM, Tumino R, Hung RJ, Amos CI, Lin X, Zhang X, Arslan AA, Sánchez MJ, Sørgjerd EP, Severi G, Hveem K, Brennan P, Langhammer A, Milne RL, Yuan JM, Melin B, Johansson M, Robbins HA, Johansson M. Lung cancer risk discrimination of prediagnostic proteomics measurements compared with existing prediction tools. J Natl Cancer Inst 2023; 115:1050-1059. [PMID: 37260165 PMCID: PMC10483263 DOI: 10.1093/jnci/djad071] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/23/2022] [Revised: 04/05/2023] [Accepted: 04/08/2023] [Indexed: 06/02/2023] Open
Abstract
BACKGROUND We sought to develop a proteomics-based risk model for lung cancer and evaluate its risk-discriminatory performance in comparison with a smoking-based risk model (PLCOm2012) and a commercially available autoantibody biomarker test. METHODS We designed a case-control study nested in 6 prospective cohorts, including 624 lung cancer participants who donated blood samples at most 3 years prior to lung cancer diagnosis and 624 smoking-matched cancer free participants who were assayed for 302 proteins. We used 470 case-control pairs from 4 cohorts to select proteins and train a protein-based risk model. We subsequently used 154 case-control pairs from 2 cohorts to compare the risk-discriminatory performance of the protein-based model with that of the Early Cancer Detection Test (EarlyCDT)-Lung and the PLCOm2012 model using receiver operating characteristics analysis and by estimating models' sensitivity. All tests were 2-sided. RESULTS The area under the curve for the protein-based risk model in the validation sample was 0.75 (95% confidence interval [CI] = 0.70 to 0.81) compared with 0.64 (95% CI = 0.57 to 0.70) for the PLCOm2012 model (Pdifference = .001). The EarlyCDT-Lung had a sensitivity of 14% (95% CI = 8.2% to 19%) and a specificity of 86% (95% CI = 81% to 92%) for incident lung cancer. At the same specificity of 86%, the sensitivity for the protein-based risk model was estimated at 49% (95% CI = 41% to 57%) and 30% (95% CI = 23% to 37%) for the PLCOm2012 model. CONCLUSION Circulating proteins showed promise in predicting incident lung cancer and outperformed a standard risk prediction model and the commercialized EarlyCDT-Lung.
Collapse
Affiliation(s)
- Xiaoshuang Feng
- Genomic Epidemiology Branch, International Agency for Research on Cancer, Lyon, France
| | - Wendy Yi-Ying Wu
- Department of Radiation Sciences, Oncology, Umea University, Umea, Sweden
| | | | - Zahra Haider
- Department of Radiation Sciences, Oncology, Umea University, Umea, Sweden
| | - Karine Alcala
- Genomic Epidemiology Branch, International Agency for Research on Cancer, Lyon, France
| | | | - Hana Zahed
- Genomic Epidemiology Branch, International Agency for Research on Cancer, Lyon, France
| | - Florence Guida
- Environment and Lifestyle Epidemiology Branch, International Agency for Research on Cancer, Lyon, France
| | - Renwei Wang
- Division of Cancer Control and Population Sciences, UPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh, PA, USA
| | - Julie K Bassett
- Cancer Epidemiology Division, Cancer Council Victoria, Melbourne, VIC, Australia
| | - Victoria Stevens
- Rollins School of Public Health, Emory University, Atlanta, GA, USA
| | - Ying Wang
- American Cancer Society, Atlanta, GA, USA
| | - Stephanie Weinstein
- Metabolic Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, MD, USA
| | - Neal D Freedman
- Metabolic Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, MD, USA
| | - Chu Chen
- Program in Epidemiology, Division of Public Health Sciences, Fred Hutchinson Cancer Center, Seattle, WA, USA
| | - Lesley Tinker
- Women’s Health Initiative Clinical Coordinating Center, Fred Hutchinson Cancer Research Center, Seattle, WA, USA
| | - Therese Haugdahl Nøst
- Department of Community Medicine, University of Tromsø, The Arctic University of Norway, Tromsø, Norway
| | - Woon-Puay Koh
- Healthy Longevity Translational Research Programme, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore
- Singapore Institute for Clinical Sciences, Agency for Science Technology and Research (A*STAR), Singapore, Singapore
| | - David Muller
- Division of Genetic Medicine, Imperial College London School of Public Health, London, UK
| | - Sandra M Colorado-Yohar
- Department of Epidemiology, Murcia Regional Health Council, IMIB-Arrixaca, Murcia, Spain
- Centro de Investigación Biomédica en Red de Epidemiología y Salud Pública (CIBERESP), Madrid, Spain
- Research Group on Demography and Health, National Faculty of Public Health, University of Antioquia, Medellín, Colombia
| | - Rosario Tumino
- Hyblean Association for Epidemiological Research, AIRE ONLUS Ragusa, Ragusa, Italy
| | - Rayjean J Hung
- Prosserman Centre for Population Health Research, Lunenfeld-Tanenbaum Research Institute, Sinai Health, Toronto, Canada
- Dalla Lana School of Public Health, University of Toronto, Toronto, Canada
| | - Christopher I Amos
- Institute for Clinical and Translational Research, Baylor College of Medicine, Houston, TX, USA
| | - Xihong Lin
- Department of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, MA, USA
- Program in Medical and Population Genetics, Broad Institute of Harvard and MIT, Cambridge, MA, USA
- Department of Statistics, Harvard University, Cambridge, MA, USA
| | - Xuehong Zhang
- Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA
| | - Alan A Arslan
- Department of Population Health, New York University School of Medicine, New York, NY, USA
| | - Maria-Jose Sánchez
- Centro de Investigación Biomédica en Red de Epidemiología y Salud Pública (CIBERESP), Madrid, Spain
- Escuela Andaluza de Salud Pública (EASP), Granada, Spain
- Instituto de Investigación Biosanitaria ib, Granada, Spain
- Department of Preventive Medicine and Public Health, University of Granada, Granada, Spain
| | - Elin Pettersen Sørgjerd
- HUNT Research Centre, Department of Public Health and Nursing, Norwegian University of Science and Technology, Levanger, Norway
| | | | - Kristian Hveem
- HUNT Research Centre, Department of Public Health and Nursing, Norwegian University of Science and Technology, Levanger, Norway
| | - Paul Brennan
- Genomic Epidemiology Branch, International Agency for Research on Cancer, Lyon, France
| | - Arnulf Langhammer
- HUNT Research Centre, Department of Public Health and Nursing, Norwegian University of Science and Technology, Levanger, Norway
- Levanger Hospital, Nord-Trøndelag Hospital Trust, Levanger, Norway
| | - Roger L Milne
- Cancer Epidemiology Division, Cancer Council Victoria, Melbourne, VIC, Australia
- Centre for Epidemiology and Biostatistics, The University of Melbourne, Melbourne, VIC, Australia
- Precision Medicine, School of Clinical Sciences at Monash Health, Monash University, Clayton, VIC, Australia
| | - Jian-Min Yuan
- Division of Cancer Control and Population Sciences, UPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh, PA, USA
- Department of Epidemiology, Graduate School of Public Health, University of Pittsburgh, Pittsburgh, PA, USA
| | - Beatrice Melin
- Department of Radiation Sciences, Oncology, Umea University, Umea, Sweden
| | - Mikael Johansson
- Department of Radiation Sciences, Oncology, Umea University, Umea, Sweden
| | - Hilary A Robbins
- Genomic Epidemiology Branch, International Agency for Research on Cancer, Lyon, France
| | - Mattias Johansson
- Genomic Epidemiology Branch, International Agency for Research on Cancer, Lyon, France
| |
Collapse
|
2
|
Albanes D, Alcala K, Alcala N, Amos CI, Arslan AA, Bassett JK, Brennan P, Cai Q, Chen C, Feng X, Freedman ND, Guida F, Hung RJ, Hveem K, Johansson M, Johansson M, Koh WP, Langhammer A, Milne RL, Muller D, Onwuka J, Sørgjerd EP, Robbins HA, Sesso HD, Severi G, Shu XO, Sieri S, Smith-Byrne K, Stevens V, Tinker L, Tjønneland A, Visvanathan K, Wang Y, Wang R, Weinstein S, Yuan JM, Zahed H, Zhang X, Zheng W. The blood proteome of imminent lung cancer diagnosis. Nat Commun 2023; 14:3042. [PMID: 37264016 PMCID: PMC10235023 DOI: 10.1038/s41467-023-37979-8] [Citation(s) in RCA: 7] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/16/2022] [Accepted: 04/05/2023] [Indexed: 06/03/2023] Open
Abstract
Identification of risk biomarkers may enhance early detection of smoking-related lung cancer. We measured between 392 and 1,162 proteins in blood samples drawn at most three years before diagnosis in 731 smoking-matched case-control sets nested within six prospective cohorts from the US, Europe, Singapore, and Australia. We identify 36 proteins with independently reproducible associations with risk of imminent lung cancer diagnosis (all p < 4 × 10-5). These include a few markers (e.g. CA-125/MUC-16 and CEACAM5/CEA) that have previously been reported in studies using pre-diagnostic blood samples for lung cancer. The 36 proteins include several growth factors (e.g. HGF, IGFBP-1, IGFP-2), tumor necrosis factor-receptors (e.g. TNFRSF6B, TNFRSF13B), and chemokines and cytokines (e.g. CXL17, GDF-15, SCF). The odds ratio per standard deviation range from 1.31 for IGFBP-1 (95% CI: 1.17-1.47) to 2.43 for CEACAM5 (95% CI: 2.04-2.89). We map the 36 proteins to the hallmarks of cancer and find that activation of invasion and metastasis, proliferative signaling, tumor-promoting inflammation, and angiogenesis are most frequently implicated.
Collapse
|
3
|
Feng X, Muller DC, Zahed H, Alcala K, Guida F, Smith-Byrne K, Yuan JM, Koh WP, Wang R, Milne RL, Bassett JK, Langhammer A, Hveem K, Stevens VL, Wang Y, Johansson M, Tjønneland A, Tumino R, Sheikh M, Johansson M, Robbins HA. Evaluation of pre-diagnostic blood protein measurements for predicting survival after lung cancer diagnosis. EBioMedicine 2023; 92:104623. [PMID: 37236058 PMCID: PMC10232655 DOI: 10.1016/j.ebiom.2023.104623] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/21/2022] [Revised: 05/05/2023] [Accepted: 05/07/2023] [Indexed: 05/28/2023] Open
Abstract
BACKGROUND To evaluate whether circulating proteins are associated with survival after lung cancer diagnosis, and whether they can improve prediction of prognosis. METHODS We measured up to 1159 proteins in blood samples from 708 participants in 6 cohorts. Samples were collected within 3 years prior to lung cancer diagnosis. We used Cox proportional hazards models to identify proteins associated with overall mortality after lung cancer diagnosis. To evaluate model performance, we used a round-robin approach in which models were fit in 5 cohorts and evaluated in the 6th cohort. Specifically, we fit a model including 5 proteins and clinical parameters and compared its performance with clinical parameters only. FINDINGS There were 86 proteins nominally associated with mortality (p < 0.05), but only CDCP1 remained statistically significant after accounting for multiple testing (hazard ratio per standard deviation: 1.19, 95% CI: 1.10-1.30, unadjusted p = 0.00004). The external C-index for the protein-based model was 0.63 (95% CI: 0.61-0.66), compared with 0.62 (95% CI: 0.59-0.64) for the model with clinical parameters only. Inclusion of proteins did not provide a statistically significant improvement in discrimination (C-index difference: 0.015, 95% CI: -0.003 to 0.035). INTERPRETATION Blood proteins measured within 3 years prior to lung cancer diagnosis were not strongly associated with lung cancer survival, nor did they importantly improve prediction of prognosis beyond clinical information. FUNDING No explicit funding for this study. Authors and data collection supported by the US National Cancer Institute (U19CA203654), INCA (France, 2019-1-TABAC-01), Cancer Research Foundation of Northern Sweden (AMP19-962), and Swedish Department of Health Ministry.
Collapse
Affiliation(s)
- Xiaoshuang Feng
- Genomic Epidemiology Branch, International Agency for Research on Cancer, Lyon, France.
| | - David C Muller
- Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London, London, United Kingdom; Department of Epidemiology and Biostatistics, School of Public Health, MRC-PHE, Centre for Environment and Health, Imperial College London, London, United Kingdom
| | - Hana Zahed
- Genomic Epidemiology Branch, International Agency for Research on Cancer, Lyon, France
| | - Karine Alcala
- Genomic Epidemiology Branch, International Agency for Research on Cancer, Lyon, France
| | - Florence Guida
- Environment and Lifestyle Epidemiology Branch, International Agency for Research on Cancer, Lyon, France
| | - Karl Smith-Byrne
- Cancer Epidemiology Unit, Oxford Population Health, University of Oxford, Oxford, United Kingdom
| | - Jian-Min Yuan
- UPMC Hillman Cancer Centre, Pittsburgh, PA, USA; Department of Epidemiology, Graduate School of Public Health, University of Pittsburgh, Pittsburgh, PA, USA
| | - Woon-Puay Koh
- Healthy Longevity Translational Research Program, Yong Loo Lin School of Medicine, National University of Singapore, Singapore; Singapore Institute for Clinical Sciences, Agency for Science Technology and Research (A∗STAR), Singapore
| | - Renwei Wang
- UPMC Hillman Cancer Centre, Pittsburgh, PA, USA
| | - Roger L Milne
- Cancer Epidemiology Division, Cancer Council Victoria, Melbourne, Australia; Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, University of Melbourne, Parkville, Australia; School of Clinical Sciences at Monash Health, Monash University, Melbourne, Australia
| | - Julie K Bassett
- Cancer Epidemiology Division, Cancer Council Victoria, Melbourne, Australia
| | - Arnulf Langhammer
- HUNT Research Center, Department of Public Health and Nursing, NTNU Norwegian University of Science and Technology, Levanger, Norway; Levanger Hospital, Nord-Trøndelag Hospital Trust, Levanger, Norway
| | - Kristian Hveem
- HUNT Research Center, Department of Public Health and Nursing, NTNU Norwegian University of Science and Technology, Levanger, Norway; Department of Public Health and Nursing, K.G. Jebsen Centre for Genetic Epidemiology, Norwegian University of Science and Technology, Trondheim, Norway
| | | | - Ying Wang
- American Cancer Society, Atlanta, GA, USA
| | - Mikael Johansson
- Department of Radiation Sciences, Oncology, Umeå University, Umeå, Sweden
| | - Anne Tjønneland
- Danish Cancer Society Research Center, Copenhagen, Denmark; Department of Public Health, University of Copenhagen, Copenhagen, Denmark
| | - Rosario Tumino
- Hyblean Association for Epidemiological Research, AIRE ONLUS Ragusa, Italy
| | - Mahdi Sheikh
- Genomic Epidemiology Branch, International Agency for Research on Cancer, Lyon, France
| | - Mattias Johansson
- Genomic Epidemiology Branch, International Agency for Research on Cancer, Lyon, France
| | - Hilary A Robbins
- Genomic Epidemiology Branch, International Agency for Research on Cancer, Lyon, France.
| |
Collapse
|
4
|
Robbins HA, Alcala K, Moez EK, Guida F, Thomas S, Zahed H, Warkentin MT, Smith-Byrne K, Brhane Y, Muller D, Feng X, Albanes D, Aldrich MC, Arslan AA, Bassett J, Berg CD, Cai Q, Chen C, Davies MPA, Diergaarde B, Field JK, Freedman ND, Huang WY, Johansson M, Jones M, Koh WP, Lam S, Lan Q, Langhammer A, Liao LM, Liu G, Malekzadeh R, Milne RL, Montuenga LM, Rohan T, Sesso HD, Severi G, Sheikh M, Sinha R, Shu XO, Stevens VL, Tammemägi MC, Tinker LF, Visvanathan K, Wang Y, Wang R, Weinstein SJ, White E, Wilson D, Yuan JM, Zhang X, Zheng W, Amos CI, Brennan P, Johansson M, Hung RJ. Design and methodological considerations for biomarker discovery and validation in the Integrative Analysis of Lung Cancer Etiology and Risk (INTEGRAL) Program. Ann Epidemiol 2023; 77:1-12. [PMID: 36404465 PMCID: PMC9835888 DOI: 10.1016/j.annepidem.2022.10.014] [Citation(s) in RCA: 9] [Impact Index Per Article: 9.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/14/2022] [Revised: 10/23/2022] [Accepted: 10/24/2022] [Indexed: 01/21/2023]
Abstract
The Integrative Analysis of Lung Cancer Etiology and Risk (INTEGRAL) program is an NCI-funded initiative with an objective to develop tools to optimize low-dose CT (LDCT) lung cancer screening. Here, we describe the rationale and design for the Risk Biomarker and Nodule Malignancy projects within INTEGRAL. The overarching goal of these projects is to systematically investigate circulating protein markers to include on a panel for use (i) pre-LDCT, to identify people likely to benefit from screening, and (ii) post-LDCT, to differentiate benign versus malignant nodules. To identify informative proteins, the Risk Biomarker project measured 1161 proteins in a nested-case control study within 2 prospective cohorts (n = 252 lung cancer cases and 252 controls) and replicated associations for a subset of proteins in 4 cohorts (n = 479 cases and 479 controls). Eligible participants had a current or former history of smoking and cases were diagnosed up to 3 years following blood draw. The Nodule Malignancy project measured 1078 proteins among participants with a heavy smoking history within four LDCT screening studies (n = 425 cases diagnosed up to 5 years following blood draw, 430 benign-nodule controls, and 398 nodule-free controls). The INTEGRAL panel will enable absolute quantification of 21 proteins. We will evaluate its performance in the Risk Biomarker project using a case-cohort study including 14 cohorts (n = 1696 cases and 2926 subcohort representatives), and in the Nodule Malignancy project within five LDCT screening studies (n = 675 cases, 680 benign-nodule controls, and 648 nodule-free controls). Future progress to advance lung cancer early detection biomarkers will require carefully designed validation, translational, and comparative studies.
Collapse
Affiliation(s)
- Hilary A Robbins
- Genomic Epidemiology Branch, International Agency for Research on Cancer, Lyon, France.
| | - Karine Alcala
- Genomic Epidemiology Branch, International Agency for Research on Cancer, Lyon, France
| | - Elham Khodayari Moez
- Prosserman Centre for Population Health Research, Lunenfeld-Tanenbaum Research Institute, Sinai Health, Toronto, Canada
| | - Florence Guida
- Environment and Lifestyle Epidemiology Branch, International Agency for Research on Cancer, Lyon, France
| | - Sera Thomas
- Prosserman Centre for Population Health Research, Lunenfeld-Tanenbaum Research Institute, Sinai Health, Toronto, Canada
| | - Hana Zahed
- Genomic Epidemiology Branch, International Agency for Research on Cancer, Lyon, France
| | - Matthew T Warkentin
- Prosserman Centre for Population Health Research, Lunenfeld-Tanenbaum Research Institute, Sinai Health, Toronto, Canada; Dalla Lana School of Public Health, University of Toronto, Toronto, Canada
| | | | - Yonathan Brhane
- Prosserman Centre for Population Health Research, Lunenfeld-Tanenbaum Research Institute, Sinai Health, Toronto, Canada
| | - David Muller
- Division of Genetic Medicine, Imperial College London School of Public Health, London, UK
| | - Xiaoshuang Feng
- Genomic Epidemiology Branch, International Agency for Research on Cancer, Lyon, France
| | - Demetrius Albanes
- Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, MD
| | - Melinda C Aldrich
- Department of Medicine, Vanderbilt University Medical Center, Nashville, TN
| | - Alan A Arslan
- Departments of Obstetrics and Gynecology and Population Health, New York University Grossman School of Medicine, New York, NY
| | - Julie Bassett
- Cancer Epidemiology Division, Cancer Council Victoria, Melbourne, Australia
| | | | - Qiuyin Cai
- Division of Epidemiology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN
| | - Chu Chen
- Program in Epidemiology and the Women's Health Initiative Clinical Coordinating Center, Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA
| | - Michael P A Davies
- Molecular & Clinical Cancer Medicine, University of Liverpool, Liverpool, UK
| | - Brenda Diergaarde
- Department of Human Genetics, Graduate School of Public Health, University of Pittsburgh, Pittsburgh, PA; UPMC Hillman Cancer Centre, Pittsburgh, PA
| | - John K Field
- Molecular & Clinical Cancer Medicine, University of Liverpool, Liverpool, UK
| | - Neal D Freedman
- Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, MD
| | - Wen-Yi Huang
- Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, MD
| | - Mikael Johansson
- Department of Radiation Sciences, Oncology, Umea University, Umea, Sweden
| | - Michael Jones
- Division of Genetics and Epidemiology, Institute of Cancer Research, London, UK
| | - Woon-Puay Koh
- Healthy Longevity Translational Research Program, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore; Singapore Institute for Clinical Sciences, Agency for Science Technology and Research (A*STAR), Singapore, Singapore
| | - Stephen Lam
- Integrative Oncology, British Columbia Cancer Agency, Vancouver, Canada
| | - Qing Lan
- Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, MD
| | - Arnulf Langhammer
- HUNT Research Center, Department of Public Health and Nursing, NTNU Norwegian University of Science and Technology, Levanger, Norway; Levanger Hospital, Nord-Trøndelag Hospital Trust, Levanger, Norway
| | - Linda M Liao
- Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, MD
| | - Geoffrey Liu
- Computational Biology and Medicine Program, Princess Margaret Cancer Center, Toronto, Canada
| | - Reza Malekzadeh
- Digestive Disease Research Institute, Tehran University of Medical Sciences, Tehran, Iran
| | - Roger L Milne
- Cancer Epidemiology Division, Cancer Council Victoria, Melbourne, Australia; Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, University of Melbourne, Parkville, Australia; School of Clinical Sciences at Monash Health, Monash University, Melbourne, Australia
| | - Luis M Montuenga
- Center of Applied Medical Research (CIMA) and Schools of Sciences and Medicine, University of Navarra, Pamplona, Spain; IDISNA, Pamplona, Spain; CIBERONC, Madrid, Spain
| | - Thomas Rohan
- Department of Epidemiology & Population Health, Albert Einstein College of Medicine, Bronx, NY
| | - Howard D Sesso
- Brigham and Women's Hospital, Harvard Medical School, Boston, MA
| | | | - Mahdi Sheikh
- Genomic Epidemiology Branch, International Agency for Research on Cancer, Lyon, France
| | - Rashmi Sinha
- Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, MD
| | - Xiao-Ou Shu
- Division of Epidemiology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN
| | | | - Martin C Tammemägi
- Department of Health Sciences, Brock University, St. Cathaarines, ON, Canada; Prevention and Cancer Control, Ontario Health, Toronto, ON, Canada
| | - Lesley F Tinker
- Women's Health Initiative Clinical Coordinating Center, Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA
| | - Kala Visvanathan
- Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD
| | - Ying Wang
- American Cancer Society, Atlanta, GA
| | - Renwei Wang
- UPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh, PA
| | - Stephanie J Weinstein
- Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, MD
| | - Emily White
- Cancer Prevention Research Program, Fred Hutchinson Cancer Research Center, Seattle, WA
| | - David Wilson
- Division of Pulmonary, Allergy, and Critical Care Medicine, Department of Medicine, University of Pittsburgh, Pittsburgh, PA
| | - Jian-Min Yuan
- Department of Epidemiology, Graduate Schoolf of Public Health, University of Pittsburgh, Pittsburgh, PA; UPMC Hillman Cancer Centre, Pittsburgh, PA
| | - Xuehong Zhang
- Brigham and Women's Hospital, Harvard Medical School, Boston, MA
| | - Wei Zheng
- Division of Epidemiology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN
| | - Christopher I Amos
- Institute for Clinical and Translational Research, Baylor College of Medicine, Houston, TX
| | - Paul Brennan
- Genomic Epidemiology Branch, International Agency for Research on Cancer, Lyon, France
| | - Mattias Johansson
- Genomic Epidemiology Branch, International Agency for Research on Cancer, Lyon, France.
| | - Rayjean J Hung
- Prosserman Centre for Population Health Research, Lunenfeld-Tanenbaum Research Institute, Sinai Health, Toronto, Canada; Dalla Lana School of Public Health, University of Toronto, Toronto, Canada.
| |
Collapse
|
5
|
Guida F, Kidman R, Ferlay J, Schüz J, Soerjomataram I, Kithaka B, Ginsburg O, Mailhot Vega RB, Galukande M, Parham G, Vaccarella S, Canfell K, Ilbawi AM, Anderson BO, Bray F, Dos-Santos-Silva I, McCormack V. Global and regional estimates of orphans attributed to maternal cancer mortality in 2020. Nat Med 2022; 28:2563-2572. [PMID: 36404355 PMCID: PMC9676732 DOI: 10.1038/s41591-022-02109-2] [Citation(s) in RCA: 8] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/03/2022] [Accepted: 10/25/2022] [Indexed: 11/21/2022]
Abstract
Despite women being disproportionally affected by cancer deaths at young ages, there are no global estimates of the resulting maternal orphans, who experience health and education disadvantages throughout their lives. We estimated the number of children who became maternal orphans in 2020 due to their mother dying from cancer in that year, for 185 countries worldwide and by cause of cancer-related death. Female cancer deaths-by country, cancer type and age (derived from GLOBOCAN estimates)-were multiplied by each woman's estimated number of children under the age of 18 years at the time of her death (fertility data were derived from United Nations World Population Prospects for birth cohort), accounting for child mortality and parity-cancer risk associations. Globally, there were 1,047,000 such orphans. Over half of these were orphans due to maternal deaths from breast (258,000, 25%), cervix (210,000, 20%) and upper-gastrointestinal cancers (136,000, 13%), and most occurred in Asia (48%: India 15%, China 10%, rest of Asia 23%) and Africa (35%). Globally, there were 40 new maternal orphans due to cancer per 100,000 children, with a declining trend with a higher Human Development Index (range: 121 in Malawi to 15 in Malta). An estimated 7 million children were prevalent maternal orphans due to cancer in mid-2020. Accelerating the implementation of the World Health Organization's cervical and breast cancer initiatives has the potential to avert not only millions of preventable female cancer deaths but also the associated, often-overlooked, intergenerational consequences of these deaths.
Collapse
Affiliation(s)
- Florence Guida
- International Agency for Research on Cancer, Lyon, France.
| | - Rachel Kidman
- Program in Public Health and Department of Family, Population and Preventive Medicine, Stony Brook University (State University of New York), Stony Brook, NY, USA
| | - Jacques Ferlay
- International Agency for Research on Cancer, Lyon, France
| | - Joachim Schüz
- International Agency for Research on Cancer, Lyon, France
| | | | | | - Ophira Ginsburg
- Centre for Global Health, US National Cancer Institute, Rockville, MD, USA
| | | | | | - Groesbeck Parham
- Department of Obstetrics and Gynecology, School of Medicine, University of North Carolina, Chapel Hill, NC, USA
| | | | - Karen Canfell
- The Daffodil Centre, The University of Sydney, a joint venture with Cancer Council NSW, Sydney, New South Wales, Australia
| | - Andre M Ilbawi
- Global Breast Cancer Initiative, Department of Non-communicable Diseases, World Health Organization (WHO), Geneva, Switzerland
| | - Benjamin O Anderson
- Global Breast Cancer Initiative, Department of Non-communicable Diseases, World Health Organization (WHO), Geneva, Switzerland
| | - Freddie Bray
- International Agency for Research on Cancer, Lyon, France
| | - Isabel Dos-Santos-Silva
- Department of Non-Communicable Diseases Epidemiology, London School of Hygiene and Tropical Medicine, London, UK
| | | |
Collapse
|
6
|
Infantino R, Boccella S, Scuteri D, Perrone M, Ricciardi F, Vitale R, Bonsale R, Parente A, Allocca I, Virtuoso A, De Luca C, Belardo C, Amodeo P, Gentile V, Cirillo G, Bagetta G, Luongo L, Maione S, Guida F. 2-pentadecyl-2-oxazoline prevents cognitive and social behaviour impairments in the Amyloid β-induced Alzheimer-like mice model: Bring the α2 adrenergic receptor back into play. Biomed Pharmacother 2022; 156:113844. [DOI: 10.1016/j.biopha.2022.113844] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/12/2022] [Revised: 10/03/2022] [Accepted: 10/06/2022] [Indexed: 11/15/2022] Open
|
7
|
Smith-Byrne K, Cerani A, Guida F, Zhou S, Agudo A, Aleksandrova K, Barricarte A, Barranco MR, Bochers CH, Gram IT, Han J, Amos CI, Hung RJ, Grankvist K, Nøst TH, Imaz L, Chirlaque-López MD, Johansson M, Kaaks R, Kühn T, Martin RM, McKay JD, Pala V, Robbins HA, Sandanger TM, Schibli D, Schulze MB, Travis RC, Vineis P, Weiderpass E, Brennan P, Johansson M, Richards JB. Circulating Isovalerylcarnitine and Lung Cancer Risk: Evidence from Mendelian Randomization and Prediagnostic Blood Measurements. Cancer Epidemiol Biomarkers Prev 2022; 31:1966-1974. [PMID: 35839461 PMCID: PMC9530646 DOI: 10.1158/1055-9965.epi-21-1033] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/02/2021] [Revised: 12/09/2021] [Accepted: 07/13/2022] [Indexed: 01/09/2023] Open
Abstract
BACKGROUND Tobacco exposure causes 8 of 10 lung cancers, and identifying additional risk factors is challenging due to confounding introduced by smoking in traditional observational studies. MATERIALS AND METHODS We used Mendelian randomization (MR) to screen 207 metabolites for their role in lung cancer predisposition using independent genome-wide association studies (GWAS) of blood metabolite levels (n = 7,824) and lung cancer risk (n = 29,266 cases/56,450 controls). A nested case-control study (656 cases and 1,296 matched controls) was subsequently performed using prediagnostic blood samples to validate MR association with lung cancer incidence data from population-based cohorts (EPIC and NSHDS). RESULTS An MR-based scan of 207 circulating metabolites for lung cancer risk identified that blood isovalerylcarnitine (IVC) was associated with a decreased odds of lung cancer after accounting for multiple testing (log10-OR = 0.43; 95% CI, 0.29-0.63). Molar measurement of IVC in prediagnostic blood found similar results (log10-OR = 0.39; 95% CI, 0.21-0.72). Results were consistent across lung cancer subtypes. CONCLUSIONS Independent lines of evidence support an inverse association of elevated circulating IVC with lung cancer risk through a novel methodologic approach that integrates genetic and traditional epidemiology to efficiently identify novel cancer biomarkers. IMPACT Our results find compelling evidence in favor of a protective role for a circulating metabolite, IVC, in lung cancer etiology. From the treatment of a Mendelian disease, isovaleric acidemia, we know that circulating IVC is modifiable through a restricted protein diet or glycine and L-carnatine supplementation. IVC may represent a modifiable and inversely associated biomarker for lung cancer.
Collapse
Affiliation(s)
- Karl Smith-Byrne
- Genomic Epidemiology Branch, International Agency for Research on Cancer (IARC-WHO), Lyon, France
| | - Agustin Cerani
- Department of Epidemiology, Biostatistics and Occupational Health, McGill University, Montreal, Quebec, Canada/Centre for Clinical Epidemiology, Lady Davis Institute for Medical Research, Jewish General Hospital, Montreal, Quebec, Canada
| | - Florence Guida
- Genomic Epidemiology Branch, International Agency for Research on Cancer (IARC-WHO), Lyon, France
| | - Sirui Zhou
- Department of Epidemiology, Biostatistics and Occupational Health, McGill University, Montreal, Quebec, Canada/Centre for Clinical Epidemiology, Lady Davis Institute for Medical Research, Jewish General Hospital, Montreal, Quebec, Canada
| | - Antonio Agudo
- Unit of Nutrition and Cancer, Cancer Epidemiology Research Program, Institut Català d'Oncologia, Spain
| | - Krasimira Aleksandrova
- Nutrition, Immunity and Metabolism Senior Scientist Group, Department of Nutrition and Gerontology, German Institute of Human Nutrition Potsdam-Rehbruecke (DIfE), Nuthetal, Germany
- University of Potsdam, Institute of Nutritional Science, Potsdam, Germany
| | - Aurelio Barricarte
- Navarra Institute for Health Research (IdiSNA) Pamplona, Spain
- CIBER in Epidemiology and Public Health (CIBERESP), Madrid, Spain
| | - Miguel Rodríguez Barranco
- CIBER in Epidemiology and Public Health (CIBERESP), Madrid, Spain
- Escuela Andaluza de Salud Pública (EASP), Granada, Spain
- Instituto de Investigación Biosanitaria ibs.GRANADA, Granada, Spain
| | - Christoph H. Bochers
- Department of Epidemiology, Biostatistics and Occupational Health, McGill University, Montreal, Quebec, Canada/Centre for Clinical Epidemiology, Lady Davis Institute for Medical Research, Jewish General Hospital, Montreal, Quebec, Canada
- University of Victoria–Genome British Columbia Proteomics Centre, Victoria, BC, Canada/Division of Medical Sciences, University of Victoria, Victoria, British Columbia, Canada
| | - Inger Torhild Gram
- Faculty of Health Sciences, Department of Community Medicine, University of Tromsø, The Arctic University of Norway, Norway
| | - Jun Han
- University of Victoria–Genome British Columbia Proteomics Centre, Victoria, BC, Canada/Division of Medical Sciences, University of Victoria, Victoria, British Columbia, Canada
| | - Christopher I. Amos
- Dan L Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, Texas
| | - Rayjean J. Hung
- Prosserman Centre for Health Research, Mount Sinai Hospital, Toronto, Canada
| | - Kjell Grankvist
- Department of Medical Biosciences, Umeå University, Umeå, Sweden
| | - Therese Haugdhal Nøst
- Faculty of Health Sciences, Department of Community Medicine, University of Tromsø, The Arctic University of Norway, Norway
| | - Liher Imaz
- Ministry of Health of the Basque Government, Public Health Division of Gipuzkoa, Donostia-San Sebastian, Spain
- Biodonostia Health Research Institute, Donostia-San Sebastian, Spain
| | - María Dolores Chirlaque-López
- CIBER in Epidemiology and Public Health (CIBERESP), Madrid, Spain
- Department of Epidemiology, Regional Health Council, IMIB-Arrixaca, Murcia University, Murcia, Spain
| | | | - Rudolf Kaaks
- German Cancer Research Center (DKFZ), Heidelberg, Department of Cancer Epidemiology
- Translational Lung Research Center (TLRC) Heidelberg, Member of the German Center for Lung Research (DZL), Germany
| | - Tilman Kühn
- German Cancer Research Center (DKFZ), Heidelberg, Department of Cancer Epidemiology
| | - Richard M. Martin
- Clinical Epidemiology & Public Health, University of Bristol, Bristol, United Kingdom
| | - James D. McKay
- Genomic Epidemiology Branch, International Agency for Research on Cancer (IARC-WHO), Lyon, France
| | - Valeria Pala
- Epidemiology and Prevention Unit, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano
| | - Hilary A. Robbins
- Genomic Epidemiology Branch, International Agency for Research on Cancer (IARC-WHO), Lyon, France
| | - Torkjel M. Sandanger
- Faculty of Health Sciences, Department of Community Medicine, University of Tromsø, The Arctic University of Norway, Norway
| | - David Schibli
- University of Victoria–Genome British Columbia Proteomics Centre, Victoria, BC, Canada/Division of Medical Sciences, University of Victoria, Victoria, British Columbia, Canada
| | - Matthias B. Schulze
- Nutrition, Immunity and Metabolism Senior Scientist Group, Department of Nutrition and Gerontology, German Institute of Human Nutrition Potsdam-Rehbruecke (DIfE), Nuthetal, Germany
- University of Potsdam, Institute of Nutritional Science, Potsdam, Germany
| | - Ruth C. Travis
- Cancer Epidemiology Unit, Nuffield Department of Population Health, University of Oxford, Oxford, United Kingdom
| | - Paolo Vineis
- Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London, London, United Kingdom
| | - Elisabete Weiderpass
- Genomic Epidemiology Branch, International Agency for Research on Cancer (IARC-WHO), Lyon, France
| | - Paul Brennan
- Genomic Epidemiology Branch, International Agency for Research on Cancer (IARC-WHO), Lyon, France
| | - Mattias Johansson
- Genomic Epidemiology Branch, International Agency for Research on Cancer (IARC-WHO), Lyon, France
| | - J. Brent Richards
- Department of Epidemiology, Biostatistics and Occupational Health, McGill University, Montreal, Quebec, Canada/Centre for Clinical Epidemiology, Lady Davis Institute for Medical Research, Jewish General Hospital, Montreal, Quebec, Canada
- Division of Endocrinology, Department of Medicine & Department of Human Genetics, McGill University, Montreal, Quebec, Canada
- Department of Twin Research and Genetic Epidemiology, King's College London, Strand, London, United Kingdom
| |
Collapse
|
8
|
Zahed H, Smith-Byrne K, Alcala K, Guida F, Johansson M, Stevens V, Langhammer A, Milne R, Yuan JM, Robbins H, Johansson M. MA11.05 The Blood Proteome of Imminent Lung Cancer. J Thorac Oncol 2022. [DOI: 10.1016/j.jtho.2022.07.139] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/14/2022]
|
9
|
Feng X, Wu WY, Onwuka J, Alcala K, Smith-Byrne K, Zahed H, Guida F, Yuan JM, Wang R, Milne R, Bassett J, Langhammer A, Hveem K, Stevens V, Wang Y, Brennan P, Melin B, Johansson M, Robbins H, Johansson M. P1.01-01 Comparison between Protein and Autoantibody Biomarkers for the Early Detection of Lung Cancer. J Thorac Oncol 2022. [DOI: 10.1016/j.jtho.2022.07.162] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
10
|
Petrovic D, Bodinier B, Dagnino S, Whitaker M, Karimi M, Campanella G, Haugdahl Nøst T, Polidoro S, Palli D, Krogh V, Tumino R, Sacerdote C, Panico S, Lund E, Dugué PA, Giles GG, Severi G, Southey M, Vineis P, Stringhini S, Bochud M, Sandanger TM, Vermeulen RCH, Guida F, Chadeau-Hyam M. Epigenetic mechanisms of lung carcinogenesis involve differentially methylated CpG sites beyond those associated with smoking. Eur J Epidemiol 2022; 37:629-640. [PMID: 35595947 PMCID: PMC9288379 DOI: 10.1007/s10654-022-00877-2] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/28/2021] [Accepted: 04/25/2022] [Indexed: 12/24/2022]
Abstract
Smoking-related epigenetic changes have been linked to lung cancer, but the contribution of epigenetic alterations unrelated to smoking remains unclear. We sought for a sparse set of CpG sites predicting lung cancer and explored the role of smoking in these associations. We analysed CpGs in relation to lung cancer in participants from two nested case-control studies, using (LASSO)-penalised regression. We accounted for the effects of smoking using known smoking-related CpGs, and through conditional-independence network. We identified 29 CpGs (8 smoking-related, 21 smoking-unrelated) associated with lung cancer. Models additionally adjusted for Comprehensive Smoking Index-(CSI) selected 1 smoking-related and 49 smoking-unrelated CpGs. Selected CpGs yielded excellent discriminatory performances, outperforming information provided by CSI only. Of the 8 selected smoking-related CpGs, two captured lung cancer-relevant effects of smoking that were missed by CSI. Further, the 50 CpGs identified in the CSI-adjusted model complementarily explained lung cancer risk. These markers may provide further insight into lung cancer carcinogenesis and help improving early identification of high-risk patients.
Collapse
Affiliation(s)
- Dusan Petrovic
- Department of Epidemiology and Biostatistics, MRC Centre for Environment and Health, School of Public Health, Imperial College London, St Mary's Campus, Norfolk Place, London, W2 1PG, UK
- Department of Epidemiology and Health Systems (DESS), University Centre for General Medicine and Public Health (UNISANTE), Lausanne, Switzerland
- Department and Division of Primary Care Medicine, University Hospital of Geneva, Geneva, Switzerland
| | - Barbara Bodinier
- Department of Epidemiology and Biostatistics, MRC Centre for Environment and Health, School of Public Health, Imperial College London, St Mary's Campus, Norfolk Place, London, W2 1PG, UK
| | - Sonia Dagnino
- Department of Epidemiology and Biostatistics, MRC Centre for Environment and Health, School of Public Health, Imperial College London, St Mary's Campus, Norfolk Place, London, W2 1PG, UK
| | - Matthew Whitaker
- Department of Epidemiology and Biostatistics, MRC Centre for Environment and Health, School of Public Health, Imperial College London, St Mary's Campus, Norfolk Place, London, W2 1PG, UK
| | - Maryam Karimi
- Department of Epidemiology and Biostatistics, MRC Centre for Environment and Health, School of Public Health, Imperial College London, St Mary's Campus, Norfolk Place, London, W2 1PG, UK
- Bureau de Biostatistique et d'Épidémiologie, Institut Gustave Roussy, Université Paris-Saclay, Villejuif, France
- Oncostat U1018, Inserm, Équipe Labellisée Ligue Contre Le Cancer, Université Paris-Saclay, Villejuif, France
| | - Gianluca Campanella
- Department of Epidemiology and Biostatistics, MRC Centre for Environment and Health, School of Public Health, Imperial College London, St Mary's Campus, Norfolk Place, London, W2 1PG, UK
| | - Therese Haugdahl Nøst
- Department of Community Medicine, UiT The Arctic University of Norway, Tromsø, Norway
| | | | - Domenico Palli
- Molecular and Nutritional Epidemiology Unit, Cancer Research and Prevention Institute-ISPO, Florence, Italy
| | - Vittorio Krogh
- Epidemiology and Prevention Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
| | - Rosario Tumino
- Hyblean Association for Epidemiological Research, AIRE- ONLUS, Ragusa, Italy
| | - Carlotta Sacerdote
- Unit of Cancer Epidemiology Città Della Salute e della Scienza University-Hospital, Via Santena 7, 10126, Turin, Italy
| | - Salvatore Panico
- Department of Clinical Medicine and Surgery, Federico II University, Naples, Italy
| | - Eiliv Lund
- Department of Community Medicine, UiT The Arctic University of Norway, Tromsø, Norway
- The Norwegian Cancer Registry, Oslo, Norway
| | - Pierre-Antoine Dugué
- Cancer Epidemiology Division, Cancer Council Victoria, Melbourne, Australia
- Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, The University of Melbourne, Melbourne, Australia
- Precision Medicine, School of Clinical Sciences at Monash Health, Monash University, Clayton, Australia
| | - Graham G Giles
- Cancer Epidemiology Division, Cancer Council Victoria, Melbourne, Australia
- Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, The University of Melbourne, Melbourne, Australia
- Precision Medicine, School of Clinical Sciences at Monash Health, Monash University, Clayton, Australia
| | - Gianluca Severi
- Centre for Research in Epidemiology and Population Health, Inserm (Institut National de La Sante Et de a Recherche Medicale), Villejuif, France
| | - Melissa Southey
- Cancer Epidemiology Division, Cancer Council Victoria, Melbourne, Australia
- Precision Medicine, School of Clinical Sciences at Monash Health, Monash University, Clayton, Australia
- Department of Clinical Pathology, Melbourne Medical School, The University of Melbourne, Melbourne, Australia
| | - Paolo Vineis
- Department of Epidemiology and Biostatistics, MRC Centre for Environment and Health, School of Public Health, Imperial College London, St Mary's Campus, Norfolk Place, London, W2 1PG, UK
| | - Silvia Stringhini
- Department of Epidemiology and Health Systems (DESS), University Centre for General Medicine and Public Health (UNISANTE), Lausanne, Switzerland
- Department and Division of Primary Care Medicine, University Hospital of Geneva, Geneva, Switzerland
| | - Murielle Bochud
- Department of Epidemiology and Health Systems (DESS), University Centre for General Medicine and Public Health (UNISANTE), Lausanne, Switzerland
| | - Torkjel M Sandanger
- Department of Community Medicine, UiT The Arctic University of Norway, Tromsø, Norway
| | - Roel C H Vermeulen
- Department of Epidemiology and Biostatistics, MRC Centre for Environment and Health, School of Public Health, Imperial College London, St Mary's Campus, Norfolk Place, London, W2 1PG, UK
- Institute for Risk Assessment Sciences, Utrecht University, Utrecht, The Netherlands
- Julius Centre for Health Sciences and Primary Care, University Medical Centre, Utrecht, Utrecht, The Netherlands
| | - Florence Guida
- Department of Epidemiology and Biostatistics, MRC Centre for Environment and Health, School of Public Health, Imperial College London, St Mary's Campus, Norfolk Place, London, W2 1PG, UK
- Group of Genetic Epidemiology, International Agency for Research on Cancer (IARC) - World Health Organization (WHO), Lyon, France
| | - Marc Chadeau-Hyam
- Department of Epidemiology and Biostatistics, MRC Centre for Environment and Health, School of Public Health, Imperial College London, St Mary's Campus, Norfolk Place, London, W2 1PG, UK.
- Institute for Risk Assessment Sciences, Utrecht University, Utrecht, The Netherlands.
| |
Collapse
|
11
|
Ciciriello F, Guida F, Gorrieri G, Musante I, Alghisi F, Panatta M, Marini G, Fiocchi A, Scudieri P. P014 Proof of concept of ionocytes’ CFTR content as a novel biomarker for cystic fibrosis diagnosis and follow-up. J Cyst Fibros 2022. [DOI: 10.1016/s1569-1993(22)00348-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
12
|
Wade KH, Yarmolinsky J, Giovannucci E, Lewis SJ, Millwood IY, Munafò MR, Meddens F, Burrows K, Bell JA, Davies NM, Mariosa D, Kanerva N, Vincent EE, Smith-Byrne K, Guida F, Gunter MJ, Sanderson E, Dudbridge F, Burgess S, Cornelis MC, Richardson TG, Borges MC, Bowden J, Hemani G, Cho Y, Spiller W, Richmond RC, Carter AR, Langdon R, Lawlor DA, Walters RG, Vimaleswaran KS, Anderson A, Sandu MR, Tilling K, Davey Smith G, Martin RM, Relton CL. Applying Mendelian randomization to appraise causality in relationships between nutrition and cancer. Cancer Causes Control 2022; 33:631-652. [PMID: 35274198 PMCID: PMC9010389 DOI: 10.1007/s10552-022-01562-1] [Citation(s) in RCA: 4] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/30/2021] [Accepted: 02/10/2022] [Indexed: 02/08/2023]
Abstract
Dietary factors are assumed to play an important role in cancer risk, apparent in consensus recommendations for cancer prevention that promote nutritional changes. However, the evidence in this field has been generated predominantly through observational studies, which may result in biased effect estimates because of confounding, exposure misclassification, and reverse causality. With major geographical differences and rapid changes in cancer incidence over time, it is crucial to establish which of the observational associations reflect causality and to identify novel risk factors as these may be modified to prevent the onset of cancer and reduce its progression. Mendelian randomization (MR) uses the special properties of germline genetic variation to strengthen causal inference regarding potentially modifiable exposures and disease risk. MR can be implemented through instrumental variable (IV) analysis and, when robustly performed, is generally less prone to confounding, reverse causation and measurement error than conventional observational methods and has different sources of bias (discussed in detail below). It is increasingly used to facilitate causal inference in epidemiology and provides an opportunity to explore the effects of nutritional exposures on cancer incidence and progression in a cost-effective and timely manner. Here, we introduce the concept of MR and discuss its current application in understanding the impact of nutritional factors (e.g., any measure of diet and nutritional intake, circulating biomarkers, patterns, preference or behaviour) on cancer aetiology and, thus, opportunities for MR to contribute to the development of nutritional recommendations and policies for cancer prevention. We provide applied examples of MR studies examining the role of nutritional factors in cancer to illustrate how this method can be used to help prioritise or deprioritise the evaluation of specific nutritional factors as intervention targets in randomised controlled trials. We describe possible biases when using MR, and methodological developments aimed at investigating and potentially overcoming these biases when present. Lastly, we consider the use of MR in identifying causally relevant nutritional risk factors for various cancers in different regions across the world, given notable geographical differences in some cancers. We also discuss how MR results could be translated into further research and policy. We conclude that findings from MR studies, which corroborate those from other well-conducted studies with different and orthogonal biases, are poised to substantially improve our understanding of nutritional influences on cancer. For such corroboration, there is a requirement for an interdisciplinary and collaborative approach to investigate risk factors for cancer incidence and progression.
Collapse
Affiliation(s)
- Kaitlin H Wade
- Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK.
- Medical Research Council (MRC) Integrative Epidemiology Unit (IEU) at the University of Bristol, Bristol, UK.
| | - James Yarmolinsky
- Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK
- Medical Research Council (MRC) Integrative Epidemiology Unit (IEU) at the University of Bristol, Bristol, UK
| | - Edward Giovannucci
- Departments of Nutrition and Epidemiology, Harvard TH Chan School of Public Health, Boston, MA, USA
| | - Sarah J Lewis
- Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK
- Medical Research Council (MRC) Integrative Epidemiology Unit (IEU) at the University of Bristol, Bristol, UK
- Bristol National Institute for Health Research (NIHR) Biomedical Research Centre, Bristol, UK
| | - Iona Y Millwood
- Clinical Trial Service Unit and Epidemiological Studies Unit (CTSU) and the Medical Research Council Population Health Research Unit (MRC PHRU), Nuffield Department of Population Health, University of Oxford, Oxford, UK
| | - Marcus R Munafò
- Medical Research Council (MRC) Integrative Epidemiology Unit (IEU) at the University of Bristol, Bristol, UK
- Bristol National Institute for Health Research (NIHR) Biomedical Research Centre, Bristol, UK
- School of Psychological Science, University of Bristol, Bristol, UK
| | - Fleur Meddens
- Department of Economics, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands
- Department of Applied Economics, Erasmus School of Economics, Erasmus University Rotterdam, Rotterdam, The Netherlands
| | - Kimberley Burrows
- Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK
- Medical Research Council (MRC) Integrative Epidemiology Unit (IEU) at the University of Bristol, Bristol, UK
| | - Joshua A Bell
- Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK
- Medical Research Council (MRC) Integrative Epidemiology Unit (IEU) at the University of Bristol, Bristol, UK
| | - Neil M Davies
- Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK
- Medical Research Council (MRC) Integrative Epidemiology Unit (IEU) at the University of Bristol, Bristol, UK
- K.G. Jebsen Center for Genetic Epidemiology, Department of Public Health and Nursing, NTNU, Norwegian University of Science and Technology, Trondheim, Norway
| | - Daniela Mariosa
- International Agency for Research On Cancer (IARC), Lyon, France
| | | | - Emma E Vincent
- Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK
- Medical Research Council (MRC) Integrative Epidemiology Unit (IEU) at the University of Bristol, Bristol, UK
- Cellular and Molecular Medicine, Faculty of Life Sciences, University of Bristol, Bristol, UK
| | - Karl Smith-Byrne
- International Agency for Research On Cancer (IARC), Lyon, France
| | - Florence Guida
- International Agency for Research On Cancer (IARC), Lyon, France
| | - Marc J Gunter
- International Agency for Research On Cancer (IARC), Lyon, France
| | - Eleanor Sanderson
- Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK
- Medical Research Council (MRC) Integrative Epidemiology Unit (IEU) at the University of Bristol, Bristol, UK
| | - Frank Dudbridge
- Department of Health Sciences, University of Leicester, Leicester, UK
| | - Stephen Burgess
- MRC Biostatistics Unit, University of Cambridge, Cambridge, UK
- Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK
| | | | - Tom G Richardson
- Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK
- Medical Research Council (MRC) Integrative Epidemiology Unit (IEU) at the University of Bristol, Bristol, UK
| | - Maria Carolina Borges
- Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK
- Medical Research Council (MRC) Integrative Epidemiology Unit (IEU) at the University of Bristol, Bristol, UK
| | - Jack Bowden
- Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK
- Medical Research Council (MRC) Integrative Epidemiology Unit (IEU) at the University of Bristol, Bristol, UK
- Research Innovation Learning and Development (RILD) Building, University of Exeter Medical School, Exeter, UK
| | - Gibran Hemani
- Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK
- Medical Research Council (MRC) Integrative Epidemiology Unit (IEU) at the University of Bristol, Bristol, UK
| | - Yoonsu Cho
- Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK
- Medical Research Council (MRC) Integrative Epidemiology Unit (IEU) at the University of Bristol, Bristol, UK
| | - Wes Spiller
- Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK
- Medical Research Council (MRC) Integrative Epidemiology Unit (IEU) at the University of Bristol, Bristol, UK
| | - Rebecca C Richmond
- Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK
- Medical Research Council (MRC) Integrative Epidemiology Unit (IEU) at the University of Bristol, Bristol, UK
| | - Alice R Carter
- Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK
- Medical Research Council (MRC) Integrative Epidemiology Unit (IEU) at the University of Bristol, Bristol, UK
| | - Ryan Langdon
- Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK
- Medical Research Council (MRC) Integrative Epidemiology Unit (IEU) at the University of Bristol, Bristol, UK
| | - Deborah A Lawlor
- Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK
- Medical Research Council (MRC) Integrative Epidemiology Unit (IEU) at the University of Bristol, Bristol, UK
- Bristol National Institute for Health Research (NIHR) Biomedical Research Centre, Bristol, UK
| | - Robin G Walters
- Clinical Trial Service Unit and Epidemiological Studies Unit (CTSU) and the Medical Research Council Population Health Research Unit (MRC PHRU), Nuffield Department of Population Health, University of Oxford, Oxford, UK
| | | | - Annie Anderson
- Population Health and Genomics, School of Medicine, University of Dundee, Dundee, Scotland, UK
| | - Meda R Sandu
- Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK
- Medical Research Council (MRC) Integrative Epidemiology Unit (IEU) at the University of Bristol, Bristol, UK
- NIHR Biomedical Research Centre, Bristol, UK
| | - Kate Tilling
- Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK
- Medical Research Council (MRC) Integrative Epidemiology Unit (IEU) at the University of Bristol, Bristol, UK
- Bristol National Institute for Health Research (NIHR) Biomedical Research Centre, Bristol, UK
| | - George Davey Smith
- Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK
- Medical Research Council (MRC) Integrative Epidemiology Unit (IEU) at the University of Bristol, Bristol, UK
- Bristol National Institute for Health Research (NIHR) Biomedical Research Centre, Bristol, UK
| | - Richard M Martin
- Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK
- Medical Research Council (MRC) Integrative Epidemiology Unit (IEU) at the University of Bristol, Bristol, UK
| | - Caroline L Relton
- Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK
- Medical Research Council (MRC) Integrative Epidemiology Unit (IEU) at the University of Bristol, Bristol, UK
- Bristol National Institute for Health Research (NIHR) Biomedical Research Centre, Bristol, UK
| |
Collapse
|
13
|
Scuteri D, Rombolà L, Hamamura K, Sakurada T, Watanabe C, Sakurada S, Guida F, Boccella S, Maione S, Gallo Afflitto G, Nucci C, Tonin P, Bagetta G, Corasaniti MT. Is there a rational basis for cannabinoids research and development in ocular pain therapy? A systematic review of preclinical evidence. Biomed Pharmacother 2021; 146:112505. [PMID: 34891121 DOI: 10.1016/j.biopha.2021.112505] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/11/2021] [Revised: 11/26/2021] [Accepted: 12/03/2021] [Indexed: 01/31/2023] Open
Abstract
BACKGROUND Purpose of the present systematic review is to investigate preclinical evidence in favor of the working hypothesis of efficacy of cannabinoids in ocular pain treatment. METHODS Literature search includes the most relevant repositories for medical scientific literature from inception until November, 24 2021. Data collection and selection of retrieved records adhere to PRISMA criteria. RESULTS In agreement with a priori established protocol the search retrieved 2471 records leaving 479 results after duplicates removal. Eleven records result from title and abstract screening to meet the inclusion criteria; only 4 results are eligible for inclusion in the qualitative synthesis impeding meta-analysis. The qualitative analysis highlights the antinociceptive and anti-inflammatory efficacy of Δ8-tetrahydrocannabinol, cannabidiol and its derivative HU-308 and of new racemic CB1 allosteric ligand GAT211 and its enantiomers GAT228 and GAT229. Moreover, CB2R agonists RO6871304 and RO6871085 and CB2R ligand HU910 provide evidence of anti-inflammatory efficacy. CB2 agonist HU308 reduces of 241% uveitis-induced leukocyte adhesion and changes lipidome profile. Methodological and design issues raise concern of risk of bias and the amount of studies is too small for generalization. Furthermore, the ocular pain model used can resemble only inflammatory but not neuropathic pain. CONCLUSIONS The role of the endocannabinoid system in ocular pain is underinvestigated, since only two studies assessing the effects of cannabinoid receptors modulators on pain behavior and other two on pain-related inflammatory processes are found. Preclinical studies investigating the efficacy of cannabinoids in ocular inflammatory and neuropathic pain models are needed to pave the way for clinical translation.
Collapse
Affiliation(s)
- D Scuteri
- Pharmacotechnology Documentation and Transfer Unit, Preclinical and Translational Pharmacology, Department of Pharmacy, Health and Nutritional Sciences, University of Calabria, 87036 Rende, Italy; Regional Center for Serious Brain Injuries, S. Anna Institute, 88900 Crotone, Italy.
| | - L Rombolà
- Preclinical and Translational Pharmacology, Department of Pharmacy, Health and Nutritional Sciences, University of Calabria, 87036 Rende, Italy.
| | - K Hamamura
- Department of Pharmacology, Daiichi University of Pharmacy, 815-8511 Fukuoka, Japan.
| | - T Sakurada
- Department of Pharmacology, Daiichi University of Pharmacy, 815-8511 Fukuoka, Japan.
| | - C Watanabe
- Department of Physiology and Anatomy, Tohoku Pharmaceutical University, 981-8558 Sendai, Japan.
| | - S Sakurada
- Department of Physiology and Anatomy, Tohoku Pharmaceutical University, 981-8558 Sendai, Japan.
| | - F Guida
- Department of Experimental Medicine, Pharmacology Division, University of Campania "L. Vanvitelli", 80138 Naples, Italy.
| | - S Boccella
- Department of Experimental Medicine, Pharmacology Division, University of Campania "L. Vanvitelli", 80138 Naples, Italy.
| | - S Maione
- Department of Experimental Medicine, Pharmacology Division, University of Campania "L. Vanvitelli", 80138 Naples, Italy; Endocannabinoid Research Group, Institute of Biomolecular Chemistry, CNR, Pozzuoli, Italy; IRCSS, Neuromed, Pozzilli, Italy.
| | - G Gallo Afflitto
- Ophthalmology Unit, Department of Experimental Medicine, University of Rome "Tor Vergata", 00133 Rome, Italy.
| | - C Nucci
- Ophthalmology Unit, Department of Experimental Medicine, University of Rome "Tor Vergata", 00133 Rome, Italy.
| | - P Tonin
- Regional Center for Serious Brain Injuries, S. Anna Institute, 88900 Crotone, Italy.
| | - G Bagetta
- Pharmacotechnology Documentation and Transfer Unit, Preclinical and Translational Pharmacology, Department of Pharmacy, Health and Nutritional Sciences, University of Calabria, 87036 Rende, Italy
| | - M T Corasaniti
- Department of Health Sciences, University "Magna Graecia" of Catanzaro, 88100 Catanzaro, Italy.
| |
Collapse
|
14
|
Guida F, Scaggion A, Fusella M, Pivato N, Roggio A, Rossato M, Zandonà R, Paiusco M. Assessment of SciMoCA as second dosimetry check in the clinical routine practice. Phys Med 2021. [DOI: 10.1016/s1120-1797(22)00345-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/17/2022] Open
|
15
|
Villegas E, Guida F, Germani A, Dusi F, Fusella M, Roggio A, Scaggion A, Zandonà R, Busato F, Paiusco M. Dosimetric study of fetal dose during external beam radiotherapy using OSLD. Phys Med 2021. [DOI: 10.1016/s1120-1797(22)00018-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
|
16
|
Sun YQ, Richmond RC, Suderman M, Min JL, Battram T, Flatberg A, Beisvag V, Nøst TH, Guida F, Jiang L, Wahl SGF, Langhammer A, Skorpen F, Walker RM, Bretherick AD, Zeng Y, Chen Y, Johansson M, Sandanger TM, Relton CL, Mai XM. Assessing the role of genome-wide DNA methylation between smoking and risk of lung cancer using repeated measurements: the HUNT study. Int J Epidemiol 2021; 50:1482-1497. [PMID: 33729499 PMCID: PMC8580278 DOI: 10.1093/ije/dyab044] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/17/2020] [Accepted: 02/18/2021] [Indexed: 12/26/2022] Open
Abstract
BACKGROUND It is unclear if smoking-related DNA methylation represents a causal pathway between smoking and risk of lung cancer. We sought to identify novel smoking-related DNA methylation sites in blood, with repeated measurements, and to appraise the putative role of DNA methylation in the pathway between smoking and lung cancer development. METHODS We derived a nested case-control study from the Trøndelag Health Study (HUNT), including 140 incident patients who developed lung cancer during 2009-13 and 140 controls. We profiled 850 K DNA methylation sites (Illumina Infinium EPIC array) in DNA extracted from blood that was collected in HUNT2 (1995-97) and HUNT3 (2006-08) for the same individuals. Epigenome-wide association studies (EWAS) were performed for a detailed smoking phenotype and for lung cancer. Two-step Mendelian randomization (MR) analyses were performed to assess the potential causal effect of smoking on DNA methylation as well as of DNA methylation (13 sites as putative mediators) on risk of lung cancer. RESULTS The EWAS for smoking in HUNT2 identified associations at 76 DNA methylation sites (P < 5 × 10-8), including 16 novel sites. Smoking was associated with DNA hypomethylation in a dose-response relationship among 83% of the 76 sites, which was confirmed by analyses using repeated measurements from blood that was collected at 11 years apart for the same individuals. Two-step MR analyses showed evidence for a causal effect of smoking on DNA methylation but no evidence for a causal link between DNA methylation and the risk of lung cancer. CONCLUSIONS DNA methylation modifications in blood did not seem to represent a causal pathway linking smoking and the lung cancer risk.
Collapse
Affiliation(s)
- Yi-Qian Sun
- Department of Clinical and Molecular Medicine, Norwegian University of Science and Technology, Trondheim, Norway
- Department of Pathology, Clinic of Laboratory Medicine, St Olav’s University Hospital, Trondheim, Norway
- Center for Oral Health Services and Research Mid-Norway (TkMidt), Trondheim, Norway
| | - Rebecca C Richmond
- MRC Integrative Epidemiology Unit, Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK
| | - Matthew Suderman
- MRC Integrative Epidemiology Unit, Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK
| | - Josine L Min
- MRC Integrative Epidemiology Unit, Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK
| | - Thomas Battram
- MRC Integrative Epidemiology Unit, Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK
| | - Arnar Flatberg
- Department of Clinical and Molecular Medicine, Norwegian University of Science and Technology, Trondheim, Norway
- Central Administration, St Olav’s University Hospital, Trondheim, Norway
| | - Vidar Beisvag
- Department of Clinical and Molecular Medicine, Norwegian University of Science and Technology, Trondheim, Norway
- Central Administration, St Olav’s University Hospital, Trondheim, Norway
| | - Therese Haugdahl Nøst
- Department of Community Medicine, Faculty of Health Sciences, Arctic University of Norway, Tromsø, Norway
- K.G. Jebsen Center for Genetic Epidemiology, Department of Public Health and Nursing, Norwegian University of Science and Technology, Trondheim, Norway
| | - Florence Guida
- Genetic Epidemiology Group, International Agency for Research on Cancer, Lyon, France
| | - Lin Jiang
- Department of Public Health and Nursing, Norwegian University of Science and Technology, Trondheim, Norway
| | - Sissel Gyrid Freim Wahl
- Department of Clinical and Molecular Medicine, Norwegian University of Science and Technology, Trondheim, Norway
- Department of Pathology, Clinic of Laboratory Medicine, St Olav’s University Hospital, Trondheim, Norway
| | - Arnulf Langhammer
- HUNT Research Centre, Department of Public Health and Nursing, Norwegian University of Science and Technology, Trondheim, Norway
| | - Frank Skorpen
- Department of Clinical and Molecular Medicine, Norwegian University of Science and Technology, Trondheim, Norway
| | - Rosie M Walker
- Centre for Genomic and Experimental Medicine, Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, UK
| | - Andrew D Bretherick
- MRC Human Genetics Unit, Institute of Genetics and Molecular Medicine, University of Edinburgh, Western General Hospital, Edinburgh, UK
| | - Yanni Zeng
- Faculty of Forensic Medicine, Zhongshan School of Medicine, Sun Yat-Sen University, Guangzhou, China
| | - Yue Chen
- School of Epidemiology and Public Health, Faculty of Medicine, University of Ottawa, Ottawa, ON, Canada
| | - Mattias Johansson
- Genetic Epidemiology Group, International Agency for Research on Cancer, Lyon, France
| | - Torkjel M Sandanger
- Department of Community Medicine, Faculty of Health Sciences, Arctic University of Norway, Tromsø, Norway
| | - Caroline L Relton
- MRC Integrative Epidemiology Unit, Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK
| | - Xiao-Mei Mai
- Department of Public Health and Nursing, Norwegian University of Science and Technology, Trondheim, Norway
| |
Collapse
|
17
|
Guida F, Tan VY, Corbin LJ, Smith-Byrne K, Alcala K, Langenberg C, Stewart ID, Butterworth AS, Surendran P, Achaintre D, Adamski J, Amiano P, Bergmann MM, Bull CJ, Dahm CC, Gicquiau A, Giles GG, Gunter MJ, Haller T, Langhammer A, Larose TL, Ljungberg B, Metspalu A, Milne RL, Muller DC, Nøst TH, Pettersen Sørgjerd E, Prehn C, Riboli E, Rinaldi S, Rothwell JA, Scalbert A, Schmidt JA, Severi G, Sieri S, Vermeulen R, Vincent EE, Waldenberger M, Timpson NJ, Johansson M. The blood metabolome of incident kidney cancer: A case-control study nested within the MetKid consortium. PLoS Med 2021; 18:e1003786. [PMID: 34543281 PMCID: PMC8496779 DOI: 10.1371/journal.pmed.1003786] [Citation(s) in RCA: 12] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/12/2021] [Revised: 10/07/2021] [Accepted: 08/27/2021] [Indexed: 12/11/2022] Open
Abstract
BACKGROUND Excess bodyweight and related metabolic perturbations have been implicated in kidney cancer aetiology, but the specific molecular mechanisms underlying these relationships are poorly understood. In this study, we sought to identify circulating metabolites that predispose kidney cancer and to evaluate the extent to which they are influenced by body mass index (BMI). METHODS AND FINDINGS We assessed the association between circulating levels of 1,416 metabolites and incident kidney cancer using pre-diagnostic blood samples from up to 1,305 kidney cancer case-control pairs from 5 prospective cohort studies. Cases were diagnosed on average 8 years after blood collection. We found 25 metabolites robustly associated with kidney cancer risk. In particular, 14 glycerophospholipids (GPLs) were inversely associated with risk, including 8 phosphatidylcholines (PCs) and 2 plasmalogens. The PC with the strongest association was PC ae C34:3 with an odds ratio (OR) for 1 standard deviation (SD) increment of 0.75 (95% confidence interval [CI]: 0.68 to 0.83, p = 2.6 × 10-8). In contrast, 4 amino acids, including glutamate (OR for 1 SD = 1.39, 95% CI: 1.20 to 1.60, p = 1.6 × 10-5), were positively associated with risk. Adjusting for BMI partly attenuated the risk association for some-but not all-metabolites, whereas other known risk factors of kidney cancer, such as smoking and alcohol consumption, had minimal impact on the observed associations. A mendelian randomisation (MR) analysis of the influence of BMI on the blood metabolome highlighted that some metabolites associated with kidney cancer risk are influenced by BMI. Specifically, elevated BMI appeared to decrease levels of several GPLs that were also found inversely associated with kidney cancer risk (e.g., -0.17 SD change [ßBMI] in 1-(1-enyl-palmitoyl)-2-linoleoyl-GPC (P-16:0/18:2) levels per SD change in BMI, p = 3.4 × 10-5). BMI was also associated with increased levels of glutamate (ßBMI: 0.12, p = 1.5 × 10-3). While our results were robust across the participating studies, they were limited to study participants of European descent, and it will, therefore, be important to evaluate if our findings can be generalised to populations with different genetic backgrounds. CONCLUSIONS This study suggests a potentially important role of the blood metabolome in kidney cancer aetiology by highlighting a wide range of metabolites associated with the risk of developing kidney cancer and the extent to which changes in levels of these metabolites are driven by BMI-the principal modifiable risk factor of kidney cancer.
Collapse
Affiliation(s)
- Florence Guida
- Genomic Epidemiology Branch, International Agency for Research on Cancer (IARC/WHO), Lyon, France
| | - Vanessa Y. Tan
- MRC Integrative Epidemiology Unit, University of Bristol, Bristol, United Kingdom
- Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, United Kingdom
| | - Laura J. Corbin
- MRC Integrative Epidemiology Unit, University of Bristol, Bristol, United Kingdom
- Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, United Kingdom
| | - Karl Smith-Byrne
- Genomic Epidemiology Branch, International Agency for Research on Cancer (IARC/WHO), Lyon, France
| | - Karine Alcala
- Genomic Epidemiology Branch, International Agency for Research on Cancer (IARC/WHO), Lyon, France
| | - Claudia Langenberg
- MRC Epidemiology Unit, University of Cambridge, Cambridge, United Kingdom
| | - Isobel D. Stewart
- MRC Epidemiology Unit, University of Cambridge, Cambridge, United Kingdom
| | - Adam S. Butterworth
- British Heart Foundation Cardiovascular Epidemiology Unit, Department of Public Health and Primary Care, University of Cambridge, Cambridge, United Kingdom
- British Heart Foundation Centre of Research Excellence, University of Cambridge, Cambridge, United Kingdom
- Health Data Research UK Cambridge, Wellcome Genome Campus and University of Cambridge, Cambridge, United Kingdom
- National Institute for Health Research Blood and Transplant Research Unit in Donor Health and Genomics, University of Cambridge, Cambridge, United Kingdom
| | - Praveen Surendran
- British Heart Foundation Cardiovascular Epidemiology Unit, Department of Public Health and Primary Care, University of Cambridge, Cambridge, United Kingdom
- British Heart Foundation Centre of Research Excellence, University of Cambridge, Cambridge, United Kingdom
- Health Data Research UK Cambridge, Wellcome Genome Campus and University of Cambridge, Cambridge, United Kingdom
- Rutherford Fund Fellow, Department of Public Health and Primary Care, University of Cambridge, Cambridge, United Kingdom
| | - David Achaintre
- Nutrition and Metabolism Branch, International Agency for Research on Cancer (IARC/WHO), Lyon, France
| | - Jerzy Adamski
- Institute of Experimental Genetics, Helmholtz Zentrum München, German Research Center for Environmental Health (GmbH), Neuherberg, Germany
- Institute of Biochemistry, Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia
- Chair of Experimental Genetics, School of Life Science, Weihenstephan, Technische Universität München, Freising, Germany
- Department of Biochemistry, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore
| | - Pilar Amiano
- Ministry of Health of the Basque Government, Sub Directorate for Public Health and Addictions of Gipuzkoa, San Sebastián, Spain
- Biodonostia Health Research Institute, Epidemiology of Chronic and Communicable Diseases Group, San Sebastián, Spain
- Spanish Consortium for Research on Epidemiology and Public Health (CIBERESP), Instituto de Salud Carlos III, Madrid, Spain
| | | | - Caroline J. Bull
- MRC Integrative Epidemiology Unit, University of Bristol, Bristol, United Kingdom
- Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, United Kingdom
- School of Cellular and Molecular Medicine, University of Bristol, Bristol, United Kingdom
- Bristol Renal, Translational Health Sciences, Bristol Medical School, University of Bristol, Bristol, United Kingdom
| | | | - Audrey Gicquiau
- Nutrition and Metabolism Branch, International Agency for Research on Cancer (IARC/WHO), Lyon, France
| | - Graham G. Giles
- Cancer Epidemiology Division, Cancer Council Victoria, Melbourne, Australia
- Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, The University of Melbourne, Melbourne, Australia
- Precision Medicine, School of Clinical Sciences at Monash Health, Monash University, Clayton, Australia
| | - Marc J. Gunter
- Nutrition and Metabolism Branch, International Agency for Research on Cancer (IARC/WHO), Lyon, France
| | - Toomas Haller
- Institute of Genomics, University of Tartu, Tartu, Estonia
| | - Arnulf Langhammer
- HUNT Research Centre, Department of Public Health and Nursing, NTNU, Norwegian University of Science and Technology, Levanger, Norway
- Levanger Hospital, Nord-Trøndelag Hospital Trust, Levanger, Norway
| | - Tricia L. Larose
- Genomic Epidemiology Branch, International Agency for Research on Cancer (IARC/WHO), Lyon, France
- HUNT Research Centre, Department of Public Health and Nursing, NTNU, Norwegian University of Science and Technology, Levanger, Norway
- Department of Community Medicine and Global Health, Institute of Health and Society, University of Oslo, Oslo, Norway
| | - Börje Ljungberg
- Department of Surgical and Perioperative Sciences, Urology and Andrology, Umeå University, Umeå, Sweden
| | | | - Roger L. Milne
- Cancer Epidemiology Division, Cancer Council Victoria, Melbourne, Australia
- Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, The University of Melbourne, Melbourne, Australia
- Precision Medicine, School of Clinical Sciences at Monash Health, Monash University, Clayton, Australia
| | - David C. Muller
- Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London, London, United Kingdom
| | - Therese H. Nøst
- Department of Community Medicine, Faculty of Health Sciences, UiT The Arctic University of Norway, Tromsø, Norway
| | - Elin Pettersen Sørgjerd
- HUNT Research Centre, Department of Public Health and Nursing, NTNU, Norwegian University of Science and Technology, Levanger, Norway
| | - Cornelia Prehn
- Metabolomics and Proteomics Core (MPC), Helmholtz Zentrum München, German Research Center for Environmental Health (GmbH), Neuherberg, Germany
| | - Elio Riboli
- Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London, London, United Kingdom
| | - Sabina Rinaldi
- Nutrition and Metabolism Branch, International Agency for Research on Cancer (IARC/WHO), Lyon, France
| | - Joseph A. Rothwell
- Université Paris-Saclay, UVSQ, Inserm, Gustave Roussy, Équipe “Exposome et Hérédité”, CESP UMR1018, Inserm, Villejuif, France
| | - Augustin Scalbert
- Nutrition and Metabolism Branch, International Agency for Research on Cancer (IARC/WHO), Lyon, France
| | - Julie A. Schmidt
- Cancer Epidemiology Unit, Nuffield Department of Population Health, University of Oxford, Oxford, United Kingdom
| | - Gianluca Severi
- Université Paris-Saclay, UVSQ, Inserm, Gustave Roussy, Équipe “Exposome et Hérédité”, CESP UMR1018, Inserm, Villejuif, France
- Department of Statistics, Computer Science and Applications (DISIA), University of Florence, Florence, Italy
| | - Sabina Sieri
- Epidemiology and Prevention Unit, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milano, Italy
| | - Roel Vermeulen
- Institute for Risk Assessment Sciences (IRAS), Utrecht University, Utrecht, the Netherlands
| | - Emma E. Vincent
- MRC Integrative Epidemiology Unit, University of Bristol, Bristol, United Kingdom
- Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, United Kingdom
- School of Cellular and Molecular Medicine, University of Bristol, Bristol, United Kingdom
- Bristol Renal, Translational Health Sciences, Bristol Medical School, University of Bristol, Bristol, United Kingdom
| | - Melanie Waldenberger
- Research Unit Molecular Epidemiology, Institute of Epidemiology, Helmholtz Zentrum München, German Research Center for Environmental Health (GmbH), Neuherberg, Germany
| | - Nicholas J. Timpson
- MRC Integrative Epidemiology Unit, University of Bristol, Bristol, United Kingdom
- Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, United Kingdom
| | - Mattias Johansson
- Genomic Epidemiology Branch, International Agency for Research on Cancer (IARC/WHO), Lyon, France
| |
Collapse
|
18
|
Nøst TH, Alcala K, Urbarova I, Byrne KS, Guida F, Sandanger TM, Johansson M. Systemic inflammation markers and cancer incidence in the UK Biobank. Eur J Epidemiol 2021; 36:841-848. [PMID: 34036468 PMCID: PMC8416852 DOI: 10.1007/s10654-021-00752-6] [Citation(s) in RCA: 143] [Impact Index Per Article: 47.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/10/2020] [Accepted: 04/16/2021] [Indexed: 12/27/2022]
Abstract
Systemic inflammation markers have been linked to increased cancer risk and mortality in a number of studies. However, few studies have estimated pre-diagnostic associations of systemic inflammation markers and cancer risk. Such markers could serve as biomarkers of cancer risk and aid in earlier identification of the disease. This study estimated associations between pre-diagnostic systemic inflammation markers and cancer risk in the prospective UK Biobank cohort of approximately 440,000 participants recruited between 2006 and 2010. We assessed associations between four immune-related markers based on blood cell counts: systemic immune-inflammation index (SII), neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), lymphocyte-to-monocyte ratio (LMR), and risk for 17 cancer sites by estimating hazard ratios (HR) using flexible parametric survival models. We observed positive associations with risk for seven out of 17 cancers with SII, NLR, PLR, and negative associations with LMR. The strongest associations were observed for SII for colorectal and lung cancer risk, with associations increasing in magnitude for cases diagnosed within one year of recruitment. For instance, the HR for colorectal cancer per standard deviation increment in SII was estimated at 1.09 (95% CI 1.02-1.16) in blood drawn five years prior to diagnosis and 1.50 (95% CI 1.24-1.80) in blood drawn one month prior to diagnosis. We observed associations between systemic inflammation markers and risk for several cancers. The increase in risk the last year prior to diagnosis may reflect a systemic immune response to an already present, yet clinically undetected cancer. Blood cell ratios could serve as biomarkers of cancer incidence risk with potential for early identification of disease in the last year prior to clinical diagnosis.
Collapse
Affiliation(s)
- Therese Haugdahl Nøst
- Department of Community Medicine, Faculty of Health Sciences, UiT The Arctic University of Norway, PO Box 6050, 9037, Langnes, Tromsø, Norway.
| | - Karine Alcala
- Genomic Epidemiology Branch, International Agency for Research on Cancer, 150 Cours Albert Thomas, 69372, Lyon CEDEX 08, France
| | - Ilona Urbarova
- Department of Community Medicine, Faculty of Health Sciences, UiT The Arctic University of Norway, PO Box 6050, 9037, Langnes, Tromsø, Norway
| | - Karl Smith Byrne
- Genomic Epidemiology Branch, International Agency for Research on Cancer, 150 Cours Albert Thomas, 69372, Lyon CEDEX 08, France
| | - Florence Guida
- Genomic Epidemiology Branch, International Agency for Research on Cancer, 150 Cours Albert Thomas, 69372, Lyon CEDEX 08, France
| | - Torkjel Manning Sandanger
- Department of Community Medicine, Faculty of Health Sciences, UiT The Arctic University of Norway, PO Box 6050, 9037, Langnes, Tromsø, Norway
| | - Mattias Johansson
- Genomic Epidemiology Branch, International Agency for Research on Cancer, 150 Cours Albert Thomas, 69372, Lyon CEDEX 08, France.
| |
Collapse
|
19
|
Zahed H, Johansson M, Ueland PM, Midttun Ø, Milne RL, Giles GG, Manjer J, Sandsveden M, Langhammer A, Sørgjerd EP, Grankvist K, Johansson M, Freedman ND, Huang WY, Chen C, Prentice R, Stevens VL, Wang Y, Le Marchand L, Wilkens LR, Weinstein SJ, Albanes D, Cai Q, Blot WJ, Arslan AA, Zeleniuch-Jacquotte A, Shu XO, Zheng W, Yuan JM, Koh WP, Visvanathan K, Sesso HD, Zhang X, Gaziano JM, Fanidi A, Muller D, Brennan P, Guida F, Robbins HA. Epidemiology of 40 blood biomarkers of one-carbon metabolism, vitamin status, inflammation, and renal and endothelial function among cancer-free older adults. Sci Rep 2021; 11:13805. [PMID: 34226613 PMCID: PMC8257595 DOI: 10.1038/s41598-021-93214-8] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/11/2021] [Accepted: 05/21/2021] [Indexed: 11/09/2022] Open
Abstract
Imbalances of blood biomarkers are associated with disease, and biomarkers may also vary non-pathologically across population groups. We described variation in concentrations of biomarkers of one-carbon metabolism, vitamin status, inflammation including tryptophan metabolism, and endothelial and renal function among cancer-free older adults. We analyzed 5167 cancer-free controls aged 40-80 years from 20 cohorts in the Lung Cancer Cohort Consortium (LC3). Centralized biochemical analyses of 40 biomarkers in plasma or serum were performed. We fit multivariable linear mixed effects models to quantify variation in standardized biomarker log-concentrations across four factors: age, sex, smoking status, and body mass index (BMI). Differences in most biomarkers across most factors were small, with 93% (186/200) of analyses showing an estimated difference lower than 0.25 standard-deviations, although most were statistically significant due to large sample size. The largest difference was for creatinine by sex, which was - 0.91 standard-deviations lower in women than men (95%CI - 0.98; - 0.84). The largest difference by age was for total cysteine (0.40 standard-deviation increase per 10-year increase, 95%CI 0.36; 0.43), and by BMI was for C-reactive protein (0.38 standard-deviation increase per 5-kg/m2 increase, 95%CI 0.34; 0.41). For 31 of 40 markers, the mean difference between current and never smokers was larger than between former and never smokers. A statistically significant (p < 0.05) association with time since smoking cessation was observed for 8 markers, including C-reactive protein, kynurenine, choline, and total homocysteine. We conclude that most blood biomarkers show small variations across demographic characteristics. Patterns by smoking status point to normalization of multiple physiological processes after smoking cessation.
Collapse
Affiliation(s)
- Hana Zahed
- Genomic Epidemiology Branch, International Agency for Research on Cancer, 150 cours Albert Thomas, 69008, Lyon, France
| | - Mattias Johansson
- Genomic Epidemiology Branch, International Agency for Research on Cancer, 150 cours Albert Thomas, 69008, Lyon, France
| | - Per M Ueland
- Department of Clinical Science, University of Bergen, Bergen, Norway
| | | | - Roger L Milne
- Cancer Epidemiology Division, Cancer Council Victoria, Melbourne, Australia
- Centre for Epidemiology and Biostatistics, School of Population and Global Health, The University of Melbourne, Melbourne, Australia
- Precision Medicine, School of Clinical Sciences at Monash Health, Monash University, Melbourne, Australia
| | - Graham G Giles
- Cancer Epidemiology Division, Cancer Council Victoria, Melbourne, Australia
- Centre for Epidemiology and Biostatistics, School of Population and Global Health, The University of Melbourne, Melbourne, Australia
- Precision Medicine, School of Clinical Sciences at Monash Health, Monash University, Melbourne, Australia
| | - Jonas Manjer
- Department of Surgery, Skane University Hospital, Malmö, Sweden
- Lund University, Malmö, Sweden
| | - Malte Sandsveden
- Department of Clinical Sciences Malmo, Lund University, Malmö, Sweden
| | - Arnulf Langhammer
- Department of Public Health and Nursing, Hunt Research Centre, Norwegian University of Science and Technology, Levanger, Norway
- Levanger Hospital, Nord-Trøndelag Hospital Trust, Levanger, Norway
| | - Elin Pettersen Sørgjerd
- Department of Public Health and Nursing, NTNU, Hunt Research Centre, Norwegian University of Science and Technology, Levanger, Norway
- Department of Endocrinology, St. Olavs Hospital, Trondheim University Hospital, Levanger, Norway
| | - Kjell Grankvist
- Department of Medical Biosciences, Umea University, Umeå, Sweden
| | - Mikael Johansson
- Department of Radiation Sciences, Oncology, Umea University, Umeå, Sweden
| | - Neal D Freedman
- Metabolic Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, USA
| | - Wen-Yi Huang
- Metabolic Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, USA
| | - Chu Chen
- Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, USA
| | - Ross Prentice
- Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, USA
| | | | - Ying Wang
- American Cancer Society, Atlanta, USA
| | - Loic Le Marchand
- University of Hawai'i Cancer Center, University of Hawai'i at Mānoa, Honolulu, USA
| | - Lynne R Wilkens
- University of Hawai'i Cancer Center, University of Hawai'i at Mānoa, Honolulu, USA
| | - Stephanie J Weinstein
- Metabolic Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, USA
| | - Demetrius Albanes
- Metabolic Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, USA
| | - Qiuyin Cai
- Vanderbilt University Medical Center, Nashville, USA
| | | | - Alan A Arslan
- Department of Obstetrics and Gynecology, NYU Langone Health, New York, NY, USA
- Department of Population Health, NYU Langone Health, New York, NY, USA
- Perlmutter Comprehensive Cancer Center, NYU Langone Health, New York, NY, USA
| | - Anne Zeleniuch-Jacquotte
- Department of Population Health, NYU Langone Health, New York, NY, USA
- Perlmutter Comprehensive Cancer Center, NYU Langone Health, New York, NY, USA
| | - Xiao-Ou Shu
- Vanderbilt University Medical Center, Nashville, USA
| | - Wei Zheng
- Vanderbilt University Medical Center, Nashville, USA
| | - Jian-Min Yuan
- University of Pittsburgh Medical Center, Pittsburgh, USA
| | | | - Kala Visvanathan
- Johns Hopkins Institute for Clinical and Translational Research, Baltimore, USA
| | - Howard D Sesso
- Brigham and Women's Hospital, Harvard Medical School, Boston, USA
- Harvard T.H. Chan School of Public Health, Boston, USA
| | - Xuehong Zhang
- Brigham and Women's Hospital, Harvard Medical School, Boston, USA
- Harvard T.H. Chan School of Public Health, Boston, USA
| | - J Michael Gaziano
- Harvard T.H. Chan School of Public Health, Boston, USA
- Brigham and Women's Hospital, Boston, USA
| | | | - David Muller
- Imperial College London School of Public Health, London, UK
| | - Paul Brennan
- Genomic Epidemiology Branch, International Agency for Research on Cancer, 150 cours Albert Thomas, 69008, Lyon, France
| | - Florence Guida
- Genomic Epidemiology Branch, International Agency for Research on Cancer, 150 cours Albert Thomas, 69008, Lyon, France
| | - Hilary A Robbins
- Genomic Epidemiology Branch, International Agency for Research on Cancer, 150 cours Albert Thomas, 69008, Lyon, France.
| |
Collapse
|
20
|
Dagnino S, Bodinier B, Guida F, Smith-Byrne K, Petrovic D, Whitaker MD, Haugdahl Nøst T, Agnoli C, Palli D, Sacerdote C, Panico S, Tumino R, Schulze MB, Johansson M, Keski-Rahkonen P, Scalbert A, Vineis P, Johansson M, Sandanger TM, Vermeulen RCH, Chadeau-Hyam M. Prospective Identification of Elevated Circulating CDCP1 in Patients Years before Onset of Lung Cancer. Cancer Res 2021; 81:3738-3748. [PMID: 33574093 PMCID: PMC7611235 DOI: 10.1158/0008-5472.can-20-3454] [Citation(s) in RCA: 18] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/12/2020] [Revised: 12/15/2020] [Accepted: 02/08/2021] [Indexed: 01/10/2023]
Abstract
Increasing evidence points to a role for inflammation in lung carcinogenesis. A small number of circulating inflammatory proteins have been identified as showing elevated levels prior to lung cancer diagnosis, indicating the potential for prospective circulating protein concentration as a marker of early carcinogenesis. To identify novel markers of lung cancer risk, we measured a panel of 92 circulating inflammatory proteins in 648 prediagnostic blood samples from two prospective cohorts in Italy and Norway (women only). To preserve the comparability of results and protect against confounding factors, the main statistical analyses were conducted in women from both studies, with replication sought in men (Italian participants). Univariate and penalized regression models revealed for the first time higher blood levels of CDCP1 protein in cases that went on to develop lung cancer compared with controls, irrespective of time to diagnosis, smoking habits, and gender. This association was validated in an additional 450 samples. Associations were stronger for future cases of adenocarcinoma where CDCP1 showed better explanatory performance. Integrative analyses combining gene expression and protein levels of CDCP1 measured in the same individuals suggested a link between CDCP1 and the expression of transcripts of LRRN3 and SEM1. Enrichment analyses indicated a potential role for CDCP1 in pathways related to cell adhesion and mobility, such as the WNT/β-catenin pathway. Overall, this study identifies lung cancer-related dysregulation of CDCP1 expression years before diagnosis. SIGNIFICANCE: Prospective proteomics analyses reveal an association between increased levels of circulating CDCP1 and lung carcinogenesis irrespective of smoking and years before diagnosis, and integrating gene expression indicates potential underlying mechanisms.See related commentary by Itzstein et al., p. 3441.
Collapse
Affiliation(s)
- Sonia Dagnino
- MRC Centre for Environment and Health, Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London, London, United Kingdom
| | - Barbara Bodinier
- MRC Centre for Environment and Health, Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London, London, United Kingdom
| | - Florence Guida
- International Agency for Research on Cancer (IARC), Lyon, France
| | - Karl Smith-Byrne
- International Agency for Research on Cancer (IARC), Lyon, France
| | - Dusan Petrovic
- MRC Centre for Environment and Health, Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London, London, United Kingdom
- Department of Epidemiology and Health Systems (DESS), University Center for General Medicine and Public Health (UNISANTE), Lausanne, Switzerland
- Department and Division of Primary Care Medicine, University Hospital of Geneva, Geneva, Switzerland
| | - Matthew D Whitaker
- MRC Centre for Environment and Health, Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London, London, United Kingdom
| | - Therese Haugdahl Nøst
- Department of Community Medicine, UiT- The Arctic University of Norway, Tromsø, Norway
| | - Claudia Agnoli
- Epidemiology and Prevention Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
| | - Domenico Palli
- Cancer Risk Factors and Life-Style Epidemiology Unit, Institute for Cancer Research, Prevention and Clinical Network - ISPRO, Florence, Italy
| | - Carlotta Sacerdote
- Unit of Cancer Epidemiology, Città della Salute e della Scienza University-Hospital, Turin, Italy
| | - Salvatore Panico
- Department of Clinical Medicine and Surgery, Federico II University, Naples, Italy
| | - Rosario Tumino
- Cancer Registry and Histopathology Department, Provincial Health Authority (ASP) Ragusa, Italy
| | - Matthias B Schulze
- Department of Molecular Epidemiology, German Institute of Human Nutrition Potsdam-Rehbruecke, Nuthetal, Germany
- Institute of Nutritional Science, University of Potsdam, Nuthetal, Germany
| | - Mikael Johansson
- Department of Radiation Sciences, Oncology, Umeå University, Umeå, Sweden
| | | | | | - Paolo Vineis
- MRC Centre for Environment and Health, Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London, London, United Kingdom
- Italian Institute of Technology, Genova, Italy
| | | | - Torkjel M Sandanger
- Department of Community Medicine, UiT- The Arctic University of Norway, Tromsø, Norway
| | - Roel C H Vermeulen
- MRC Centre for Environment and Health, Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London, London, United Kingdom
- Division of Environmental Epidemiology, Institute for Risk Assessment Sciences, Utrecht University, Utrecht, the Netherlands
| | - Marc Chadeau-Hyam
- MRC Centre for Environment and Health, Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London, London, United Kingdom.
- Division of Environmental Epidemiology, Institute for Risk Assessment Sciences, Utrecht University, Utrecht, the Netherlands
| |
Collapse
|
21
|
Palazzo E, Boccella S, Marabese I, Pierretti G, Guida F, Maione S. The Cold Case of Metabotropic Glutamate Receptor 6: Unjust Detention in the Retina? Curr Neuropharmacol 2020; 18:120-125. [PMID: 31573889 PMCID: PMC7324884 DOI: 10.2174/1570159x17666191001141849] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/10/2019] [Revised: 08/20/2019] [Accepted: 09/29/2019] [Indexed: 02/03/2023] Open
Abstract
It is a common opinion that metabotropic glutamate receptor subtype 6 (mGluR6) is expressed exclusively in the retina, and in particular in the dendrites of ON-bipolar cells. Glutamate released in darkness from photoreceptors activates mGluR6, which is negatively associated with a membrane non-selective cation channel, the transient receptor potential melanoma-related 1, TRPM1, resulting in cell hyperpolarization. The evidence that mGluR6 is expressed not only in the retina but also in other tissues and cell populations has accumulated over time. The expression of mGluR6 has been identified in microglia, bone marrow stromal and prostate cancer cells, B lymphocytes, melanocytes and keratinocytes and non-neural tissues such as testis, kidney, cornea, conjunctiva, and eyelid. The receptor also appears to be expressed in brain areas, such as the hypothalamus, cortex, hippocampus, nucleus of tractus solitarius, superior colliculus, axons of the corpus callosum and accessory olfactory bulb. The pharmacological activation of mGluR6 in the hippocampus produced an anxiolytic-like effect and in the periaqueductal gray analgesic potential. This review aims to collect all the evidence on the expression and functioning of mGluR6 outside the retina that has been accumulated over the years for a broader view of the potential of the receptor whose retinal confinement appears understimated.
Collapse
Affiliation(s)
- E Palazzo
- Department of Experimental Medicine, Pharmacology Division, University of Campania "L. Vanvitelli", Naples, Italy
| | - S Boccella
- Department of Experimental Medicine, Pharmacology Division, University of Campania "L. Vanvitelli", Naples, Italy
| | - I Marabese
- Department of Experimental Medicine, Pharmacology Division, University of Campania "L. Vanvitelli", Naples, Italy
| | - G Pierretti
- Department of Plastic Surgery, University of Campania "L. Vanvitelli", Naples, Italy
| | - F Guida
- Department of Experimental Medicine, Pharmacology Division, University of Campania "L. Vanvitelli", Naples, Italy
| | - S Maione
- Department of Experimental Medicine, Pharmacology Division, University of Campania "L. Vanvitelli", Naples, Italy
| |
Collapse
|
22
|
Dagnino S, Bodinier B, Grigoryan H, Rappaport SM, Karimi M, Guida F, Polidoro S, Edmands WIB, Naccarati A, Fiorito G, Sacerdote C, Krogh V, Vermeulen R, Vineis P, Chadeau-Hyam M. Agnostic Cys34-albumin adductomics and DNA methylation: Implication of N-acetylcysteine in lung carcinogenesis years before diagnosis. Int J Cancer 2020; 146:3294-3303. [PMID: 31513294 DOI: 10.1002/ijc.32680] [Citation(s) in RCA: 9] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/07/2019] [Revised: 08/04/2019] [Accepted: 08/19/2019] [Indexed: 01/12/2023]
Abstract
Although smoking and oxidative stress are known contributors to lung carcinogenesis, their mechanisms of action remain poorly understood. To shed light into these mechanisms, we applied a novel approach using Cys34-adductomics in a lung cancer nested case-control study (n = 212). Adductomics profiles were integrated with DNA-methylation data at established smoking-related CpG sites measured in the same individuals. Our analysis identified 42 Cys34-albumin adducts, of which 2 were significantly differentially abundant in cases and controls: adduct of N-acetylcysteine (NAC, p = 4.15 × 10-3 ) and of cysteinyl-glycine (p = 7.89 × 10-3 ). Blood levels of the former were found associated to the methylation levels at 11 smoking-related CpG sites. We detect, for the first time in prospective blood samples, and irrespective of time to diagnosis, decreased levels of NAC adduct in lung cancer cases. Altogether, our results highlight the potential role of these adducts in the oxidative stress response contributing to lung carcinogenesis years before diagnosis.
Collapse
Affiliation(s)
- Sonia Dagnino
- MRC-PHE Centre for Environment and Health, Imperial College London, London, United Kingdom
- Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London, London, United Kingdom
| | - Barbara Bodinier
- MRC-PHE Centre for Environment and Health, Imperial College London, London, United Kingdom
- Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London, London, United Kingdom
| | | | | | - Maryam Karimi
- MRC-PHE Centre for Environment and Health, Imperial College London, London, United Kingdom
- Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London, London, United Kingdom
| | - Florence Guida
- International Agency for Research on Cancer (IARC), Lyon, France
| | | | | | | | | | - Carlotta Sacerdote
- Piedmont Reference Centre for Epidemiology and Cancer Prevention (CPO Piemonte), Turin, Italy
| | - Vittorio Krogh
- Fondazione IRCCS - Istituto Nazionale dei Tumori, Milan, Italy
| | - Roel Vermeulen
- MRC-PHE Centre for Environment and Health, Imperial College London, London, United Kingdom
- Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London, London, United Kingdom
- Division of Environmental Epidemiology, Institute for Risk Assessment Sciences, Utrecht University, Utrecht, The Netherlands
| | - Paolo Vineis
- MRC-PHE Centre for Environment and Health, Imperial College London, London, United Kingdom
- Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London, London, United Kingdom
- IIGM, Italian Institute for Genomic Medicine, Torino, Italy
| | - Marc Chadeau-Hyam
- MRC-PHE Centre for Environment and Health, Imperial College London, London, United Kingdom
- Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London, London, United Kingdom
- Division of Environmental Epidemiology, Institute for Risk Assessment Sciences, Utrecht University, Utrecht, The Netherlands
| |
Collapse
|
23
|
Guida F, Barbato A, Ciocca M, Schwarz M, Lorentini S, Mastella E, Cirrone GAP, Petringa G, Liotta M, Tarabelli De Fatis P, Masi M, Mettivier G, Russo P. Dose intercomparison at Italian hadrontherapy centers. Phys Med 2019; 68:83-87. [PMID: 31765885 DOI: 10.1016/j.ejmp.2019.11.009] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/07/2019] [Revised: 11/12/2019] [Accepted: 11/13/2019] [Indexed: 11/18/2022] Open
Abstract
PURPOSE To perform the first dosimetric intercomparison for proton beams in Italy using ionization chambers, according to the IAEA TRS-398 code of practice. METHODS Measurement sites included: National Center for Oncological Hadron Therapy (CNAO, Pavia), Center for Proton Therapy (CTP, Trento) and Center for Hadron Therapy and for advanced Nuclear Applications (CATANA, Catania). For comparison we also included a 6 MV photon beam produced at Istituti Clinici Scientifici Maugeri (ICSM, Pavia). For proton beams, both single pseudo-monoenergetic layers (in order to obtain a planned dose of 2 Gy at the reference depth of 2 cm in a water phantom) and Spread-out Bragg peaks (SOBP) have been delivered. Measurements were performed with a PTW Farmer 30010-1 and a PTW Advanced Markus type 34,045 ionization chamber. RESULTS Data obtained at CATANA, CNAO and CPT in terms of absorbed dose to water depth show good consistency within the experimental uncertainties, with a weighted mean of 1.99 ± 0.01 Gy and a standard error of 0.003 Gy, with reference to a nominal dose of 2 Gy as designed by the treatment planning system. CONCLUSIONS The results showed a standard deviation of less than 1% for single layer and SOBP beams, for all chambers and a percent deviation less than 1.5% for single layer measurements. The weighted means of the absorbed doses for clinical proton beams (118.19 MeV and 173.61 MeV) are consistent within less than 1%. These results agree within the 1.5% difference considered acceptable for national dose intercomparison.
Collapse
Affiliation(s)
- F Guida
- Università di Napoli Federico II, Dipartimento di Fisica "Ettore Pancini", Napoli, Italy; INFN Sezione di Napoli, Napoli, Italy
| | - A Barbato
- Università di Napoli Federico II, Dipartimento di Fisica "Ettore Pancini", Napoli, Italy; INFN Sezione di Napoli, Napoli, Italy
| | | | - M Schwarz
- Centro di Protonterapia, APSS, Trento, Italy
| | - S Lorentini
- Centro di Protonterapia, APSS, Trento, Italy
| | | | | | - G Petringa
- INFN-LNS, Catania, Italy; Università di Catania, Dipartimento di Fisica ed Astronomia, Catania, Italy
| | - M Liotta
- Istituti Clinici Scientifici Maugeri, Pavia, Italy
| | | | - M Masi
- Università di Napoli Federico II, Dipartimento di Fisica "Ettore Pancini", Napoli, Italy; INFN Sezione di Napoli, Napoli, Italy
| | - G Mettivier
- Università di Napoli Federico II, Dipartimento di Fisica "Ettore Pancini", Napoli, Italy; INFN Sezione di Napoli, Napoli, Italy.
| | - P Russo
- Università di Napoli Federico II, Dipartimento di Fisica "Ettore Pancini", Napoli, Italy; INFN Sezione di Napoli, Napoli, Italy
| |
Collapse
|
24
|
Battram T, Richmond RC, Baglietto L, Haycock PC, Perduca V, Bojesen SE, Gaunt TR, Hemani G, Guida F, Carreras-Torres R, Hung R, Amos CI, Freeman JR, Sandanger TM, Nøst TH, Nordestgaard BG, Teschendorff AE, Polidoro S, Vineis P, Severi G, Hodge AM, Giles GG, Grankvist K, Johansson MB, Johansson M, Davey Smith G, Relton CL. Appraising the causal relevance of DNA methylation for risk of lung cancer. Int J Epidemiol 2019; 48:1493-1504. [PMID: 31549173 PMCID: PMC6857764 DOI: 10.1093/ije/dyz190] [Citation(s) in RCA: 35] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 09/02/2019] [Indexed: 12/31/2022] Open
Abstract
BACKGROUND DNA methylation changes in peripheral blood have recently been identified in relation to lung cancer risk. Some of these changes have been suggested to mediate part of the effect of smoking on lung cancer. However, limitations with conventional mediation analyses mean that the causal nature of these methylation changes has yet to be fully elucidated. METHODS We first performed a meta-analysis of four epigenome-wide association studies (EWAS) of lung cancer (918 cases, 918 controls). Next, we conducted a two-sample Mendelian randomization analysis, using genetic instruments for methylation at CpG sites identified in the EWAS meta-analysis, and 29 863 cases and 55 586 controls from the TRICL-ILCCO lung cancer consortium, to appraise the possible causal role of methylation at these sites on lung cancer. RESULTS Sixteen CpG sites were identified from the EWAS meta-analysis [false discovery rate (FDR) < 0.05], for 14 of which we could identify genetic instruments. Mendelian randomization provided little evidence that DNA methylation in peripheral blood at the 14 CpG sites plays a causal role in lung cancer development (FDR > 0.05), including for cg05575921-AHRR where methylation is strongly associated with both smoke exposure and lung cancer risk. CONCLUSIONS The results contrast with previous observational and mediation analysis, which have made strong claims regarding the causal role of DNA methylation. Thus, previous suggestions of a mediating role of methylation at sites identified in peripheral blood, such as cg05575921-AHRR, could be unfounded. However, this study does not preclude the possibility that differential DNA methylation at other sites is causally involved in lung cancer development, especially within lung tissue.
Collapse
Affiliation(s)
- Thomas Battram
- MRC Integrative Epidemiology Unit
- Population Health Sciences, University of Bristol, Bristol, UK
| | - Rebecca C Richmond
- MRC Integrative Epidemiology Unit
- Population Health Sciences, University of Bristol, Bristol, UK
| | - Laura Baglietto
- Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy
| | - Philip C Haycock
- MRC Integrative Epidemiology Unit
- Population Health Sciences, University of Bristol, Bristol, UK
| | - Vittorio Perduca
- Laboratoire de Mathématiques Appliquées, Université Paris Descartes, Paris, France
| | - Stig E Bojesen
- Department of Clinical Biochemistry, Herlev and Gentofte Hospital, Copenhagen University Hospital, Herlev, Denmark
- Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark
- Copenhagen City Heart Study, Frederiksberg Hospital, Copenhagen University Hospital, Copenhagen, Denmark
| | - Tom R Gaunt
- MRC Integrative Epidemiology Unit
- Population Health Sciences, University of Bristol, Bristol, UK
| | - Gibran Hemani
- MRC Integrative Epidemiology Unit
- Population Health Sciences, University of Bristol, Bristol, UK
| | - Florence Guida
- Genetic Epidemiology Division, International Agency for Research on Cancer, Lyon, France
| | - Robert Carreras-Torres
- Genetic Epidemiology Division, International Agency for Research on Cancer, Lyon, France
| | - Rayjean Hung
- Lunenfeld-Tanenbaum Research Institute, Sinai Health System, Toronto, ON, Canada
| | - Christopher I Amos
- Biomedical Data Science, Geisel School of Medicine, Dartmouth College, Hanover, NH, USA
| | - Joshua R Freeman
- Department of Biostatistics and Epidemiology, University of Massachusetts, Amherst, MA, USA
| | - Torkjel M Sandanger
- Department of Community Medicine,Arctic University of Norway, Tromso, Norway
| | - Therese H Nøst
- Department of Community Medicine,Arctic University of Norway, Tromso, Norway
| | - Børge G Nordestgaard
- Department of Clinical Biochemistry, Herlev and Gentofte Hospital, Copenhagen University Hospital, Herlev, Denmark
- Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark
- Copenhagen City Heart Study, Frederiksberg Hospital, Copenhagen University Hospital, Copenhagen, Denmark
| | - Andrew E Teschendorff
- Department of Women's Cancer, Institute for Women's Health, University College London, London, UK
- UCL Cancer Institute, University College London, London, UK
- Chinese Academy of Sciences (CAS) Key Laboratory of Computational Biology, CAS–Max Planck Gesellschaft (MPG) Partner Institute for Computational Biology, Shanghai, China
| | - Silvia Polidoro
- Molecular and Genetic Epidemiology Unit, Italian Institute for Genomic Medicine (IIGM), Turin, Italy
| | - Paolo Vineis
- Molecular and Genetic Epidemiology Unit, Italian Institute for Genomic Medicine (IIGM), Turin, Italy
- Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London, London, UK
| | - Gianluca Severi
- CESP (Inserm U1018), Facultés de Médicine Université Paris-Sud, UVSQ, Université Paris-Saclay, Gustave Roussy, 94805, Villejuif, France
- Cancer Epidemiology & Intelligence Division, Cancer Council Victoria, Melbourne, VIC, Australia
- Centre for Epidemiology and Biostatistics, Melbourne School of Population & Global Health, University of Melbourne, Melbourne, VIC, Australia
| | - Allison M Hodge
- Cancer Epidemiology & Intelligence Division, Cancer Council Victoria, Melbourne, VIC, Australia
- Centre for Epidemiology and Biostatistics, Melbourne School of Population & Global Health, University of Melbourne, Melbourne, VIC, Australia
| | - Graham G Giles
- Cancer Epidemiology & Intelligence Division, Cancer Council Victoria, Melbourne, VIC, Australia
- Centre for Epidemiology and Biostatistics, Melbourne School of Population & Global Health, University of Melbourne, Melbourne, VIC, Australia
| | | | | | - Mattias Johansson
- Genetic Epidemiology Division, International Agency for Research on Cancer, Lyon, France
| | - George Davey Smith
- MRC Integrative Epidemiology Unit
- Population Health Sciences, University of Bristol, Bristol, UK
| | - Caroline L Relton
- MRC Integrative Epidemiology Unit
- Population Health Sciences, University of Bristol, Bristol, UK
| |
Collapse
|
25
|
Matrat M, Radoï L, Févotte J, Guida F, Cénée S, Cyr D, Sanchez M, Menvielle G, Schmaus A, Marrer E, Luce D, Stücker I. Occupational exposure to wood dust and risk of lung cancer: the ICARE study. Occup Environ Med 2019; 76:901-907. [PMID: 31537717 DOI: 10.1136/oemed-2019-105802] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/08/2019] [Revised: 07/22/2019] [Accepted: 08/25/2019] [Indexed: 11/04/2022]
Abstract
OBJECTIVES In a previous analysis of data from a French population-based case-control study (the Investigation of occupational and environmental CAuses of REspiratory cancers (ICARE) study), 'having ever worked' in wood-related occupations was associated with excess lung cancer risk after adjusting for smoking but not for occupational factors. The present study aimed to investigate the relationship between lung cancer risk and wood dust exposure after adjusting for occupational exposures. METHODS Data were obtained from 2276 cases and 2780 controls on smoking habits and lifelong occupational history, using a standardised questionnaire with a job-specific questionnaire for wood dust exposure. Logistic regression models were used to calculate ORs and 95% CIs adjusted for age, area of residence, tobacco smoking, the number of job periods and exposure to silica, asbestos and diesel motor exhaust (DME). RESULTS No significant association was found between lung cancer and wood dust exposure after adjustment for smoking, asbestos, silica and DME exposures. The risk of lung cancer was slightly increased among those who were exposed to wood dust more than 10 years, and had over 40 years since the first exposure. CONCLUSION Our findings do not provide a strong support to the hypothesis that wood dust exposure is a risk factor for lung cancer. This study showed the importance of taking into account smoking and occupational coexposures in studies on lung cancer and wood dust exposure. Further studies evaluating the level and frequency of exposure during various tasks in woodwork are needed.
Collapse
Affiliation(s)
- Mireille Matrat
- Université Paris-Saclay, Université Paris-Sud, UVSQ, CESP, U1018, Equipe Epidemiologie des Cancers, Gènes et Environnement, INSERM, Villejuif, France .,Faculty of Medicine IFR 10, University Paris-Est Créteil, Créteil, France
| | - Loredana Radoï
- Université Paris-Saclay, Université Paris-Sud, UVSQ, CESP, U1018, Equipe Epidemiologie des Cancers, Gènes et Environnement, INSERM, Villejuif, France.,Faculty of Dental Surgery, University Paris Descartes, Paris, France
| | - Joëlle Févotte
- Unité Mixte de Recherche Epidémiologique et de Surveillance Transport Travail Environnement (UMRESTTE), Université Claude Bernard Lyon 1, Lyon, France
| | - Florence Guida
- Université Paris-Saclay, Université Paris-Sud, UVSQ, CESP, U1018, Equipe Epidemiologie des Cancers, Gènes et Environnement, INSERM, Villejuif, France
| | - Sylvie Cénée
- Université Paris-Saclay, Université Paris-Sud, UVSQ, CESP, U1018, Equipe Epidemiologie des Cancers, Gènes et Environnement, INSERM, Villejuif, France
| | - Diane Cyr
- Population-Based Epidemiological Cohorts Unit (UMS 011) INSERM-UVSQ, INSERM, Villejuif, France.,UMS 011, University of Versailles St-Quentin, Villejuif, France
| | - Marie Sanchez
- Université Paris-Saclay, Université Paris-Sud, UVSQ, CESP, U1018, Equipe Epidemiologie des Cancers, Gènes et Environnement, INSERM, Villejuif, France
| | - Gwenn Menvielle
- Institut Pierre Louis d'Epidémiologie et de Santé Publique (IPLESP, UMR1136), Sorbonne Universités, INSERM, Paris, France
| | - Annie Schmaus
- Population-Based Epidemiological Cohorts Unit (UMS 011) INSERM-UVSQ, INSERM, Villejuif, France.,UMS 011, University of Versailles St-Quentin, Villejuif, France
| | - Emilie Marrer
- Registre des tumeurs du Haut Rhin, Centre Hospitalier de Mulhouse ARER 68, Mulhouse, France
| | - Danièle Luce
- UMRS 1085 IRSET, INSERM, Pointe-à-Pitre, France.,Campus de Fouillole, University of Rennes 1, Pointe à Pitre, France
| | - Isabelle Stücker
- Université Paris-Saclay, Université Paris-Sud, UVSQ, CESP, U1018, Equipe Epidemiologie des Cancers, Gènes et Environnement, INSERM, Villejuif, France
| | | |
Collapse
|
26
|
Rifino N, Rigamonti A, Guida F, Bonato C, De Nobili G, Spena G, Salmaggi A. P14.128 Lack of development of Pneumocystis Jirovecii Pneumonia in a cohort of 103 Italian glioblastoma patients not receiving prophylaxis during post-surgical chemoradiotherapy. Neuro Oncol 2019. [DOI: 10.1093/neuonc/noz126.363] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
BACKGROUND
Patients diagnosed with high grade gliomas (HGG) usually receive surgery, radiation, temozolomide (TMZ) and corticosteroids. A major concern in patients who receive chemoradiotherapy (CRT) is the risk of developing secondary myelosuppression and a related infection during treatment. CRT may also lead to a long-lasting reduction of WBC, associated with early death from tumor progression. Among treatment-related infections, Pneumocystis Jirovecii Pneumonia (PJP) has been reported, since then, PJP prophylaxis has been required by the FDA. However, evidence for PJP during CRT is very limited limited and the rate of PJP still low.
MATERIAL AND METHODS
We did a retrospective, Institutional Review Board-approved cohort study in 103 patients (60 men and 43 women), who were consecutively diagnosed with GBM in “A. Manzoni” Hospital in Lecco during the period May 2007 to December 2013. All of these patients were treated with CRT according to the Stupp protocol without PJP prophylaxis. Haematological toxicities of CRT were assessed according to Common Terminology Criteria for Adverse Events (CTCAE, version 5.0; November 27, 2017). The objective of our study was to investigate the association between CRT and myelosuppression and we evaluated the types of infection contracted on CRT and in particular if the absence of a proper PJP prophylaxis led to an increased rate of PJP.
RESULTS
In our cohort, among 103 patients receiving CRT, 18% developed severe lymphopenia. Among all the subjects enrolled, a total of 9 patients (8.7%) had documented infectious complications during the CRT. Three patients developed community acquired pneumonia. Moreover, we documented three cases of fever without source, two urinary tract infections, one herpes zoster, one herpes simplex 1, one phlegmon and one purulent otitis. However, no one of these patients was diagnosed as PJP despite PJP prophylaxis was not given.
CONCLUSION
In conclusion, our data seem to support a lack of undisputable evidence for a favorable risk/benefit profile in the use of PJP prophylaxis for all newly diagnosed GBM patients undergoing the CRT, also considering the rate of adverse reactions (15.2%) and severe adverse reactions (around 3%, mainly leukopenia) in non-HIV adults receiving trimethoprim/sulphametoxazole for prolonged periods.
Collapse
Affiliation(s)
- N Rifino
- A. Manzoni Hospital, Lecco, Italy
- University of Milano-Bicocca, Milan, Italy
| | | | - F Guida
- A. Manzoni Hospital, Lecco, Italy
| | - C Bonato
- A. Manzoni Hospital, Lecco, Italy
| | | | - G Spena
- A. Manzoni Hospital, Lecco, Italy
| | | |
Collapse
|
27
|
McCrory C, Leahy S, Ribeiro AI, Fraga S, Barros H, Avendano M, Vineis P, Layte R, Baglietto L, Bartley M, Bellone M, Berger E, Bochud M, Candiani G, Carmeli C, Carra L, Castagne R, Chadeau‐Hyam M, Cima S, Costa G, Courtin E, Delpierre C, D'Errico A, Donkin A, Dugué P, Elliott P, Fagherazzi G, Fiorito G, Gandini M, Gares V, Gerbouin‐Rerrolle P, Giles G, Goldberg M, Greco D, Guida F, Hodge A, Karimi M, Karisola P, Kelly M, Kivimaki M, Laine J, Lang T, Laurent A, Lepage B, Lorsch D, Machell G, Mackenbach J, Marmot M, Milne R, Muennig P, Nusselder W, Petrovic D, Polidoro S, Preisig M, Recalcati P, Reinhard E, Ricceri F, Robinson O, Jose Rubio Valverde, Severi G, Simmons T, Stringhini S, Terhi V, Than J, Vergnaud A, Vigna‐Taglianti F, Vollenweider P, Zins M. Maternal educational inequalities in measured body mass index trajectories in three European countries. Paediatr Perinat Epidemiol 2019; 33:226-237. [PMID: 31090081 DOI: 10.1111/ppe.12552] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/01/2018] [Revised: 03/05/2019] [Accepted: 03/16/2019] [Indexed: 12/17/2022]
Abstract
BACKGROUND Social inequalities in the prevalence of childhood overweight and obesity are well-established, but less is known about when the social gradient first emerges and how it evolves across childhood and adolescence. OBJECTIVE This study examines maternal education differentials in children's body mass trajectories in infancy, childhood and adolescence using data from four contemporary European child cohorts. METHODS Prospective data on children's body mass index (BMI) were obtained from four cohort studies-Generation XXI (G21-Portugal), Growing Up in Ireland (GUI) infant and child cohorts, and the Millennium Cohort Study (MCS-UK)-involving a total sample of 41,399 children and 120,140 observations. Children's BMI trajectories were modelled by maternal education level using mixed-effect models. RESULTS Maternal educational inequalities in children's BMI were evident as early as three years of age. Children from lower maternal educational backgrounds were characterised by accelerated BMI growth, and the extent of the disparity was such that boys from primary-educated backgrounds measured 0.42 kg/m2 (95% CI 0.24, 0.60) heavier at 7 years of age in G21, 0.90 kg/m2 (95% CI 0.60, 1.19) heavier at 13 years of age in GUI and 0.75 kg/m2 (95% CI 0.52, 0.97) heavier in MCS at 14 years of age. The corresponding figures for girls were 0.71 kg/m2 (95% CI 0.50, 0.91), 1.31 kg/m2 (95% CI 1.00, 1.62) and 0.76 kg/m2 (95% CI 0.53, 1.00) in G21, GUI and MCS, respectively. CONCLUSIONS Maternal education is a strong predictor of BMI across European nations. Socio-economic differentials emerge early and widen across childhood, highlighting the need for early intervention.
Collapse
Affiliation(s)
- Cathal McCrory
- Department of Medical Gerontology, The Irish Longitudinal Study on Ageing (TILDA), Trinity College Dublin, Dublin, Ireland
| | - Siobhan Leahy
- Faculty of Education and Health Sciences, Health Research Institute, University of Limerick, Limerick, Ireland
| | - Ana Isabel Ribeiro
- EPIUnit - Instituto de Saúde Pública, Universidade do Porto, Porto, Portugal
| | - Silvia Fraga
- EPIUnit - Instituto de Saúde Pública, Universidade do Porto, Porto, Portugal
| | - Henrique Barros
- EPIUnit - Instituto de Saúde Pública, Universidade do Porto, Porto, Portugal
| | - Mauricio Avendano
- Department of Social Science, Health and Medicine, Kings College London, London, UK
| | - Paolo Vineis
- Department of Epidemiology and Biostatistics, MRC-PHE Centre for Environment and Health, School of Public Health, Imperial College London, London, UK
| | - Richard Layte
- Department of Sociology, Trinity College Dublin, Dublin, Ireland
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
28
|
Alfano R, Guida F, Galobardes B, Chadeau-Hyam M, Delpierre C, Ghantous A, Henderson J, Herceg Z, Jain P, Nawrot TS, Relton C, Vineis P, Castagné R, Plusquin M. Socioeconomic position during pregnancy and DNA methylation signatures at three stages across early life: epigenome-wide association studies in the ALSPAC birth cohort. Int J Epidemiol 2019; 48:30-44. [PMID: 30590607 PMCID: PMC6443021 DOI: 10.1093/ije/dyy259] [Citation(s) in RCA: 35] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/16/2018] [Accepted: 11/06/2018] [Indexed: 12/13/2022] Open
Abstract
BACKGROUND Socioeconomic experiences are recognized determinants of health, and recent work has shown that social disadvantages in early life may induce sustained biological changes at molecular level that are detectable later in life. However, the dynamics and persistence of biological embedding of socioeconomic position (SEP) remains vastly unexplored. METHODS Using the data from the ALSPAC birth cohort, we performed epigenome-wide association studies of DNA methylation changes at three life stages (birth, n = 914; childhood at mean age 7.5 years, n = 973; and adolescence at mean age 15.5 years, n = 974), measured using the Illumina HumanMethylation450 Beadchip, in relation to pregnancy SEP indicators (maternal and paternal education and occupation). RESULTS Across the four early life SEP metrics investigated, only maternal education was associated with methylation levels at birth, and four CpGs mapped to SULF1, GLB1L2 and RPUSD1 genes were identified [false discovery rate (FDR)-corrected P-value <0.05]. No epigenetic signature was found associated with maternal education in child samples, but methylation levels at 20 CpG loci were found significantly associated with maternal education in adolescence. Although no overlap was found between the differentially methylated CpG sites at different ages, we identified two CpG sites at birth and during adolescence which are 219 bp apart in the SULF1 gene that encodes an heparan sulphatase involved in modulation of signalling pathways. Using data from an independent birth cohort, the ENVIRONAGE cohort, we were not able to replicate these findings. CONCLUSIONS Taken together, our results suggest that parental SEP, and particularly maternal education, may influence the offspring's methylome at birth and adolescence.
Collapse
Affiliation(s)
- Rossella Alfano
- Department of Epidemiology and Biostatistics, Imperial College London, London, UK
- Medical Research Council-Health Protection Agency Centre for Environment and Health, Imperial College London, London, UK
- Centre for Environmental Sciences, Hasselt University, Diepenbeek, Belgium
| | - Florence Guida
- Department of Epidemiology and Biostatistics, Imperial College London, London, UK
- Medical Research Council-Health Protection Agency Centre for Environment and Health, Imperial College London, London, UK
| | - Bruna Galobardes
- Department of Population Health Sciences, University of Bristol, Bristol, UK
| | - Marc Chadeau-Hyam
- Department of Epidemiology and Biostatistics, Imperial College London, London, UK
- Medical Research Council-Health Protection Agency Centre for Environment and Health, Imperial College London, London, UK
- Division of Environmental Epidemiology, Institute for Risk Assessment Sciences (IRAS), Utrecht University, Utrecht, The Netherlands
| | - Cyrille Delpierre
- INSERM, UMR1027, Université Toulouse III-Paul Sabatier, Toulouse, France
| | - Akram Ghantous
- Epigenetics Group, International Agency for Research on Cancer (IARC), Lyon, France
| | - John Henderson
- Department of Population Health Sciences, University of Bristol, Bristol, UK
| | - Zdenko Herceg
- Epigenetics Group, International Agency for Research on Cancer (IARC), Lyon, France
| | - Pooja Jain
- Department of Epidemiology and Biostatistics, Imperial College London, London, UK
- NIHR-Health Protection Research Unit, Respiratory Infections and Immunity, Imperial College London, London, UK
| | - Tim S Nawrot
- Centre for Environmental Sciences, Hasselt University, Diepenbeek, Belgium
| | - Caroline Relton
- MRC Integrative Epidemiology Unit, University of Bristol, Bristol, UK
| | - Paolo Vineis
- Department of Epidemiology and Biostatistics, Imperial College London, London, UK
- Medical Research Council-Health Protection Agency Centre for Environment and Health, Imperial College London, London, UK
- IIGM, Italian Institute for Genomic Medicine, Turin, Italy
| | - Raphaële Castagné
- Department of Epidemiology and Biostatistics, Imperial College London, London, UK
- INSERM, UMR1027, Université Toulouse III-Paul Sabatier, Toulouse, France
| | - Michelle Plusquin
- Department of Epidemiology and Biostatistics, Imperial College London, London, UK
- Medical Research Council-Health Protection Agency Centre for Environment and Health, Imperial College London, London, UK
- Centre for Environmental Sciences, Hasselt University, Diepenbeek, Belgium
| |
Collapse
|
29
|
Muller DC, Larose TL, Hodge A, Guida F, Langhammer A, Grankvist K, Meyer K, Cai Q, Arslan AA, Zeleniuch-Jacquotte A, Albanes D, Giles GG, Sesso HD, Lee IM, Gaziano JM, Yuan JM, Hoffman Bolton J, Buring JE, Visvanathan K, Le Marchand L, Purdue MP, Caporaso NE, Midttun Ø, Ueland PM, Prentice RL, Weinstein SJ, Stevens VL, Zheng W, Blot WJ, Shu XO, Zhang X, Xiang YB, Koh WP, Hveem K, Thomson CA, Pettinger M, Engström G, Brunnström H, Milne RL, Stampfer MJ, Han J, Johansson M, Brennan P, Severi G, Johansson M. Circulating high sensitivity C reactive protein concentrations and risk of lung cancer: nested case-control study within Lung Cancer Cohort Consortium. BMJ 2019; 364:k4981. [PMID: 30606716 PMCID: PMC6315896 DOI: 10.1136/bmj.k4981] [Citation(s) in RCA: 22] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Accepted: 11/01/2018] [Indexed: 12/21/2022]
Abstract
OBJECTIVES To conduct a comprehensive analysis of prospectively measured circulating high sensitivity C reactive protein (hsCRP) concentration and risk of lung cancer overall, by smoking status (never, former, and current smokers), and histological sub-type. DESIGN Nested case-control study. SETTING 20 population based cohort studies in Asia, Europe, Australia, and the United States. PARTICIPANTS 5299 patients with incident lung cancer, with individually incidence density matched controls. EXPOSURE Circulating hsCRP concentrations in prediagnostic serum or plasma samples. MAIN OUTCOME MEASURE Incident lung cancer diagnosis. RESULTS A positive association between circulating hsCRP concentration and the risk of lung cancer for current (odds ratio associated with a doubling in hsCRP concentration 1.09, 95% confidence interval 1.05 to 1.13) and former smokers (1.09, 1.04 to 1.14) was observed, but not for never smokers (P<0.01 for interaction). This association was strong and consistent across all histological subtypes, except for adenocarcinoma, which was not strongly associated with hsCRP concentration regardless of smoking status (odds ratio for adenocarcinoma overall 0.97, 95% confidence interval 0.94 to 1.01). The association between circulating hsCRP concentration and the risk of lung cancer was strongest in the first two years of follow-up for former and current smokers. Including hsCRP concentration in a risk model, in addition to smoking based variables, did not improve risk discrimination overall, but slightly improved discrimination for cancers diagnosed in the first two years of follow-up. CONCLUSIONS Former and current smokers with higher circulating hsCRP concentrations had a higher risk of lung cancer overall. Circulating hsCRP concentration was not associated with the risk of lung adenocarcinoma. Circulating hsCRP concentration could be a prediagnostic marker of lung cancer rather than a causal risk factor.
Collapse
Affiliation(s)
- David C Muller
- Genetic Epidemiology Group, International Agency for Research on Cancer, Lyon, France
- Department of Epidemiology and Biostatistics, Imperial College London, Norfolk Place, London W2 1PG, UK
| | - Tricia L Larose
- Genetic Epidemiology Group, International Agency for Research on Cancer, Lyon, France
- KG Jebsen Center for Genetic Epidemiology, Department of Public Health and Nursing, Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology, Trondheim, Norway
| | - Allison Hodge
- Cancer Epidemiology and Intelligence Division, Cancer Council Victoria, Melbourne, VIC, Australia
- Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, The University of Melbourne, Parkville, VIC, Australia
| | - Florence Guida
- Genetic Epidemiology Group, International Agency for Research on Cancer, Lyon, France
| | - Arnulf Langhammer
- HUNT Research Centre, Department of Public Health and Nursing, Norwegian University of Science and Technology, Levanger, Norway
| | - Kjell Grankvist
- Department of Medical Biosciences, Umeå University, Umeå, Sweden
| | | | - Qiuyin Cai
- Division of Epidemiology, Department of Medicine, Vanderbilt Epidemiology Center and Vanderbilt-Ingram Cancer, Vanderbilt University School of Medicine, Nashville, TN, USA
| | - Alan A Arslan
- Department of Obstetrics and Gynecology, New York University School of Medicine, New York, NY, USA
- Department of Population Health and Environmental Medicine, New York University School of Medicine, New York, NY, USA
| | - Anne Zeleniuch-Jacquotte
- Department of Population Health and Environmental Medicine, New York University School of Medicine, New York, NY, USA
| | - Demetrius Albanes
- Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
| | - Graham G Giles
- Cancer Epidemiology and Intelligence Division, Cancer Council Victoria, Melbourne, VIC, Australia
- Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, The University of Melbourne, Parkville, VIC, Australia
| | - Howard D Sesso
- Department of Epidemiology, Harvard TH Chan School of Public Health, Boston, MA, USA
- Division of Aging, Department of Medicine, Brigham and Women's Hospital, Boston, MA, USA
- Division of Preventive Medicine, Department of Medicine, Brigham and Women's Hospital, Boston, MA, USA
| | - I-Min Lee
- Department of Epidemiology, Harvard TH Chan School of Public Health, Boston, MA, USA
- Division of Preventive Medicine, Department of Medicine, Brigham and Women's Hospital, Boston, MA, USA
| | - J Michael Gaziano
- Division of Aging, Department of Medicine, Brigham and Women's Hospital, Boston, MA, USA
- Division of Preventive Medicine, Department of Medicine, Brigham and Women's Hospital, Boston, MA, USA
- Boston VA Medical Center, Boston, MA, USA
| | - Jian-Min Yuan
- UPMC Hillman Cancer Center, University of Pittsburgh, USA
- Department of Epidemiology, Graduate School of Public Health, University of Pittsburgh, USA
| | - Judith Hoffman Bolton
- George W Comstock Center for Public Health Research and Prevention Health Monitoring Unit, Department of Epidemiology, Johns Hopkins University Bloomberg School of Public Health, Baltimore, MD, USA
| | - Julie E Buring
- Department of Epidemiology, Harvard TH Chan School of Public Health, Boston, MA, USA
- Division of Preventive Medicine, Department of Medicine, Brigham and Women's Hospital, Boston, MA, USA
| | - Kala Visvanathan
- George W Comstock Center for Public Health Research and Prevention Health Monitoring Unit, Department of Epidemiology, Johns Hopkins University Bloomberg School of Public Health, Baltimore, MD, USA
| | - Loic Le Marchand
- Epidemiology Program, Cancer Research Center of Hawaii, University of Hawaii, Honolulu, HI, USA
| | - Mark P Purdue
- Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, Bethesda, MD, USA
| | - Neil E Caporaso
- Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, Bethesda, MD, USA
| | | | - Per M Ueland
- Department of Clinical Science, University of Bergen, Bergen, Norway
- Laboratory of Clinical Biochemistry, Haukeland University Hospital, Bergen, Norway
| | - Ross L Prentice
- Division of Public Health Sciences Fred Hutchinson Cancer Research Center, Seattle, WA, USA
| | - Stephanie J Weinstein
- Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
| | - Victoria L Stevens
- Epidemiology Research Program, American Cancer Society, Atlanta, GA, USA
| | - Wei Zheng
- Division of Epidemiology, Department of Medicine, Vanderbilt Epidemiology Center and Vanderbilt-Ingram Cancer, Vanderbilt University School of Medicine, Nashville, TN, USA
| | - William J Blot
- Division of Epidemiology, Department of Medicine, Vanderbilt Epidemiology Center and Vanderbilt-Ingram Cancer, Vanderbilt University School of Medicine, Nashville, TN, USA
| | - Xiao-Ou Shu
- Division of Epidemiology, Department of Medicine, Vanderbilt Epidemiology Center and Vanderbilt-Ingram Cancer, Vanderbilt University School of Medicine, Nashville, TN, USA
| | - Xuehong Zhang
- Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA
| | - Yong-Bing Xiang
- State Key Laboratory of Oncogene and Related Genes and Department of Epidemiology, Shanghai Cancer Institute, Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China
| | | | - Kristian Hveem
- KG Jebsen Center for Genetic Epidemiology, Department of Public Health and Nursing, Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology, Trondheim, Norway
- HUNT Research Centre, Department of Public Health and Nursing, Norwegian University of Science and Technology, Levanger, Norway
| | - Cynthia A Thomson
- Health Promotion Sciences, Mel and Enid Zuckerman College of Public Health, University of Arizona, Tucson, AZ, USA
| | - Mary Pettinger
- Division of Public Health Sciences Fred Hutchinson Cancer Research Center, Seattle, WA, USA
| | - Gunnar Engström
- Department of Clinical Science in Malmö, Lund University, Malmö, Sweden
| | - Hans Brunnström
- Pathology, Department of Clinical Sciences Lund, Laboratory Medicine Region Skåne, Lund University, Lund, Sweden
| | - Roger L Milne
- Cancer Epidemiology and Intelligence Division, Cancer Council Victoria, Melbourne, VIC, Australia
- Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, The University of Melbourne, Parkville, VIC, Australia
| | - Meir J Stampfer
- Department of Epidemiology, Harvard TH Chan School of Public Health, Boston, MA, USA
- Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA
- Department of Nutrition, Harvard TH Chan School of Public Health, Boston, MA, USA
| | - Jiali Han
- Department of Epidemiology, Richard M Fairbanks School of Public Health, Indiana University, Indianapolis, IN, USA
- Melvin and Bren Simon Cancer Center, Indiana University, Indianapolis, IN, USA
| | | | - Paul Brennan
- Genetic Epidemiology Group, International Agency for Research on Cancer, Lyon, France
| | - Gianluca Severi
- Cancer Epidemiology and Intelligence Division, Cancer Council Victoria, Melbourne, VIC, Australia
- Italian Institute for Genomic Medicine (IIGM), Torino, Italy
- Centre de Recherche en Epidemiologie et Santé des Populations (CESP) UMR1018 Inserm, Facultés de Médicine Université Paris-Saclay, UPS, UVSQ, Villejuif, France
| | - Mattias Johansson
- Genetic Epidemiology Group, International Agency for Research on Cancer, Lyon, France
| |
Collapse
|
30
|
Monaco L, Guida F, Onofrio G, Di Martino N. Mesenteric cyst and recurrent abdominal pain in a patient with Gorlin-Goltz syndrome: a case report. G Chir 2019; 40:66-69. [PMID: 30771802] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/09/2023]
Abstract
Gorlin-Goltz syndrome (GGS) is an infrequent autosomal do-minant multisystemic disease with complete penetrance and variable expressivity. It is estimated to have an incidence of 1:50,000 - 1:150,000 cases with a M/F = 1:1. This report describes a case of recurrent abdominal pain due to a large mesenteric cyst in a 38-year-old female patient affected by a rare disease: Gorlin-Goltz syndrome.
Collapse
|
31
|
Larose TL, Guida F, Fanidi A, Langhammer A, Kveem K, Stevens VL, Jacobs EJ, Smith-Warner SA, Giovannucci E, Albanes D, Weinstein SJ, Freedman ND, Prentice R, Pettinger M, Thomson CA, Cai Q, Wu J, Blot WJ, Arslan AA, Zeleniuch-Jacquotte A, Le Marchand L, Wilkens LR, Haiman CA, Zhang X, Stampfer MJ, Hodge AM, Giles GG, Severi G, Johansson M, Grankvist K, Wang R, Yuan JM, Gao YT, Koh WP, Shu XO, Zheng W, Xiang YB, Li H, Lan Q, Visvanathan K, Hoffman Bolton J, Ueland PM, Midttun Ø, Caporaso N, Purdue M, Sesso HD, Buring JE, Lee IM, Gaziano JM, Manjer J, Brunnström H, Brennan P, Johansson M. Circulating cotinine concentrations and lung cancer risk in the Lung Cancer Cohort Consortium (LC3). Int J Epidemiol 2018; 47:1760-1771. [PMID: 29901778 PMCID: PMC6280953 DOI: 10.1093/ije/dyy100] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/30/2018] [Accepted: 05/15/2018] [Indexed: 12/21/2022] Open
Abstract
Background Self-reported smoking is the principal measure used to assess lung cancer risk in epidemiological studies. We evaluated if circulating cotinine-a nicotine metabolite and biomarker of recent tobacco exposure-provides additional information on lung cancer risk. Methods The study was conducted in the Lung Cancer Cohort Consortium (LC3) involving 20 prospective cohort studies. Pre-diagnostic serum cotinine concentrations were measured in one laboratory on 5364 lung cancer cases and 5364 individually matched controls. We used conditional logistic regression to evaluate the association between circulating cotinine and lung cancer, and assessed if cotinine provided additional risk-discriminative information compared with self-reported smoking (smoking status, smoking intensity, smoking duration), using receiver-operating characteristic (ROC) curve analysis. Results We observed a strong positive association between cotinine and lung cancer risk for current smokers [odds ratio (OR ) per 500 nmol/L increase in cotinine (OR500): 1.39, 95% confidence interval (CI): 1.32-1.47]. Cotinine concentrations consistent with active smoking (≥115 nmol/L) were common in former smokers (cases: 14.6%; controls: 9.2%) and rare in never smokers (cases: 2.7%; controls: 0.8%). Former and never smokers with cotinine concentrations indicative of active smoking (≥115 nmol/L) also showed increased lung cancer risk. For current smokers, the risk-discriminative performance of cotinine combined with self-reported smoking (AUCintegrated: 0.69, 95% CI: 0.68-0.71) yielded a small improvement over self-reported smoking alone (AUCsmoke: 0.66, 95% CI: 0.64-0.68) (P = 1.5x10-9). Conclusions Circulating cotinine concentrations are consistently associated with lung cancer risk for current smokers and provide additional risk-discriminative information compared with self-report smoking alone.
Collapse
Affiliation(s)
- Tricia L Larose
- Genetic Epidemiology Group, International Agency for Research on Cancer, Lyon, France
- K.G. Jebsen Center for Genetic Epidemiology, Norwegian University of Science and Technology, Trondheim, Norway
| | - Florence Guida
- Genetic Epidemiology Group, International Agency for Research on Cancer, Lyon, France
| | - Anouar Fanidi
- Genetic Epidemiology Group, International Agency for Research on Cancer, Lyon, France
- MRC Epidemiology Unit, University of Cambridge School of Clinical Medicine, Cambridge, UK
| | - Arnulf Langhammer
- HUNT Research Centre, Norwegian University of Science and Technology, Levanger, Norway
| | - Kristian Kveem
- K.G. Jebsen Center for Genetic Epidemiology, Norwegian University of Science and Technology, Trondheim, Norway
- HUNT Research Centre, Norwegian University of Science and Technology, Levanger, Norway
| | - Victoria L Stevens
- Epidemiology Research Program, American Cancer Society, Atlanta, GA, USA
| | - Eric J Jacobs
- Epidemiology Research Program, American Cancer Society, Atlanta, GA, USA
| | - Stephanie A Smith-Warner
- Department of Epidemiology
- Department of Nutrition, Harvard T.H. Chan School of Public Health, Boston, MA, USA
| | - Edward Giovannucci
- Department of Epidemiology
- Department of Nutrition, Harvard T.H. Chan School of Public Health, Boston, MA, USA
- Channing Division of Network Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA, USA
| | - Demetrius Albanes
- Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, MD, USA
| | - Stephanie J Weinstein
- Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, MD, USA
| | - Neal D Freedman
- Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, MD, USA
| | - Ross Prentice
- Fred Hutchinson Cancer Research Center, Seattle, WA, USA
| | - Mary Pettinger
- Fred Hutchinson Cancer Research Center, Seattle, WA, USA
| | | | - Qiuyin Cai
- Vanderbilt Epidemiology Center and Vanderbilt-Ingram Cancer Center, Vanderbilt University School of Medicine, Nashville, TN, USA
| | - Jie Wu
- Vanderbilt Epidemiology Center and Vanderbilt-Ingram Cancer Center, Vanderbilt University School of Medicine, Nashville, TN, USA
| | - William J Blot
- Vanderbilt Epidemiology Center and Vanderbilt-Ingram Cancer Center, Vanderbilt University School of Medicine, Nashville, TN, USA
- International Epidemiology Institute, Rockville, MD, USA
| | - Alan A Arslan
- Departments of Obstetrics and Gynecology, Population Health, and Environmental Medicine
| | | | - Loic Le Marchand
- Epidemiology Program, Cancer Research Center of Hawaii, University of Hawaii, Honolulu, HI, USA
| | - Lynne R Wilkens
- Epidemiology Program, Cancer Research Center of Hawaii, University of Hawaii, Honolulu, HI, USA
| | - Christopher A Haiman
- Epidemiology Program, Cancer Research Center of Hawaii, University of Hawaii, Honolulu, HI, USA
| | - Xuehong Zhang
- Channing Division of Network Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA, USA
| | - Meir J Stampfer
- Department of Epidemiology
- Department of Nutrition, Harvard T.H. Chan School of Public Health, Boston, MA, USA
- Channing Division of Network Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA, USA
| | - Allison M Hodge
- Cancer Epidemiology Centre, Cancer Council Victoria, Melbourne, VIC, Australia
| | - Graham G Giles
- Cancer Epidemiology Centre, Cancer Council Victoria, Melbourne, VIC, Australia
- Centre for Epidemiology and Biostatistics, University of Melbourne, Melbourne, VIC, Australia
| | - Gianluca Severi
- Cancer Epidemiology Centre, Cancer Council Victoria, Melbourne, VIC, Australia
- Italian Institute for Genomic Medicine (IIGM), Torino, Piedmont, Italy
- Centre de Recherche en Epidemiologie et Saé des Populations (CESP) UMR1018 Inserm, Facultés de Médicine Université Paris-Saclay, Villejuif, France
| | - Mikael Johansson
- Department of Radiation Sciences, Umeå University, Umeå, Västerbotten, Sweden
| | - Kjell Grankvist
- Department of Radiation Sciences, Umeå University, Umeå, Västerbotten, Sweden
| | - Renwei Wang
- UPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh, PA, USA
| | - Jian-Min Yuan
- UPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh, PA, USA
- Department of Epidemiology, University of Pittsburgh, Pittsburgh, PA, USA
| | - Yu-Tang Gao
- Department of Epidemiology, Shanghai Jiaotong University, Shanghai, China
| | - Woon-Puay Koh
- Health Services and Systems Research, Duke-NUS Medical School, Singapore
| | - Xiao-Ou Shu
- Department of Medicine, Vanderbilt University School of Medicine, Nashville, TN, USA
| | - Wei Zheng
- Department of Medicine, Vanderbilt University School of Medicine, Nashville, TN, USA
| | - Yong-Bing Xiang
- State Key Laboratory of Oncogenes and Related Genes, Shanghai Cancer Institute, Shanghai Jiaotong University School of Medicine, Shanghai, China
| | - Honglan Li
- Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, USA
| | - Qing Lan
- Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, USA
| | - Kala Visvanathan
- George W. Comstock Center for Public Health Research and Prevention Health Monitoring Unit, Johns Hopkins University Bloomberg School of Public Health, Baltimore, MD, USA
| | - Judith Hoffman Bolton
- George W. Comstock Center for Public Health Research and Prevention Health Monitoring Unit, Johns Hopkins University Bloomberg School of Public Health, Baltimore, MD, USA
| | - Per Magne Ueland
- Department of Clinical Sciences, Laboratory of Clinical Biochemistry, University of Bergen, Bergen, Norway
- Laboratory of Clinical Biochemistry, Haukeland University Hospital, Bergen, Norway
| | | | - Neil Caporaso
- Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, MD, USA
| | - Mark Purdue
- Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, MD, USA
| | - Howard D Sesso
- Department of Epidemiology
- Division of Aging, Brigham and Women’s Hospital, Boston, MA, USA
- Division of Preventive Medicine, Brigham and Women’s Hospital, Boston, MA, USA
| | - Julie E Buring
- Department of Epidemiology
- Division of Preventive Medicine, Brigham and Women’s Hospital, Boston, MA, USA
| | - I-Min Lee
- Department of Epidemiology
- Division of Preventive Medicine, Brigham and Women’s Hospital, Boston, MA, USA
| | - J Michael Gaziano
- Division of Aging, Brigham and Women’s Hospital, Boston, MA, USA
- Division of Preventive Medicine, Brigham and Women’s Hospital, Boston, MA, USA
- Boston VA Medical Center, Boston, MA, USA
| | - Jonas Manjer
- Department of Surgery, Skåne University Hospital Malmö Lund University, Malmö, Sweden
| | - Hans Brunnström
- Department of Clinical Sciences Lund, Laboratory Medicine Region Skåne, Lund University, Lund, Sweden
| | - Paul Brennan
- Genetic Epidemiology Group, International Agency for Research on Cancer, Lyon, France
| | - Mattias Johansson
- Genetic Epidemiology Group, International Agency for Research on Cancer, Lyon, France
| |
Collapse
|
32
|
Sandanger TM, Nøst TH, Guida F, Rylander C, Campanella G, Muller DC, van Dongen J, Boomsma DI, Johansson M, Vineis P, Vermeulen R, Lund E, Chadeau-Hyam M. DNA methylation and associated gene expression in blood prior to lung cancer diagnosis in the Norwegian Women and Cancer cohort. Sci Rep 2018; 8:16714. [PMID: 30425263 PMCID: PMC6233189 DOI: 10.1038/s41598-018-34334-6] [Citation(s) in RCA: 27] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/22/2018] [Accepted: 10/08/2018] [Indexed: 12/20/2022] Open
Abstract
The majority of lung cancer is caused by tobacco smoking, and lung cancer-relevant epigenetic markers have been identified in relation to smoking exposure. Still, smoking-related markers appear to mediate little of the effect of smoking on lung cancer. Thus in order to identify disease-relevant markers and enhance our understanding of pathways, a wide search is warranted. Through an epigenome-wide search within a case-control study (131 cases, 129 controls) nested in a Norwegian prospective cohort of women, we found 25 CpG sites associated with lung cancer. Twenty-three were classified as associated with smoking (LC-AwS), and two were classified as unassociated with smoking (LC-non-AwS), as they remained associated with lung cancer after stringent adjustment for smoking exposure using the comprehensive smoking index (CSI): cg10151248 (PC, CSI-adjusted odds ratio (OR) = 0.34 [0.23-0.52] per standard deviation change in methylation) and cg13482620 (B3GNTL1, CSI-adjusted OR = 0.33 [0.22-0.50]). Analysis among never smokers and a cohort of smoking-discordant twins confirmed the classification of the two LC-non-AwS CpG sites. Gene expression profiles demonstrated that the LC-AwS CpG sites had different enriched pathways than LC-non-AwS sites. In conclusion, using blood-derived DNA methylation and gene expression profiles from a prospective lung cancer case-control study in women, we identified 25 CpG lung cancer markers prior to diagnosis, two of which were LC-non-AwS markers and related to distinct pathways.
Collapse
Affiliation(s)
- Torkjel Manning Sandanger
- Department of Community Medicine, Faculty of Health Sciences, UiT - The Arctic University of Norway, Tromsø, Norway.
| | - Therese Haugdahl Nøst
- Department of Community Medicine, Faculty of Health Sciences, UiT - The Arctic University of Norway, Tromsø, Norway
| | - Florence Guida
- MRC/PHE Centre for Environmental Health, Department of Epidemiology and Biostatistics, Imperial College London, London, United Kingdom
- Genetic Epidemiology Group, International Agency for Research on Cancer, Lyon, France
| | - Charlotta Rylander
- Department of Community Medicine, Faculty of Health Sciences, UiT - The Arctic University of Norway, Tromsø, Norway
| | - Gianluca Campanella
- MRC/PHE Centre for Environmental Health, Department of Epidemiology and Biostatistics, Imperial College London, London, United Kingdom
| | - David C Muller
- MRC/PHE Centre for Environmental Health, Department of Epidemiology and Biostatistics, Imperial College London, London, United Kingdom
| | - Jenny van Dongen
- Netherlands Twin Register, Vrije Universiteit, Department of Biological Psychology, Amsterdam, The Netherlands
| | - Dorret I Boomsma
- Netherlands Twin Register, Vrije Universiteit, Department of Biological Psychology, Amsterdam, The Netherlands
| | - Mattias Johansson
- Genetic Epidemiology Group, International Agency for Research on Cancer, Lyon, France
| | - Paolo Vineis
- MRC/PHE Centre for Environmental Health, Department of Epidemiology and Biostatistics, Imperial College London, London, United Kingdom
- Italian Institute for Genomic Medicine (IIGM), Turin, Italy
| | - Roel Vermeulen
- MRC/PHE Centre for Environmental Health, Department of Epidemiology and Biostatistics, Imperial College London, London, United Kingdom
- Institute for Risk Assessment Sciences (IRAS), Division of Environmental Epidemiology, Utrecht University, Utrecht, The Netherlands
| | - Eiliv Lund
- Department of Community Medicine, Faculty of Health Sciences, UiT - The Arctic University of Norway, Tromsø, Norway
| | - Marc Chadeau-Hyam
- MRC/PHE Centre for Environmental Health, Department of Epidemiology and Biostatistics, Imperial College London, London, United Kingdom
- Institute for Risk Assessment Sciences (IRAS), Division of Environmental Epidemiology, Utrecht University, Utrecht, The Netherlands
| |
Collapse
|
33
|
Guida F, Sun N, Bantis LE, Muller DC, Li P, Taguchi A, Dhillon D, Kundnani DL, Patel NJ, Yan Q, Byrnes G, Moons KGM, Tjønneland A, Panico S, Agnoli C, Vineis P, Palli D, Bueno-de-Mesquita B, Peeters PH, Agudo A, Huerta JM, Dorronsoro M, Barranco MR, Ardanaz E, Travis RC, Byrne KS, Boeing H, Steffen A, Kaaks R, Hüsing A, Trichopoulou A, Lagiou P, La Vecchia C, Severi G, Boutron-Ruault MC, Sandanger TM, Weiderpass E, Nøst TH, Tsilidis K, Riboli E, Grankvist K, Johansson M, Goodman GE, Feng Z, Brennan P, Johansson M, Hanash SM. Assessment of Lung Cancer Risk on the Basis of a Biomarker Panel of Circulating Proteins. JAMA Oncol 2018; 4:e182078. [PMID: 30003238 PMCID: PMC6233784 DOI: 10.1001/jamaoncol.2018.2078] [Citation(s) in RCA: 88] [Impact Index Per Article: 14.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/24/2017] [Accepted: 04/10/2018] [Indexed: 11/14/2022]
Abstract
Importance There is an urgent need to improve lung cancer risk assessment because current screening criteria miss a large proportion of cases. Objective To investigate whether a lung cancer risk prediction model based on a panel of selected circulating protein biomarkers can outperform a traditional risk prediction model and current US screening criteria. Design, Setting, and Participants Prediagnostic samples from 108 ever-smoking patients with lung cancer diagnosed within 1 year after blood collection and samples from 216 smoking-matched controls from the Carotene and Retinol Efficacy Trial (CARET) cohort were used to develop a biomarker risk score based on 4 proteins (cancer antigen 125 [CA125], carcinoembryonic antigen [CEA], cytokeratin-19 fragment [CYFRA 21-1], and the precursor form of surfactant protein B [Pro-SFTPB]). The biomarker score was subsequently validated blindly using absolute risk estimates among 63 ever-smoking patients with lung cancer diagnosed within 1 year after blood collection and 90 matched controls from 2 large European population-based cohorts, the European Prospective Investigation into Cancer and Nutrition (EPIC) and the Northern Sweden Health and Disease Study (NSHDS). Main Outcomes and Measures Model validity in discriminating between future lung cancer cases and controls. Discrimination estimates were weighted to reflect the background populations of EPIC and NSHDS validation studies (area under the receiver-operating characteristics curve [AUC], sensitivity, and specificity). Results In the validation study of 63 ever-smoking patients with lung cancer and 90 matched controls (mean [SD] age, 57.7 [8.7] years; 68.6% men) from EPIC and NSHDS, an integrated risk prediction model that combined smoking exposure with the biomarker score yielded an AUC of 0.83 (95% CI, 0.76-0.90) compared with 0.73 (95% CI, 0.64-0.82) for a model based on smoking exposure alone (P = .003 for difference in AUC). At an overall specificity of 0.83, based on the US Preventive Services Task Force screening criteria, the sensitivity of the integrated risk prediction (biomarker) model was 0.63 compared with 0.43 for the smoking model. Conversely, at an overall sensitivity of 0.42, based on the US Preventive Services Task Force screening criteria, the integrated risk prediction model yielded a specificity of 0.95 compared with 0.86 for the smoking model. Conclusions and Relevance This study provided a proof of principle in showing that a panel of circulating protein biomarkers may improve lung cancer risk assessment and may be used to define eligibility for computed tomography screening.
Collapse
Affiliation(s)
- Florence Guida
- Genetic Epidemiology Group, International Agency for Research on Cancer, Lyon, France
| | - Nan Sun
- Department of Clinical Cancer Prevention, The University of Texas MD Anderson Cancer Center, Houston
| | - Leonidas E Bantis
- Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston
| | - David C Muller
- Department of Epidemiology and Biostatistics, Imperial College London School of Public Health, London, United Kingdom
| | - Peng Li
- Genetic Epidemiology Group, International Agency for Research on Cancer, Lyon, France
- Laboratory of Population Health, Max Planck Institute for Demographic Research, Rostock, Germany
| | - Ayumu Taguchi
- Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston
| | - Dilsher Dhillon
- Department of Clinical Cancer Prevention, The University of Texas MD Anderson Cancer Center, Houston
| | - Deepali L Kundnani
- Department of Clinical Cancer Prevention, The University of Texas MD Anderson Cancer Center, Houston
| | - Nikul J Patel
- Department of Clinical Cancer Prevention, The University of Texas MD Anderson Cancer Center, Houston
| | - Qingxiang Yan
- Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston
| | - Graham Byrnes
- Environment and Radiation Section, International Agency for Research on Cancer, Lyon, France
| | - Karel G M Moons
- Department of Epidemiology, Julius Center for Health Sciences and Primary Care, University Medical Center, Utrecht, Netherlands
| | - Anne Tjønneland
- Unit of Diet, Genes, and Environment, Danish Cancer Society Research Center, Copenhagen
| | - Salvatore Panico
- Department of Clinical Medicine and Surgery, Federico II University, Naples, Italy
| | - Claudia Agnoli
- Epidemiology and Prevention Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
| | - Paolo Vineis
- Department of Epidemiology and Biostatistics, Imperial College London School of Public Health, London, United Kingdom
- Molecular and Genetic Epidemiology Unit, Human Genetics Foundation, Torino, Italy
| | - Domenico Palli
- Cancer Risk Factors and Life-Style Epidemiology Unit, Cancer Research and Prevention Institute-Istituto per lo Studio e la Prevenzione Oncologica, Florence, Italy
| | - Bas Bueno-de-Mesquita
- Department of Epidemiology and Biostatistics, Imperial College London School of Public Health, London, United Kingdom
- Department for Determinants of Chronic Diseases, National Institute for Public Health and the Environment, Bilthoven, Netherlands
| | - Petra H Peeters
- Department of Epidemiology, Julius Center for Health Sciences and Primary Care, University Medical Center, Utrecht, Netherlands
| | - Antonio Agudo
- Unit of Nutirition and Cancer, Cancer Epidemiology Research Program, Catalan Institute of Oncology, Bellvitge Institute for Biomedical Research (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain
| | - Jose M Huerta
- Department of Epidemiology, Murcia Regional Health Council, Biomedical Research Institute of Murcia (IMIB-Arrixaca), Murcia, Spain
- Centro de Investigación Biomédica en Red Epidemiología y Salud Pública (CIBERESP), Madrid, Spain
| | - Miren Dorronsoro
- Public Health Direction and Biodonostia Research Institute-CIBERESP, San Sebastian, Spain
| | - Miguel Rodriguez Barranco
- Centro de Investigación Biomédica en Red Epidemiología y Salud Pública (CIBERESP), Madrid, Spain
- Escuela Andaluza de Salud Pública, Instituto de Investigación Biosanitaria, Granada, Spain
- Hospitales Universitarios de Granada/Universidad de Granada, Granada, Spain
| | - Eva Ardanaz
- Centro de Investigación Biomédica en Red Epidemiología y Salud Pública (CIBERESP), Madrid, Spain
- Epidemiology, Prevention, and Promotion Health Service, Navarra Public Health Institute, Pamplona, Spain
- Instituto de Investigación Sanitaria de Navarra (IdiSNA), Navarra Institute for Health Research, Pamplona, Spain
| | - Ruth C Travis
- Cancer Epidemiology Unit, Nuffield Department of Population Health, University of Oxford, Oxford, United Kingdom
| | - Karl Smith Byrne
- Cancer Epidemiology Unit, Nuffield Department of Population Health, University of Oxford, Oxford, United Kingdom
| | - Heiner Boeing
- Department of Epidemiology, German Institute of Human Nutrition, Potsdam-Rehbruecke
| | - Annika Steffen
- Department of Epidemiology, German Institute of Human Nutrition, Potsdam-Rehbruecke
| | - Rudolf Kaaks
- Divison of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg
| | - Anika Hüsing
- Divison of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg
| | - Antonia Trichopoulou
- Hellenic Health Foundation, Athens, Greece
- World Health Organization Collaborating Center for Nutrition and Health, Unit of Nutritional Epidemiology and Nutrition in Public Health, Department of Hygiene, Epidemiology and Medical Statistics, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece
| | - Pagona Lagiou
- Hellenic Health Foundation, Athens, Greece
- World Health Organization Collaborating Center for Nutrition and Health, Unit of Nutritional Epidemiology and Nutrition in Public Health, Department of Hygiene, Epidemiology and Medical Statistics, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece
- Department of Epidemiology, Harvard School of Public Health, Boston, Massachusetts
| | - Carlo La Vecchia
- Hellenic Health Foundation, Athens, Greece
- Department of Clinical Sciences and Community Health, Università degli Studi di Milano, Milano, Italy
| | - Gianluca Severi
- Molecular and Genetic Epidemiology Unit, Human Genetics Foundation, Torino, Italy
- Université Paris-Saclay, Université Paris-Sud, Université de Versailles Saint-Quentin-en-Yvelines, Centre de Recherche en Epidémiologie et Santé des Populations, National Institute for Health and Medical Research (INSERM), Villejuif, France
| | - Marie-Christine Boutron-Ruault
- Université Paris-Saclay, Université Paris-Sud, Université de Versailles Saint-Quentin-en-Yvelines, Centre de Recherche en Epidémiologie et Santé des Populations, National Institute for Health and Medical Research (INSERM), Villejuif, France
| | - Torkjel M Sandanger
- Department of Community Medicine, Universtiy of Tromsø, Arctic University of Norway, Tromsø
| | - Elisabete Weiderpass
- Department of Community Medicine, Universtiy of Tromsø, Arctic University of Norway, Tromsø
- Department of Research, Cancer Registry of Norway, Institute of Population-Based Cancer Research, Oslo, Norway
- Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden
- Genetic Epidemiology Group, Folkhälsan Research Center, Helsinki, Finland
| | - Therese H Nøst
- Department of Community Medicine, Universtiy of Tromsø, Arctic University of Norway, Tromsø
| | - Kostas Tsilidis
- Department of Epidemiology and Biostatistics, Imperial College London School of Public Health, London, United Kingdom
- Department of Hygiene and Epidemiology, School of Medicine, University of Ioannina, Ioannina, Greece
| | - Elio Riboli
- Department of Epidemiology and Biostatistics, Imperial College London School of Public Health, London, United Kingdom
| | - Kjell Grankvist
- Department of Medical Biosciences, Clinical Chemistry, Umeå University, Umeå, Sweden
| | - Mikael Johansson
- Department of Radiation Sciences, Oncology, Umeå University, Umeå, Sweden
| | - Gary E Goodman
- Public Health Sciences Division, Program in Epidemiology, Fred Hutchinson Cancer Research Center, Seattle, Washington
| | - Ziding Feng
- Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston
| | - Paul Brennan
- Genetic Epidemiology Group, International Agency for Research on Cancer, Lyon, France
| | - Mattias Johansson
- Genetic Epidemiology Group, International Agency for Research on Cancer, Lyon, France
| | - Samir M Hanash
- Department of Clinical Cancer Prevention, The University of Texas MD Anderson Cancer Center, Houston
| |
Collapse
|
34
|
Guida F, Nøst TH, Relton C, Brennan P, Sandanger TM, Chadeau-Hyam M, Johansson M. Abstract 2209: Lung cancer risk prediction using DNA methylation markers. Cancer Res 2018. [DOI: 10.1158/1538-7445.am2018-2209] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
There is an urgent need to improve lung cancer risk assessment as current screening criteria miss a large proportion of cases and result in a high rate of false positives on low-dose CT screening. A fixed effect meta-analyses of 4 epigenome-wide association studies of lung cancer revealed differential DNA methylation at 16 CpG sites (FDR<0.05). The current study aimed to evaluate the extent to which such methylation markers can improve upon smoking-based risk-discrimination among ever smokers. We used data on 662 ever smoking lung cancer case-control pairs from 4 individual prospective cohorts that measured DNA methylation using the Illumina Infinium HumanMethylation450 BeadChip in peripheral blood samples before diagnosis: The Italian part of the European Prospective Investigation into Cancer (EPIC) cohort, the Melbourne Collaborative Cohort (MCCS), the Norwegian Women and Cancer cohort (NOWAC) and the Northern Sweden Health and Disease Study (NSHDS). We adopted a training-testing design where the training was performed on MCCS and NSHDS (N=511 case-control pairs), and the testing on EPIC-Italy and NOWAC (N=151 case-control pairs). Logistic regressions with lasso penalties were performed in the training set to select the best set of CpGs jointly predicting lung cancer. A methylation score was trained by fitting a logistic regression model including the selected CpGs in the training set. A baseline score based on self-reported smoking information (duration, cigarettes/day for current smokers and time since smoking cessation for former smokers) was also developed. The discriminative performances of both scores, as well as integrated model where both smoking and methylation info was incorporated, were assessed by the AUC under the ROC curves in the validation set. The methylation score based on the 9 selected CpG sites yielded an AUC of 0.78 [0.73-0.84] compared to 0.73 [0.68-0.79] for the baseline-smoking score. The model integrating both scores yielded an AUC of 0.79 [0.73-0.84], a notable 0.06-increase in AUC from using the smoking score alone (P=0.008 for difference in AUC). In conclusion, specific methylation biomarkers have a strong potential to improve lung cancer risk assessment and current USPSTF criteria for CT-screening. During the conference, we will present absolute risk estimates based on the integrated risk prediction model.
Citation Format: Florence Guida, Therese H. Nøst, Caroline Relton, Paul Brennan, Torkjel M. Sandanger, Marc Chadeau-Hyam, Mattias Johansson. Lung cancer risk prediction using DNA methylation markers [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2018; 2018 Apr 14-18; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2018;78(13 Suppl):Abstract nr 2209.
Collapse
Affiliation(s)
- Florence Guida
- 1International Agency for Research on Cancer, Lyon, France
| | | | | | - Paul Brennan
- 1International Agency for Research on Cancer, Lyon, France
| | | | | | | |
Collapse
|
35
|
|
36
|
Ben Khedher S, Neri M, Guida F, Matrat M, Cenée S, Sanchez M, Radoi L, Menvielle G, Marrer E, Luce D, Stücker I. Occupational exposure to textile dust and lung cancer risk: Results from the ICARE Study. Am J Ind Med 2018; 61:216-228. [PMID: 29281122 DOI: 10.1002/ajim.22799] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 11/03/2017] [Indexed: 12/13/2022]
Abstract
BACKGROUND To investigate the association of lung cancer with occupational exposure to textile dust and specifically to cotton dust in the population-based case-control study ICARE. METHODS Lifelong occupational history of 2926 cases and 3555 controls was collected using standardized questionnaires, with specific questions for textile dust exposure. Odds ratios (ORs) and 95% confidence intervals (CI) were estimated using unconditional logistic regression models controlling for confounding factors including smoking and asbestos exposure. RESULTS An inverse association between textile dust exposure and lung cancer was found among workers exposed ≥5% of their work time (OR = 0.80, 95%CI = 0.58-1.09), more pronounced for distant exposures (40+ years; up to a 56% reduced risk, statistically significant). The OR of lung cancer was significantly decreased among workers exposed to cotton fibers (OR = 0.70, 95%CI = 0.48-0.97). CONCLUSIONS Our results provide some evidence of a decreased risk of lung cancer associated with exposure to textile dust, particularly cotton.
Collapse
Affiliation(s)
- Soumaya Ben Khedher
- CESP, Fac. de Médecine-Univ. Paris-Sud, Fac. de Médecine-UVSQ, INSERM, Université Paris-Saclay, Villejuif, France
| | - Monica Neri
- CESP, Fac. de Médecine-Univ. Paris-Sud, Fac. de Médecine-UVSQ, INSERM, Université Paris-Saclay, Villejuif, France
| | - Florence Guida
- CESP, Fac. de Médecine-Univ. Paris-Sud, Fac. de Médecine-UVSQ, INSERM, Université Paris-Saclay, Villejuif, France
- International Agency for Research on Cancer (IARC), Lyon Cedex 08, France
| | - Mireille Matrat
- CESP, Fac. de Médecine-Univ. Paris-Sud, Fac. de Médecine-UVSQ, INSERM, Université Paris-Saclay, Villejuif, France
- Faculty of Medicine IFR 10, University Paris Est-Créteil, Créteil Cedex, France
- Centre Hospitalier Intercommunal, Service de Pneumologie et de Pathologie Professionnelle, Créteil Cedex, France
| | - Sylvie Cenée
- CESP, Fac. de Médecine-Univ. Paris-Sud, Fac. de Médecine-UVSQ, INSERM, Université Paris-Saclay, Villejuif, France
| | - Marie Sanchez
- CESP, Fac. de Médecine-Univ. Paris-Sud, Fac. de Médecine-UVSQ, INSERM, Université Paris-Saclay, Villejuif, France
| | - Loredana Radoi
- CESP, Fac. de Médecine-Univ. Paris-Sud, Fac. de Médecine-UVSQ, INSERM, Université Paris-Saclay, Villejuif, France
- Faculty of Dental Surgery, University Paris Descartes, Paris, France
| | - Gwenn Menvielle
- Sorbonne Universités, UPMC Univ Paris 06, INSERM, Institut Pierre Louis d'épidémiologie et de Santé Publique (IPLESP UMRS 1136), Paris, France
| | | | - Danièle Luce
- INSERM, U 1085_IRSET, Pointe-à-Pitre, France
- University of Rennes 1, Rennes, France
| | - Isabelle Stücker
- CESP, Fac. de Médecine-Univ. Paris-Sud, Fac. de Médecine-UVSQ, INSERM, Université Paris-Saclay, Villejuif, France
| |
Collapse
|
37
|
Hovanec J, Siemiatycki J, Conway DI, Olsson A, Stücker I, Guida F, Jöckel KH, Pohlabeln H, Ahrens W, Brüske I, Wichmann HE, Gustavsson P, Consonni D, Merletti F, Richiardi L, Simonato L, Fortes C, Parent ME, McLaughlin J, Demers P, Landi MT, Caporaso N, Tardón A, Zaridze D, Szeszenia-Dabrowska N, Rudnai P, Lissowska J, Fabianova E, Field J, Dumitru RS, Bencko V, Foretova L, Janout V, Kromhout H, Vermeulen R, Boffetta P, Straif K, Schüz J, Kendzia B, Pesch B, Brüning T, Behrens T. Lung cancer and socioeconomic status in a pooled analysis of case-control studies. PLoS One 2018; 13:e0192999. [PMID: 29462211 PMCID: PMC5819792 DOI: 10.1371/journal.pone.0192999] [Citation(s) in RCA: 76] [Impact Index Per Article: 12.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/14/2016] [Accepted: 02/02/2018] [Indexed: 11/19/2022] Open
Abstract
BACKGROUND An association between low socioeconomic status (SES) and lung cancer has been observed in several studies, but often without adequate control for smoking behavior. We studied the association between lung cancer and occupationally derived SES, using data from the international pooled SYNERGY study. METHODS Twelve case-control studies from Europe and Canada were included in the analysis. Based on occupational histories of study participants we measured SES using the International Socio-Economic Index of Occupational Status (ISEI) and the European Socio-economic Classification (ESeC). We divided the ISEI range into categories, using various criteria. Stratifying by gender, we calculated odds ratios (OR) and 95% confidence intervals (CI) by unconditional logistic regression, adjusting for age, study, and smoking behavior. We conducted analyses by histological subtypes of lung cancer and subgroup analyses by study region, birth cohort, education and occupational exposure to known lung carcinogens. RESULTS The analysis dataset included 17,021 cases and 20,885 controls. There was a strong elevated OR between lung cancer and low SES, which was attenuated substantially after adjustment for smoking, however a social gradient persisted. SES differences in lung cancer risk were higher among men (lowest vs. highest SES category: ISEI OR 1.84 (95% CI 1.61-2.09); ESeC OR 1.53 (95% CI 1.44-1.63)), than among women (lowest vs. highest SES category: ISEI OR 1.54 (95% CI 1.20-1.98); ESeC OR 1.34 (95% CI 1.19-1.52)). CONCLUSION SES remained a risk factor for lung cancer after adjustment for smoking behavior.
Collapse
Affiliation(s)
- Jan Hovanec
- Institute for Prevention and Occupational Medicine of the German Social Accident Insurance (IPA), Institute of the Ruhr-Universität Bochum, Bochum, Germany
| | - Jack Siemiatycki
- University of Montreal, Hospital Research Center (CRCHUM) and School of Public Health, Montreal, Canada
| | - David I. Conway
- Dental School, College of Medicine Veterinary and Life Sciences, University of Glasgow, Glasgow, United Kingdom
| | - Ann Olsson
- International Agency for Research on Cancer (IARC), Lyon, France
- Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden
| | - Isabelle Stücker
- Inserm, Centre for Research in Epidemiology and Population Health (CESP), U1018, Environmental Epidemiology of Cancer Team, Villejuif, France
- University Paris-Sud, UMRS 1018, Villejuif, France
| | - Florence Guida
- Inserm, Centre for Research in Epidemiology and Population Health (CESP), U1018, Environmental Epidemiology of Cancer Team, Villejuif, France
- University Paris-Sud, UMRS 1018, Villejuif, France
| | - Karl-Heinz Jöckel
- Institute for Medical Informatics, Biometry and Epidemiology, University Hospital Essen, Essen, Germany
| | - Hermann Pohlabeln
- Leibniz-Institute for Prevention Research and Epidemiology -BIPS GmbH, Bremen, Germany
| | - Wolfgang Ahrens
- Leibniz-Institute for Prevention Research and Epidemiology -BIPS GmbH, Bremen, Germany
- Institute for Statistics, University Bremen, Bremen, Germany
| | - Irene Brüske
- Institute of Epidemiology I, Helmholtz Zentrum München, Neuherberg, Germany
| | - Heinz-Erich Wichmann
- Institute of Epidemiology I, Helmholtz Zentrum München, Neuherberg, Germany
- Institute of Medical Statistics and Epidemiology, Technical University Munich, Munich, Germany
| | - Per Gustavsson
- Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden
| | - Dario Consonni
- Unit of Epidemiology, Fondazione IRCCS Ca' Granda-Ospedale Maggiore Policlinico, Milan, Italy
| | - Franco Merletti
- Unit of Cancer Epidemiology, Department of Medical Sciences, University of Turin, Turin, Italy
| | - Lorenzo Richiardi
- Unit of Cancer Epidemiology, Department of Medical Sciences, University of Turin, Turin, Italy
| | - Lorenzo Simonato
- Laboratory of Public Health and Population Studies, Department of Molecular Medicine, University of Padova, Padova, Italy
| | - Cristina Fortes
- Epidemiology Unit, Istituto Dermopatico dell'Immacolata (IDI-IRCCS-FLMM), Rome, Italy
| | - Marie-Elise Parent
- INRS-Institut Armand-Frappier, Université du Québec, Laval, Québec, Canada
| | | | - Paul Demers
- Cancer Care Ontario, Occupational Cancer Research Centre, Toronto, Canada
| | - Maria Teresa Landi
- National Cancer Institute, Division of Cancer Epidemiology and Genetics, Bethesda, United States of America
| | - Neil Caporaso
- National Cancer Institute, Division of Cancer Epidemiology and Genetics, Bethesda, United States of America
| | - Adonina Tardón
- Molecular Epidemiology of Cancer Unit, University of Oviedo-Ciber de Epidemiologia, CIBERESP, Oviedo, Spain
| | - David Zaridze
- Institute of Carcinogenesis, Russian Cancer Research Centre, Moscow, Russia
| | | | - Peter Rudnai
- National Centre for Public Health, Budapest, Hungary
| | - Jolanta Lissowska
- The M Sklodowska-Curie Cancer Center and Institute of Oncology, Warsaw, Poland
| | - Eleonora Fabianova
- Regional Authority of Public Health, Preventive Occupational Medicine, Banska Bystrica, Slovakia
| | - John Field
- Roy Castle Lung Cancer Research Programme, Cancer Research Centre, University of Liverpool, Liverpool, United Kingdom
| | | | - Vladimir Bencko
- Institute of Hygiene and Epidemiology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic
| | - Lenka Foretova
- Masaryk Memorial Cancer Institute and Medical Faculty of Masaryk University, Dept. of Cancer Epidemiology & Genetics, Brno, Czech Republic
| | - Vladimir Janout
- Palacky University, Faculty of Medicine, Olomouc, Czech Republic
- Department of Epidemiology and Public Health, Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic
| | - Hans Kromhout
- Environmental Epidemiology Division, Institute for Risk Assessment Sciences, Utrecht University, Utrecht, The Netherlands
| | - Roel Vermeulen
- Environmental Epidemiology Division, Institute for Risk Assessment Sciences, Utrecht University, Utrecht, The Netherlands
| | - Paolo Boffetta
- The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York, United States of America
| | - Kurt Straif
- International Agency for Research on Cancer (IARC), Lyon, France
| | - Joachim Schüz
- International Agency for Research on Cancer (IARC), Lyon, France
| | - Benjamin Kendzia
- Institute for Prevention and Occupational Medicine of the German Social Accident Insurance (IPA), Institute of the Ruhr-Universität Bochum, Bochum, Germany
| | - Beate Pesch
- Institute for Prevention and Occupational Medicine of the German Social Accident Insurance (IPA), Institute of the Ruhr-Universität Bochum, Bochum, Germany
| | - Thomas Brüning
- Institute for Prevention and Occupational Medicine of the German Social Accident Insurance (IPA), Institute of the Ruhr-Universität Bochum, Bochum, Germany
| | - Thomas Behrens
- Institute for Prevention and Occupational Medicine of the German Social Accident Insurance (IPA), Institute of the Ruhr-Universität Bochum, Bochum, Germany
| |
Collapse
|
38
|
Guida F, Turco F, Iannotta M, De Gregorio D, Palumbo I, Sarnelli G, Furiano A, Napolitano F, Boccella S, Luongo L, Mazzitelli M, Usiello A, De Filippis F, Iannotti FA, Piscitelli F, Ercolini D, de Novellis V, Di Marzo V, Cuomo R, Maione S. Antibiotic-induced microbiota perturbation causes gut endocannabinoidome changes, hippocampal neuroglial reorganization and depression in mice. Brain Behav Immun 2018; 67:230-245. [PMID: 28890155 DOI: 10.1016/j.bbi.2017.09.001] [Citation(s) in RCA: 205] [Impact Index Per Article: 34.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/22/2017] [Revised: 09/04/2017] [Accepted: 09/04/2017] [Indexed: 12/11/2022] Open
Abstract
The microbiota-gut-brain axis (MGBA) regulates the reciprocal interaction between chronic inflammatory bowel and psychiatric disorders. This interaction involves multiple pathways that are highly debated. We examined the behavioural, biochemical and electrophysiological alterations, as well as gut microbiota composition in a model of antibiotic-induced experimental dysbiosis. Inflammation of the small intestine was also assessed. Mice were exposed to a mixture of antimicrobials for 2weeks. Afterwards, they received Lactobacillus casei DG (LCDG) or a vehicle for up to 7days via oral gavage. Perturbation of microbiota was accompanied by a general inflammatory state and alteration of some endocannabinoidome members in the gut. Behavioural changes, including increased immobility in the tail suspension test and reduced social recognition were observed, and were associated with altered BDNF/TrkB signalling, TRPV1 phosphorylation and neuronal firing in the hippocampus. Moreover, morphological rearrangements of non-neuronal cells in brain areas controlling emotional behaviour were detected. Subsequent probiotic administration, compared with vehicle, counteracted most of these gut inflammatory, behavioural, biochemical and functional alterations. Interestingly, levels of Lachnospiraceae were found to significantly correlate with the behavioural changes observed in dysbiotic mice. Our findings clarify some of the biomolecular and functional modifications leading to the development of affective disorders associated with gut microbiota alterations.
Collapse
Affiliation(s)
- F Guida
- Department of Experimental Medicine, Section of Pharmacology L. Donatelli, Università degli Studi della Campania "Luigi Vanvitelli", Naples, Italy; Endocannabinoid Research Group, Italy.
| | - F Turco
- Department of Clinical Medicine and Surgery, Federico II University of Naples, Naples, Italy
| | - M Iannotta
- Department of Experimental Medicine, Section of Pharmacology L. Donatelli, Università degli Studi della Campania "Luigi Vanvitelli", Naples, Italy
| | - D De Gregorio
- Department of Experimental Medicine, Section of Pharmacology L. Donatelli, Università degli Studi della Campania "Luigi Vanvitelli", Naples, Italy
| | - I Palumbo
- Department of Clinical Medicine and Surgery, Federico II University of Naples, Naples, Italy
| | - G Sarnelli
- Department of Clinical Medicine and Surgery, Federico II University of Naples, Naples, Italy
| | - A Furiano
- Department of Experimental Medicine, Section of Pharmacology L. Donatelli, Università degli Studi della Campania "Luigi Vanvitelli", Naples, Italy
| | - F Napolitano
- Ceinge Biotecnologie Avanzate, Naples, Italy; Department of Molecular Medicine and Medical Biotechnology, University of Naples "Federico II", Naples, Italy
| | - S Boccella
- Department of Experimental Medicine, Section of Pharmacology L. Donatelli, Università degli Studi della Campania "Luigi Vanvitelli", Naples, Italy
| | - L Luongo
- Department of Experimental Medicine, Section of Pharmacology L. Donatelli, Università degli Studi della Campania "Luigi Vanvitelli", Naples, Italy; Endocannabinoid Research Group, Italy
| | - M Mazzitelli
- Department of Experimental Medicine, Section of Pharmacology L. Donatelli, Università degli Studi della Campania "Luigi Vanvitelli", Naples, Italy
| | - A Usiello
- Ceinge Biotecnologie Avanzate, Naples, Italy; Department of Environmental, Biological and Pharmaceutical Sciences and Technologies, Università degli Studi della Campania "Luigi Vanvitelli", Caserta, Italy
| | - F De Filippis
- Department of Agricultural Sciences, Division of Microbiology, University of Naples Federico II, Portici, Italy; Task Force on Microbiome Studies, University of Naples Federico II, Italy
| | - F A Iannotti
- Institute of Biomolecular Chemistry, Consiglio Nazionale delle Ricerche, Pozzuoli, Italy; Endocannabinoid Research Group, Italy
| | - F Piscitelli
- Institute of Biomolecular Chemistry, Consiglio Nazionale delle Ricerche, Pozzuoli, Italy; Endocannabinoid Research Group, Italy
| | - D Ercolini
- Department of Agricultural Sciences, Division of Microbiology, University of Naples Federico II, Portici, Italy; Task Force on Microbiome Studies, University of Naples Federico II, Italy
| | - V de Novellis
- Department of Experimental Medicine, Section of Pharmacology L. Donatelli, Università degli Studi della Campania "Luigi Vanvitelli", Naples, Italy; Endocannabinoid Research Group, Italy
| | - V Di Marzo
- Institute of Biomolecular Chemistry, Consiglio Nazionale delle Ricerche, Pozzuoli, Italy; Endocannabinoid Research Group, Italy.
| | - R Cuomo
- Department of Clinical Medicine and Surgery, Federico II University of Naples, Naples, Italy; Task Force on Microbiome Studies, University of Naples Federico II, Italy
| | - S Maione
- Department of Experimental Medicine, Section of Pharmacology L. Donatelli, Università degli Studi della Campania "Luigi Vanvitelli", Naples, Italy; Endocannabinoid Research Group, Italy.
| |
Collapse
|
39
|
Larose T, Guida F, Brennan P, Johansson M. P2.06-001 Circulating Cotinine Concentrations, Self-Reported Smoking, and Lung Cancer Risk in the Lung Cancer Cohort Consortium (LC3). J Thorac Oncol 2017. [DOI: 10.1016/j.jtho.2017.11.049] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
40
|
Plusquin M, Guida F, Polidoro S, Vermeulen R, Raaschou-Nielsen O, Campanella G, Hoek G, Kyrtopoulos SA, Georgiadis P, Naccarati A, Sacerdote C, Krogh V, Bas Bueno-de-Mesquita H, Monique Verschuren WM, Sayols-Baixeras S, Panni T, Peters A, Hebels DGAJ, Kleinjans J, Vineis P, Chadeau-Hyam M. DNA methylation and exposure to ambient air pollution in two prospective cohorts. Environ Int 2017; 108:127-136. [PMID: 28843141 PMCID: PMC6139298 DOI: 10.1016/j.envint.2017.08.006] [Citation(s) in RCA: 89] [Impact Index Per Article: 12.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 01/30/2017] [Revised: 08/09/2017] [Accepted: 08/09/2017] [Indexed: 05/17/2023]
Abstract
Long-term exposure to air pollution has been associated with several adverse health effects including cardiovascular, respiratory diseases and cancers. However, underlying molecular alterations remain to be further investigated. The aim of this study is to investigate the effects of long-term exposure to air pollutants on (a) average DNA methylation at functional regions and, (b) individual differentially methylated CpG sites. An assumption is that omic measurements, including the methylome, are more sensitive to low doses than hard health outcomes. This study included blood-derived DNA methylation (Illumina-HM450 methylation) for 454 Italian and 159 Dutch participants from the European Prospective Investigation into Cancer and Nutrition (EPIC). Long-term air pollution exposure levels, including NO2, NOx, PM2.5, PMcoarse, PM10, PM2.5 absorbance (soot) were estimated using models developed within the ESCAPE project, and back-extrapolated to the time of sampling when possible. We meta-analysed the associations between the air pollutants and global DNA methylation, methylation in functional regions and epigenome-wide methylation. CpG sites found differentially methylated with air pollution were further investigated for functional interpretation in an independent population (EnviroGenoMarkers project), where (N=613) participants had both methylation and gene expression data available. Exposure to NO2 was associated with a significant global somatic hypomethylation (p-value=0.014). Hypomethylation of CpG island's shores and shelves and gene bodies was significantly associated with higher exposures to NO2 and NOx. Meta-analysing the epigenome-wide findings of the 2 cohorts did not show genome-wide significant associations at single CpG site level. However, several significant CpG were found if the analyses were separated by countries. By regressing gene expression levels against methylation levels of the exposure-related CpG sites, we identified several significant CpG-transcript pairs and highlighted 5 enriched pathways for NO2 and 9 for NOx mainly related to the immune system and its regulation. Our findings support results on global hypomethylation associated with air pollution, and suggest that the shores and shelves of CpG islands and gene bodies are mostly affected by higher exposure to NO2 and NOx. Functional differences in the immune system were suggested by transcriptome analyses.
Collapse
Affiliation(s)
- Michelle Plusquin
- Department of Epidemiology and Biostatistics, The School of Public Health, Imperial College London, London, United Kingdom; Medical Research Council-Health Protection Agency Centre for Environment and Health, Imperial College London, London, United Kingdom; Centre for Environmental Sciences, Hasselt University, Hasselt, Belgium
| | - Florence Guida
- Department of Epidemiology and Biostatistics, The School of Public Health, Imperial College London, London, United Kingdom; Medical Research Council-Health Protection Agency Centre for Environment and Health, Imperial College London, London, United Kingdom
| | | | - Roel Vermeulen
- Medical Research Council-Health Protection Agency Centre for Environment and Health, Imperial College London, London, United Kingdom; Institute for Risk Assessment Sciences (IRAS), Division of Environmental Epidemiology, Utrecht University, Utrecht, The Netherlands
| | - Ole Raaschou-Nielsen
- Danish Cancer Society Research Center, Copenhagen, Denmark; Department of Environmental Science, Aarhus University, Roskilde, Denmark
| | - Gianluca Campanella
- Department of Epidemiology and Biostatistics, The School of Public Health, Imperial College London, London, United Kingdom; Medical Research Council-Health Protection Agency Centre for Environment and Health, Imperial College London, London, United Kingdom
| | - Gerard Hoek
- Institute for Risk Assessment Sciences (IRAS), Division of Environmental Epidemiology, Utrecht University, Utrecht, The Netherlands
| | - Soterios A Kyrtopoulos
- National Hellenic Research Foundation, Institute of Biology, Medicinal Chemistry and Biotechnology, 48 Vas. Constantinou Ave., Athens 11635, Greece
| | - Panagiotis Georgiadis
- National Hellenic Research Foundation, Institute of Biology, Medicinal Chemistry and Biotechnology, 48 Vas. Constantinou Ave., Athens 11635, Greece
| | | | - Carlotta Sacerdote
- Unit of Cancer Epidemiology-CERMS, Department of Medical Sciences, University of Turin and Città Della Salute E Della Scienza Hospital, Turin, Italy
| | - Vittorio Krogh
- Epidemiology Unit, Department of Preventive and Predictive Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
| | - H Bas Bueno-de-Mesquita
- Department of Epidemiology and Biostatistics, The School of Public Health, Imperial College London, London, United Kingdom; Department for Determinants of Chronic Diseases (DCD), National Institute for Public Health and the Environment (RIVM), Bilthoven, The Netherlands; Department of Social & Preventive Medicine, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia
| | - W M Monique Verschuren
- Julius Center for Health Sciences and Primary Care, UMC Utrecht, Utrecht, The Netherlands; Centre for Nutrition, Prevention and Health Services, National Institute for Public Health and the Environment, Bilthoven, The Netherlands
| | - Sergi Sayols-Baixeras
- Cardiovascular Epidemiology and Genetics Research Group, IMIM (Hospital del Mar Medical Research Institute), 08003 Barcelona, Catalonia, Spain; Universitat Pompeu Fabra (UPF), 08003 Barcelona, Catalonia, Spain
| | - Tommaso Panni
- Institute of Epidemiology II, Helmholtz Zentrum München - German Research Center for Environmental Health, Neuherberg, Germany
| | - Annette Peters
- Institute of Epidemiology II, Helmholtz Zentrum München - German Research Center for Environmental Health, Neuherberg, Germany
| | - Dennie G A J Hebels
- Department of Toxicogenomics, Maastricht University, The Netherlands; Department of Cell Biology-Inspired Tissue Engineering, MERLN Institute, Maastricht University, Maastricht, The Netherlands
| | - Jos Kleinjans
- Department of Toxicogenomics, Maastricht University, The Netherlands
| | - Paolo Vineis
- Department of Epidemiology and Biostatistics, The School of Public Health, Imperial College London, London, United Kingdom; Medical Research Council-Health Protection Agency Centre for Environment and Health, Imperial College London, London, United Kingdom; IIGM, Italian Institute for Genomic Medicine, Turin, Italy
| | - Marc Chadeau-Hyam
- Department of Epidemiology and Biostatistics, The School of Public Health, Imperial College London, London, United Kingdom; Medical Research Council-Health Protection Agency Centre for Environment and Health, Imperial College London, London, United Kingdom; Institute for Risk Assessment Sciences (IRAS), Division of Environmental Epidemiology, Utrecht University, Utrecht, The Netherlands.
| |
Collapse
|
41
|
Ben Khedher S, Neri M, Guida F, Matrat M, Cenée S, Sanchez M, Menvielle G, Molinié F, Luce D, Stücker I. Occupational exposure to endotoxins and lung cancer risk: results of the ICARE Study. Occup Environ Med 2017; 74:667-679. [PMID: 28490662 PMCID: PMC5574383 DOI: 10.1136/oemed-2016-104117] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/28/2016] [Revised: 04/06/2017] [Accepted: 04/13/2017] [Indexed: 01/21/2023]
Abstract
Objectives To investigate the role of occupational exposure to endotoxins in lung cancer in a French population-based case–control study (ICARE (Investigation of occupational and environmental causes of respiratory cancers)). Methods Detailed information was collected on the occupational history and smoking habits from 2926 patients with histologically confirmed lung cancer and 3555 matched controls. We evaluated each subject’s endotoxin exposure after cross referencing International Standard Classification of Occupations (ISCO) codes (for job tasks) and Nomenclature d'Activités Françaises (NAF) codes (for activity sectors). Endotoxin exposure levels were attributed to each work environment based on literature reports. ORs and 95% CIs were estimated using unconditional logistic regression models and controlled for main confounding factors. Results An inverse association between exposure to endotoxins and lung cancer was found (OR=0.80, 95% CI 0.66 to 0.95). Negative trends were shown with duration and cumulative exposure, and the risk was decreased decades after exposure cessation (all statistically significant). Lung cancer risk was particularly reduced among workers highly exposed (eg, in dairy, cattle, poultry, pig farms), but also in those weakly exposed (eg, in waste treatment). Statistically significant interactions were shown with smoking, and never/light smokers were more sensitive to an endotoxin effect than heavy smokers (eg, OR=0.14, 95% CI 0.06 to 0.32 and OR=0.80, 95% CI 0.45 to 1.40, respectively, for the quartiles with the highest cumulative exposure, compared with those never exposed). Pronounced inverse associations were shown with adenocarcinoma histological subtype (OR=0.37, 95% CI 0.25 to 0.55 in the highly exposed). Conclusions Our findings suggest that exposure to endotoxins, even at a low level, reduces the risk of lung cancer.
Collapse
Affiliation(s)
- Soumaya Ben Khedher
- Centre de recherche en Epidemiologie et Sante des Populations, Universite Paris-Sud, illejuif, France
| | - Monica Neri
- Centre de recherche en Epidemiologie et Sante des Populations, Universite Paris-Sud, illejuif, France
| | - Florence Guida
- Department of Epidemiology and Biostatistics, Imperial College London, MRC-PHE Centre for Environment and Health, School of Public Health, London, UK
| | - Mireille Matrat
- Centre de recherche en Epidemiologie et Sante des Populations, Universite Paris-Sud, illejuif, France.,Faculty of medicine, University Paris Est-Créteil, Créteil Cedex, France.,Centre Hospitalier Intercommunal, Service de Pneumologie et de Pathologie Professionnelle, Créteil Cedex, France
| | - Sylvie Cenée
- Centre de recherche en Epidemiologie et Sante des Populations, Universite Paris-Sud, illejuif, France
| | - Marie Sanchez
- Centre de recherche en Epidemiologie et Sante des Populations, Universite Paris-Sud, illejuif, France
| | - Gwenn Menvielle
- Department of Social Epidemiology, Sorbonne University, Paris, France
| | | | - Danièle Luce
- Faculté de Médecine, INSERM, Pointe-à-Pitre, France.,University of Rennes, Rennes, France
| | - Isabelle Stücker
- Centre de recherche en Epidemiologie et Sante des Populations, Universite Paris-Sud, illejuif, France
| | | |
Collapse
|
42
|
Stringhini S, Carmeli C, Jokela M, Avendaño M, Muennig P, Guida F, Ricceri F, d'Errico A, Barros H, Bochud M, Chadeau-Hyam M, Clavel-Chapelon F, Costa G, Delpierre C, Fraga S, Goldberg M, Giles GG, Krogh V, Kelly-Irving M, Layte R, Lasserre AM, Marmot MG, Preisig M, Shipley MJ, Vollenweider P, Zins M, Kawachi I, Steptoe A, Mackenbach JP, Vineis P, Kivimäki M. Socioeconomic status and the 25 × 25 risk factors as determinants of premature mortality: a multicohort study and meta-analysis of 1·7 million men and women. Lancet 2017; 389:1229-1237. [PMID: 28159391 PMCID: PMC5368415 DOI: 10.1016/s0140-6736(16)32380-7] [Citation(s) in RCA: 685] [Impact Index Per Article: 97.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/05/2016] [Revised: 10/05/2016] [Accepted: 11/01/2016] [Indexed: 12/15/2022]
Abstract
BACKGROUND In 2011, WHO member states signed up to the 25 × 25 initiative, a plan to cut mortality due to non-communicable diseases by 25% by 2025. However, socioeconomic factors influencing non-communicable diseases have not been included in the plan. In this study, we aimed to compare the contribution of socioeconomic status to mortality and years-of-life-lost with that of the 25 × 25 conventional risk factors. METHODS We did a multicohort study and meta-analysis with individual-level data from 48 independent prospective cohort studies with information about socioeconomic status, indexed by occupational position, 25 × 25 risk factors (high alcohol intake, physical inactivity, current smoking, hypertension, diabetes, and obesity), and mortality, for a total population of 1 751 479 (54% women) from seven high-income WHO member countries. We estimated the association of socioeconomic status and the 25 × 25 risk factors with all-cause mortality and cause-specific mortality by calculating minimally adjusted and mutually adjusted hazard ratios [HR] and 95% CIs. We also estimated the population attributable fraction and the years of life lost due to suboptimal risk factors. FINDINGS During 26·6 million person-years at risk (mean follow-up 13·3 years [SD 6·4 years]), 310 277 participants died. HR for the 25 × 25 risk factors and mortality varied between 1·04 (95% CI 0·98-1·11) for obesity in men and 2 ·17 (2·06-2·29) for current smoking in men. Participants with low socioeconomic status had greater mortality compared with those with high socioeconomic status (HR 1·42, 95% CI 1·38-1·45 for men; 1·34, 1·28-1·39 for women); this association remained significant in mutually adjusted models that included the 25 × 25 factors (HR 1·26, 1·21-1·32, men and women combined). The population attributable fraction was highest for smoking, followed by physical inactivity then socioeconomic status. Low socioeconomic status was associated with a 2·1-year reduction in life expectancy between ages 40 and 85 years, the corresponding years-of-life-lost were 0·5 years for high alcohol intake, 0·7 years for obesity, 3·9 years for diabetes, 1·6 years for hypertension, 2·4 years for physical inactivity, and 4·8 years for current smoking. INTERPRETATION Socioeconomic circumstances, in addition to the 25 × 25 factors, should be targeted by local and global health strategies and health risk surveillance to reduce mortality. FUNDING European Commission, Swiss State Secretariat for Education, Swiss National Science Foundation, the Medical Research Council, NordForsk, Portuguese Foundation for Science and Technology.
Collapse
Affiliation(s)
- Silvia Stringhini
- Institute of Social and Preventive Medicine and Departments of Psychiatry and Internal Medicine, Lausanne University Hospital, Lausanne, Switzerland.
| | - Cristian Carmeli
- Institute of Social and Preventive Medicine and Departments of Psychiatry and Internal Medicine, Lausanne University Hospital, Lausanne, Switzerland
| | - Markus Jokela
- Institute of Behavioural Sciences, University of Helsinki, Helsinki, Finland
| | - Mauricio Avendaño
- Department of Global Health and Social Medicine, King's College London, London, UK; Harvard T H Chan School of Public Health, Boston MA, USA
| | - Peter Muennig
- Global Research Analytics for Population Health, Health Policy and Management, Columbia University, New York, NY, USA
| | - Florence Guida
- MRC-PHE Centre for Environment and Health, School of Public Health, Department of Epidemiology and Biostatistics, Imperial College London, London, UK
| | - Fulvio Ricceri
- Epidemiology Unit, ASL TO3 Piedmont Region, Grugliasco, Italy
| | - Angelo d'Errico
- Epidemiology Unit, ASL TO3 Piedmont Region, Grugliasco, Italy
| | - Henrique Barros
- EPIUnit-Institute of Public Health, University of Porto, Porto, Portugal; Department of Clinical Epidemiology, Predictive Medicine and Public Health, University of Porto Medical School, Porto, Portugal
| | - Murielle Bochud
- Institute of Social and Preventive Medicine and Departments of Psychiatry and Internal Medicine, Lausanne University Hospital, Lausanne, Switzerland
| | - Marc Chadeau-Hyam
- MRC-PHE Centre for Environment and Health, School of Public Health, Department of Epidemiology and Biostatistics, Imperial College London, London, UK
| | | | - Giuseppe Costa
- Department of Biological and Clinical Sciences, Universtiy of Turin, Turin, Italy
| | - Cyrille Delpierre
- INSERM, UMR1027, Toulouse, France; Université Toulouse III Paul-Sabatier, UMR1027, Toulouse, France
| | - Silvia Fraga
- EPIUnit-Institute of Public Health, University of Porto, Porto, Portugal
| | - Marcel Goldberg
- Population-based Epidemiological Cohorts Unit, INSERM UMS 11, Villejuif, France; Paris Descartes University, Paris, France
| | - Graham G Giles
- Cancer Epidemiology Centre, Cancer Council Victoria, Melbourne, VIC, Australia
| | - Vittorio Krogh
- Epidemiology and Prevention Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
| | - Michelle Kelly-Irving
- INSERM, UMR1027, Toulouse, France; Université Toulouse III Paul-Sabatier, UMR1027, Toulouse, France
| | - Richard Layte
- Department of Sociology, Trinity College Dublin, Dublin, Ireland
| | - Aurélie M Lasserre
- Institute of Social and Preventive Medicine and Departments of Psychiatry and Internal Medicine, Lausanne University Hospital, Lausanne, Switzerland
| | - Michael G Marmot
- University College London, Department of Epidemiology and Public Health, London, UK
| | - Martin Preisig
- Institute of Social and Preventive Medicine and Departments of Psychiatry and Internal Medicine, Lausanne University Hospital, Lausanne, Switzerland
| | - Martin J Shipley
- University College London, Department of Epidemiology and Public Health, London, UK
| | - Peter Vollenweider
- Institute of Social and Preventive Medicine and Departments of Psychiatry and Internal Medicine, Lausanne University Hospital, Lausanne, Switzerland
| | - Marie Zins
- Population-based Epidemiological Cohorts Unit, INSERM UMS 11, Villejuif, France; Paris Descartes University, Paris, France
| | - Ichiro Kawachi
- Harvard T H Chan School of Public Health, Boston MA, USA
| | - Andrew Steptoe
- University College London, Department of Epidemiology and Public Health, London, UK
| | - Johan P Mackenbach
- Department of Public Health, Erasmus University Medical Center, Rotterdam, Netherlands
| | - Paolo Vineis
- MRC-PHE Centre for Environment and Health, School of Public Health, Department of Epidemiology and Biostatistics, Imperial College London, London, UK
| | - Mika Kivimäki
- University College London, Department of Epidemiology and Public Health, London, UK; Clinicum, Faculty of Medicine, University of Helsinki, Finland
| |
Collapse
|
43
|
Guida F, Luongo L, Boccella S, Giordano ME, Romano R, Bellini G, Manzo I, Furiano A, Rizzo A, Imperatore R, Iannotti FA, D'Aniello E, Piscitelli F, Sca Rossi F, Cristino L, Di Marzo V, de Novellis V, Maione S. Palmitoylethanolamide induces microglia changes associated with increased migration and phagocytic activity: involvement of the CB2 receptor. Sci Rep 2017; 7:375. [PMID: 28336953 PMCID: PMC5428303 DOI: 10.1038/s41598-017-00342-1] [Citation(s) in RCA: 85] [Impact Index Per Article: 12.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/15/2016] [Accepted: 02/22/2017] [Indexed: 12/22/2022] Open
Abstract
The endogenous fatty acid amide palmitoylethanolamide (PEA) has been shown to exert anti-inflammatory actions mainly through inhibition of the release of pro-inflammatory molecules from mast cells, monocytes and macrophages. Indirect activation of the endocannabinoid (eCB) system is among the several mechanisms of action that have been proposed to underlie the different effects of PEA in vivo. In this study, we used cultured rat microglia and human macrophages to evaluate whether PEA affects eCB signaling. PEA was found to increase CB2 mRNA and protein expression through peroxisome proliferator-activated receptor-α (PPAR-α) activation. This novel gene regulation mechanism was demonstrated through: (i) pharmacological PPAR-α manipulation, (ii) PPAR-α mRNA silencing, (iii) chromatin immunoprecipitation. Moreover, exposure to PEA induced morphological changes associated with a reactive microglial phenotype, including increased phagocytosis and migratory activity. Our findings suggest indirect regulation of microglial CB2R expression as a new possible mechanism underlying the effects of PEA. PEA can be explored as a useful tool for preventing/treating the symptoms associated with neuroinflammation in CNS disorders.
Collapse
Affiliation(s)
- F Guida
- Department of Experimental Medicine, Section of Pharmacology L. Donatelli, Università degli Studi della Campania "Luigi Vanvitelli" (Ex SUN), 80138, Naples, Italy.,Endocannabinoid Research Group, Institute of Biomolecular Chemistry, C.N.R., Pozzuoli, Italy
| | - L Luongo
- Department of Experimental Medicine, Section of Pharmacology L. Donatelli, Università degli Studi della Campania "Luigi Vanvitelli" (Ex SUN), 80138, Naples, Italy.,Endocannabinoid Research Group, Institute of Biomolecular Chemistry, C.N.R., Pozzuoli, Italy
| | - S Boccella
- Department of Experimental Medicine, Section of Pharmacology L. Donatelli, Università degli Studi della Campania "Luigi Vanvitelli" (Ex SUN), 80138, Naples, Italy
| | - M E Giordano
- Department of Experimental Medicine, Section of Pharmacology L. Donatelli, Università degli Studi della Campania "Luigi Vanvitelli" (Ex SUN), 80138, Naples, Italy
| | - R Romano
- Department of Experimental Medicine, Section of Pharmacology L. Donatelli, Università degli Studi della Campania "Luigi Vanvitelli" (Ex SUN), 80138, Naples, Italy
| | - G Bellini
- Department of Women, Child and General and Specialistic Surgery, Università degli Studi della Campania "Luigi Vanvitelli" (Ex SUN), 80138, Naples, Italy
| | - I Manzo
- Department of Women, Child and General and Specialistic Surgery, Università degli Studi della Campania "Luigi Vanvitelli" (Ex SUN), 80138, Naples, Italy
| | - A Furiano
- Department of Experimental Medicine, Section of Pharmacology L. Donatelli, Università degli Studi della Campania "Luigi Vanvitelli" (Ex SUN), 80138, Naples, Italy
| | - A Rizzo
- Department of Experimental Medicine, Section of Microbiology and Clinical Microbiology, Università degli Studi della Campania "Luigi Vanvitelli" (Ex SUN), 80138, Naples, Italy
| | - R Imperatore
- Institute of Biomolecular Chemistry, Consiglio Nazionale delle Ricerche, Pozzuoli, Italy.,Department of Science and Technology, University of Sannio, Benevento, Italy
| | - F A Iannotti
- Institute of Biomolecular Chemistry, Consiglio Nazionale delle Ricerche, Pozzuoli, Italy.,Endocannabinoid Research Group, Institute of Biomolecular Chemistry, C.N.R., Pozzuoli, Italy
| | - E D'Aniello
- Institute of Biomolecular Chemistry, Consiglio Nazionale delle Ricerche, Pozzuoli, Italy.,Endocannabinoid Research Group, Institute of Biomolecular Chemistry, C.N.R., Pozzuoli, Italy
| | - F Piscitelli
- Institute of Biomolecular Chemistry, Consiglio Nazionale delle Ricerche, Pozzuoli, Italy.,Endocannabinoid Research Group, Institute of Biomolecular Chemistry, C.N.R., Pozzuoli, Italy
| | - F Sca Rossi
- Department of Women, Child and General and Specialistic Surgery, Università degli Studi della Campania "Luigi Vanvitelli" (Ex SUN), 80138, Naples, Italy
| | - L Cristino
- Institute of Biomolecular Chemistry, Consiglio Nazionale delle Ricerche, Pozzuoli, Italy.,Endocannabinoid Research Group, Institute of Biomolecular Chemistry, C.N.R., Pozzuoli, Italy
| | - V Di Marzo
- Institute of Biomolecular Chemistry, Consiglio Nazionale delle Ricerche, Pozzuoli, Italy.,Endocannabinoid Research Group, Institute of Biomolecular Chemistry, C.N.R., Pozzuoli, Italy
| | - V de Novellis
- Department of Experimental Medicine, Section of Pharmacology L. Donatelli, Università degli Studi della Campania "Luigi Vanvitelli" (Ex SUN), 80138, Naples, Italy.,Endocannabinoid Research Group, Institute of Biomolecular Chemistry, C.N.R., Pozzuoli, Italy
| | - S Maione
- Department of Experimental Medicine, Section of Pharmacology L. Donatelli, Università degli Studi della Campania "Luigi Vanvitelli" (Ex SUN), 80138, Naples, Italy. .,Endocannabinoid Research Group, Institute of Biomolecular Chemistry, C.N.R., Pozzuoli, Italy.
| |
Collapse
|
44
|
Olsson AC, Vermeulen R, Schüz J, Kromhout H, Pesch B, Peters S, Behrens T, Portengen L, Mirabelli D, Gustavsson P, Kendzia B, Almansa J, Luzon V, Vlaanderen J, Stücker I, Guida F, Consonni D, Caporaso N, Landi MT, Field J, Brüske I, Wichmann HE, Siemiatycki J, Parent ME, Richiardi L, Merletti F, Jöckel KH, Ahrens W, Pohlabeln H, Plato N, Tardón A, Zaridze D, McLaughlin J, Demers P, Szeszenia-Dabrowska N, Lissowska J, Rudnai P, Fabianova E, Stanescu Dumitru R, Bencko V, Foretova L, Janout V, Boffetta P, Bueno-de-Mesquita B, Forastiere F, Brüning T, Straif K. Exposure-Response Analyses of Asbestos and Lung Cancer Subtypes in a Pooled Analysis of Case-Control Studies. Epidemiology 2017; 28:288-299. [PMID: 28141674 PMCID: PMC5287435 DOI: 10.1097/ede.0000000000000604] [Citation(s) in RCA: 54] [Impact Index Per Article: 7.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/20/2015] [Accepted: 11/22/2016] [Indexed: 11/26/2022]
Abstract
BACKGROUND Evidence is limited regarding risk and the shape of the exposure-response curve at low asbestos exposure levels. We estimated the exposure-response for occupational asbestos exposure and assessed the joint effect of asbestos exposure and smoking by sex and lung cancer subtype in general population studies. METHODS We pooled 14 case-control studies conducted in 1985-2010 in Europe and Canada, including 17,705 lung cancer cases and 21,813 controls with detailed information on tobacco habits and lifetime occupations. We developed a quantitative job-exposure-matrix to estimate job-, time period-, and region-specific exposure levels. Fiber-years (ff/ml-years) were calculated for each subject by linking the matrix with individual occupational histories. We fit unconditional logistic regression models to estimate odds ratios (ORs), 95% confidence intervals (CIs), and trends. RESULTS The fully adjusted OR for ever-exposure to asbestos was 1.24 (95% CI, 1.18, 1.31) in men and 1.12 (95% CI, 0.95, 1.31) in women. In men, increasing lung cancer risk was observed with increasing exposure in all smoking categories and for all three major lung cancer subtypes. In women, lung cancer risk for all subtypes was increased in current smokers (ORs ~two-fold). The joint effect of asbestos exposure and smoking did not deviate from multiplicativity among men, and was more than additive among women. CONCLUSIONS Our results in men showed an excess risk of lung cancer and its subtypes at low cumulative exposure levels, with a steeper exposure-response slope in this exposure range than at higher, previously studied levels. (See video abstract at, http://links.lww.com/EDE/B161.).
Collapse
Affiliation(s)
- Ann C. Olsson
- From the International Agency for Research on Cancer, Lyon, France; The Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden; Institute for Risk Assessment Sciences, Utrecht, The Netherlands; Institute for Prevention and Occupational Medicine of the German Social Accident Insurance – Institute of the Ruhr-Universität Bochum (IPA), Bochum, Germany; Occupational Respiratory Epidemiology, School of Population Health, University of Western Australia, Perth, Australia; Cancer Epidemiology Unit, Department of Medical Sciences, University of Turin and CPO Piemonte, Turin, Italy; INSERM, Centre for research in Epidemiology and Population Health (CESP), U1018, Environmental epidemiology of cancer Team, Villejuif, France; Université Paris-Sud, UMRS 1018, Villejuif, France; Epidemiology Unit, Fondazione IRCCS Ca’ Granda—Ospedale Maggiore Policlinico, Milan, Italy; National Cancer Institute, Bethesda, MD; Roy Castle Lung Cancer Research Programme, The University of Liverpool Cancer Research Centre, Department of Molecular and Clinical Cancer Medicine, Institute of Translational Medicine, Liverpool, United Kingdom; Institut für Epidemiologie, Deutsches Forschungszentrum fur Gesundheit und Umwelt, Neuherberg, Germany; University of Montreal Hospital Research Center (CRCHUM), Montreal, Canada; INRS-Institut Armand-Frappier, Université du Québec, Laval, Québec, Canada; Institute for Medical Informatics, Biometry and Epidemiology, University of Duisburg-Essen, Essen, Germany; Leibniz Institute for Prevention Research and Epidemiology – BIPS, Bremen, Germany; The Biomedical Research Centre Network for Epidemiology and Public Health (CIBERESP), University of Oviedo, Oviedo, Spain; Russian Cancer Research Centre, Moscow, Russia; Public Health Ontario, Toronto, Canada; Occupational Cancer Research Centre, Cancer Care Ontario, Toronto, Canada; The Nofer Institute of Occupational Medicine, Lodz, Poland; The M Sklodowska-Curie Cancer Center and Institute of Oncology, Warsaw, Poland; National Centre for Public Health, Budapest, Hungary; Regional Authority of Public Health, Banska Bystrica, Slovakia; Institute of Public Health, Bucharest, Romania; Institute of Hygiene and Epidemiology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic; Masaryk Memorial Cancer Institute and Medical Faculty of Masaryk University, Department of Cancer Epidemiology & Genetics, Brno, Czech Republic; Faculty of Medicine, Palacky University, Olomouc, Czech Republic; The Tisch Cancer Institute and Institute for Translational Epidemiology, Icahn School of Medicine at Mount Sinai, New York, NY; National Institute for Public Health and the Environment (RIVM), Bilthoven, The Netherlands; and Department of Epidemiology, ASL RomaE, Rome, Italy
| | - Roel Vermeulen
- From the International Agency for Research on Cancer, Lyon, France; The Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden; Institute for Risk Assessment Sciences, Utrecht, The Netherlands; Institute for Prevention and Occupational Medicine of the German Social Accident Insurance – Institute of the Ruhr-Universität Bochum (IPA), Bochum, Germany; Occupational Respiratory Epidemiology, School of Population Health, University of Western Australia, Perth, Australia; Cancer Epidemiology Unit, Department of Medical Sciences, University of Turin and CPO Piemonte, Turin, Italy; INSERM, Centre for research in Epidemiology and Population Health (CESP), U1018, Environmental epidemiology of cancer Team, Villejuif, France; Université Paris-Sud, UMRS 1018, Villejuif, France; Epidemiology Unit, Fondazione IRCCS Ca’ Granda—Ospedale Maggiore Policlinico, Milan, Italy; National Cancer Institute, Bethesda, MD; Roy Castle Lung Cancer Research Programme, The University of Liverpool Cancer Research Centre, Department of Molecular and Clinical Cancer Medicine, Institute of Translational Medicine, Liverpool, United Kingdom; Institut für Epidemiologie, Deutsches Forschungszentrum fur Gesundheit und Umwelt, Neuherberg, Germany; University of Montreal Hospital Research Center (CRCHUM), Montreal, Canada; INRS-Institut Armand-Frappier, Université du Québec, Laval, Québec, Canada; Institute for Medical Informatics, Biometry and Epidemiology, University of Duisburg-Essen, Essen, Germany; Leibniz Institute for Prevention Research and Epidemiology – BIPS, Bremen, Germany; The Biomedical Research Centre Network for Epidemiology and Public Health (CIBERESP), University of Oviedo, Oviedo, Spain; Russian Cancer Research Centre, Moscow, Russia; Public Health Ontario, Toronto, Canada; Occupational Cancer Research Centre, Cancer Care Ontario, Toronto, Canada; The Nofer Institute of Occupational Medicine, Lodz, Poland; The M Sklodowska-Curie Cancer Center and Institute of Oncology, Warsaw, Poland; National Centre for Public Health, Budapest, Hungary; Regional Authority of Public Health, Banska Bystrica, Slovakia; Institute of Public Health, Bucharest, Romania; Institute of Hygiene and Epidemiology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic; Masaryk Memorial Cancer Institute and Medical Faculty of Masaryk University, Department of Cancer Epidemiology & Genetics, Brno, Czech Republic; Faculty of Medicine, Palacky University, Olomouc, Czech Republic; The Tisch Cancer Institute and Institute for Translational Epidemiology, Icahn School of Medicine at Mount Sinai, New York, NY; National Institute for Public Health and the Environment (RIVM), Bilthoven, The Netherlands; and Department of Epidemiology, ASL RomaE, Rome, Italy
| | - Joachim Schüz
- From the International Agency for Research on Cancer, Lyon, France; The Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden; Institute for Risk Assessment Sciences, Utrecht, The Netherlands; Institute for Prevention and Occupational Medicine of the German Social Accident Insurance – Institute of the Ruhr-Universität Bochum (IPA), Bochum, Germany; Occupational Respiratory Epidemiology, School of Population Health, University of Western Australia, Perth, Australia; Cancer Epidemiology Unit, Department of Medical Sciences, University of Turin and CPO Piemonte, Turin, Italy; INSERM, Centre for research in Epidemiology and Population Health (CESP), U1018, Environmental epidemiology of cancer Team, Villejuif, France; Université Paris-Sud, UMRS 1018, Villejuif, France; Epidemiology Unit, Fondazione IRCCS Ca’ Granda—Ospedale Maggiore Policlinico, Milan, Italy; National Cancer Institute, Bethesda, MD; Roy Castle Lung Cancer Research Programme, The University of Liverpool Cancer Research Centre, Department of Molecular and Clinical Cancer Medicine, Institute of Translational Medicine, Liverpool, United Kingdom; Institut für Epidemiologie, Deutsches Forschungszentrum fur Gesundheit und Umwelt, Neuherberg, Germany; University of Montreal Hospital Research Center (CRCHUM), Montreal, Canada; INRS-Institut Armand-Frappier, Université du Québec, Laval, Québec, Canada; Institute for Medical Informatics, Biometry and Epidemiology, University of Duisburg-Essen, Essen, Germany; Leibniz Institute for Prevention Research and Epidemiology – BIPS, Bremen, Germany; The Biomedical Research Centre Network for Epidemiology and Public Health (CIBERESP), University of Oviedo, Oviedo, Spain; Russian Cancer Research Centre, Moscow, Russia; Public Health Ontario, Toronto, Canada; Occupational Cancer Research Centre, Cancer Care Ontario, Toronto, Canada; The Nofer Institute of Occupational Medicine, Lodz, Poland; The M Sklodowska-Curie Cancer Center and Institute of Oncology, Warsaw, Poland; National Centre for Public Health, Budapest, Hungary; Regional Authority of Public Health, Banska Bystrica, Slovakia; Institute of Public Health, Bucharest, Romania; Institute of Hygiene and Epidemiology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic; Masaryk Memorial Cancer Institute and Medical Faculty of Masaryk University, Department of Cancer Epidemiology & Genetics, Brno, Czech Republic; Faculty of Medicine, Palacky University, Olomouc, Czech Republic; The Tisch Cancer Institute and Institute for Translational Epidemiology, Icahn School of Medicine at Mount Sinai, New York, NY; National Institute for Public Health and the Environment (RIVM), Bilthoven, The Netherlands; and Department of Epidemiology, ASL RomaE, Rome, Italy
| | - Hans Kromhout
- From the International Agency for Research on Cancer, Lyon, France; The Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden; Institute for Risk Assessment Sciences, Utrecht, The Netherlands; Institute for Prevention and Occupational Medicine of the German Social Accident Insurance – Institute of the Ruhr-Universität Bochum (IPA), Bochum, Germany; Occupational Respiratory Epidemiology, School of Population Health, University of Western Australia, Perth, Australia; Cancer Epidemiology Unit, Department of Medical Sciences, University of Turin and CPO Piemonte, Turin, Italy; INSERM, Centre for research in Epidemiology and Population Health (CESP), U1018, Environmental epidemiology of cancer Team, Villejuif, France; Université Paris-Sud, UMRS 1018, Villejuif, France; Epidemiology Unit, Fondazione IRCCS Ca’ Granda—Ospedale Maggiore Policlinico, Milan, Italy; National Cancer Institute, Bethesda, MD; Roy Castle Lung Cancer Research Programme, The University of Liverpool Cancer Research Centre, Department of Molecular and Clinical Cancer Medicine, Institute of Translational Medicine, Liverpool, United Kingdom; Institut für Epidemiologie, Deutsches Forschungszentrum fur Gesundheit und Umwelt, Neuherberg, Germany; University of Montreal Hospital Research Center (CRCHUM), Montreal, Canada; INRS-Institut Armand-Frappier, Université du Québec, Laval, Québec, Canada; Institute for Medical Informatics, Biometry and Epidemiology, University of Duisburg-Essen, Essen, Germany; Leibniz Institute for Prevention Research and Epidemiology – BIPS, Bremen, Germany; The Biomedical Research Centre Network for Epidemiology and Public Health (CIBERESP), University of Oviedo, Oviedo, Spain; Russian Cancer Research Centre, Moscow, Russia; Public Health Ontario, Toronto, Canada; Occupational Cancer Research Centre, Cancer Care Ontario, Toronto, Canada; The Nofer Institute of Occupational Medicine, Lodz, Poland; The M Sklodowska-Curie Cancer Center and Institute of Oncology, Warsaw, Poland; National Centre for Public Health, Budapest, Hungary; Regional Authority of Public Health, Banska Bystrica, Slovakia; Institute of Public Health, Bucharest, Romania; Institute of Hygiene and Epidemiology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic; Masaryk Memorial Cancer Institute and Medical Faculty of Masaryk University, Department of Cancer Epidemiology & Genetics, Brno, Czech Republic; Faculty of Medicine, Palacky University, Olomouc, Czech Republic; The Tisch Cancer Institute and Institute for Translational Epidemiology, Icahn School of Medicine at Mount Sinai, New York, NY; National Institute for Public Health and the Environment (RIVM), Bilthoven, The Netherlands; and Department of Epidemiology, ASL RomaE, Rome, Italy
| | - Beate Pesch
- From the International Agency for Research on Cancer, Lyon, France; The Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden; Institute for Risk Assessment Sciences, Utrecht, The Netherlands; Institute for Prevention and Occupational Medicine of the German Social Accident Insurance – Institute of the Ruhr-Universität Bochum (IPA), Bochum, Germany; Occupational Respiratory Epidemiology, School of Population Health, University of Western Australia, Perth, Australia; Cancer Epidemiology Unit, Department of Medical Sciences, University of Turin and CPO Piemonte, Turin, Italy; INSERM, Centre for research in Epidemiology and Population Health (CESP), U1018, Environmental epidemiology of cancer Team, Villejuif, France; Université Paris-Sud, UMRS 1018, Villejuif, France; Epidemiology Unit, Fondazione IRCCS Ca’ Granda—Ospedale Maggiore Policlinico, Milan, Italy; National Cancer Institute, Bethesda, MD; Roy Castle Lung Cancer Research Programme, The University of Liverpool Cancer Research Centre, Department of Molecular and Clinical Cancer Medicine, Institute of Translational Medicine, Liverpool, United Kingdom; Institut für Epidemiologie, Deutsches Forschungszentrum fur Gesundheit und Umwelt, Neuherberg, Germany; University of Montreal Hospital Research Center (CRCHUM), Montreal, Canada; INRS-Institut Armand-Frappier, Université du Québec, Laval, Québec, Canada; Institute for Medical Informatics, Biometry and Epidemiology, University of Duisburg-Essen, Essen, Germany; Leibniz Institute for Prevention Research and Epidemiology – BIPS, Bremen, Germany; The Biomedical Research Centre Network for Epidemiology and Public Health (CIBERESP), University of Oviedo, Oviedo, Spain; Russian Cancer Research Centre, Moscow, Russia; Public Health Ontario, Toronto, Canada; Occupational Cancer Research Centre, Cancer Care Ontario, Toronto, Canada; The Nofer Institute of Occupational Medicine, Lodz, Poland; The M Sklodowska-Curie Cancer Center and Institute of Oncology, Warsaw, Poland; National Centre for Public Health, Budapest, Hungary; Regional Authority of Public Health, Banska Bystrica, Slovakia; Institute of Public Health, Bucharest, Romania; Institute of Hygiene and Epidemiology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic; Masaryk Memorial Cancer Institute and Medical Faculty of Masaryk University, Department of Cancer Epidemiology & Genetics, Brno, Czech Republic; Faculty of Medicine, Palacky University, Olomouc, Czech Republic; The Tisch Cancer Institute and Institute for Translational Epidemiology, Icahn School of Medicine at Mount Sinai, New York, NY; National Institute for Public Health and the Environment (RIVM), Bilthoven, The Netherlands; and Department of Epidemiology, ASL RomaE, Rome, Italy
| | - Susan Peters
- From the International Agency for Research on Cancer, Lyon, France; The Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden; Institute for Risk Assessment Sciences, Utrecht, The Netherlands; Institute for Prevention and Occupational Medicine of the German Social Accident Insurance – Institute of the Ruhr-Universität Bochum (IPA), Bochum, Germany; Occupational Respiratory Epidemiology, School of Population Health, University of Western Australia, Perth, Australia; Cancer Epidemiology Unit, Department of Medical Sciences, University of Turin and CPO Piemonte, Turin, Italy; INSERM, Centre for research in Epidemiology and Population Health (CESP), U1018, Environmental epidemiology of cancer Team, Villejuif, France; Université Paris-Sud, UMRS 1018, Villejuif, France; Epidemiology Unit, Fondazione IRCCS Ca’ Granda—Ospedale Maggiore Policlinico, Milan, Italy; National Cancer Institute, Bethesda, MD; Roy Castle Lung Cancer Research Programme, The University of Liverpool Cancer Research Centre, Department of Molecular and Clinical Cancer Medicine, Institute of Translational Medicine, Liverpool, United Kingdom; Institut für Epidemiologie, Deutsches Forschungszentrum fur Gesundheit und Umwelt, Neuherberg, Germany; University of Montreal Hospital Research Center (CRCHUM), Montreal, Canada; INRS-Institut Armand-Frappier, Université du Québec, Laval, Québec, Canada; Institute for Medical Informatics, Biometry and Epidemiology, University of Duisburg-Essen, Essen, Germany; Leibniz Institute for Prevention Research and Epidemiology – BIPS, Bremen, Germany; The Biomedical Research Centre Network for Epidemiology and Public Health (CIBERESP), University of Oviedo, Oviedo, Spain; Russian Cancer Research Centre, Moscow, Russia; Public Health Ontario, Toronto, Canada; Occupational Cancer Research Centre, Cancer Care Ontario, Toronto, Canada; The Nofer Institute of Occupational Medicine, Lodz, Poland; The M Sklodowska-Curie Cancer Center and Institute of Oncology, Warsaw, Poland; National Centre for Public Health, Budapest, Hungary; Regional Authority of Public Health, Banska Bystrica, Slovakia; Institute of Public Health, Bucharest, Romania; Institute of Hygiene and Epidemiology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic; Masaryk Memorial Cancer Institute and Medical Faculty of Masaryk University, Department of Cancer Epidemiology & Genetics, Brno, Czech Republic; Faculty of Medicine, Palacky University, Olomouc, Czech Republic; The Tisch Cancer Institute and Institute for Translational Epidemiology, Icahn School of Medicine at Mount Sinai, New York, NY; National Institute for Public Health and the Environment (RIVM), Bilthoven, The Netherlands; and Department of Epidemiology, ASL RomaE, Rome, Italy
| | - Thomas Behrens
- From the International Agency for Research on Cancer, Lyon, France; The Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden; Institute for Risk Assessment Sciences, Utrecht, The Netherlands; Institute for Prevention and Occupational Medicine of the German Social Accident Insurance – Institute of the Ruhr-Universität Bochum (IPA), Bochum, Germany; Occupational Respiratory Epidemiology, School of Population Health, University of Western Australia, Perth, Australia; Cancer Epidemiology Unit, Department of Medical Sciences, University of Turin and CPO Piemonte, Turin, Italy; INSERM, Centre for research in Epidemiology and Population Health (CESP), U1018, Environmental epidemiology of cancer Team, Villejuif, France; Université Paris-Sud, UMRS 1018, Villejuif, France; Epidemiology Unit, Fondazione IRCCS Ca’ Granda—Ospedale Maggiore Policlinico, Milan, Italy; National Cancer Institute, Bethesda, MD; Roy Castle Lung Cancer Research Programme, The University of Liverpool Cancer Research Centre, Department of Molecular and Clinical Cancer Medicine, Institute of Translational Medicine, Liverpool, United Kingdom; Institut für Epidemiologie, Deutsches Forschungszentrum fur Gesundheit und Umwelt, Neuherberg, Germany; University of Montreal Hospital Research Center (CRCHUM), Montreal, Canada; INRS-Institut Armand-Frappier, Université du Québec, Laval, Québec, Canada; Institute for Medical Informatics, Biometry and Epidemiology, University of Duisburg-Essen, Essen, Germany; Leibniz Institute for Prevention Research and Epidemiology – BIPS, Bremen, Germany; The Biomedical Research Centre Network for Epidemiology and Public Health (CIBERESP), University of Oviedo, Oviedo, Spain; Russian Cancer Research Centre, Moscow, Russia; Public Health Ontario, Toronto, Canada; Occupational Cancer Research Centre, Cancer Care Ontario, Toronto, Canada; The Nofer Institute of Occupational Medicine, Lodz, Poland; The M Sklodowska-Curie Cancer Center and Institute of Oncology, Warsaw, Poland; National Centre for Public Health, Budapest, Hungary; Regional Authority of Public Health, Banska Bystrica, Slovakia; Institute of Public Health, Bucharest, Romania; Institute of Hygiene and Epidemiology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic; Masaryk Memorial Cancer Institute and Medical Faculty of Masaryk University, Department of Cancer Epidemiology & Genetics, Brno, Czech Republic; Faculty of Medicine, Palacky University, Olomouc, Czech Republic; The Tisch Cancer Institute and Institute for Translational Epidemiology, Icahn School of Medicine at Mount Sinai, New York, NY; National Institute for Public Health and the Environment (RIVM), Bilthoven, The Netherlands; and Department of Epidemiology, ASL RomaE, Rome, Italy
| | - Lützen Portengen
- From the International Agency for Research on Cancer, Lyon, France; The Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden; Institute for Risk Assessment Sciences, Utrecht, The Netherlands; Institute for Prevention and Occupational Medicine of the German Social Accident Insurance – Institute of the Ruhr-Universität Bochum (IPA), Bochum, Germany; Occupational Respiratory Epidemiology, School of Population Health, University of Western Australia, Perth, Australia; Cancer Epidemiology Unit, Department of Medical Sciences, University of Turin and CPO Piemonte, Turin, Italy; INSERM, Centre for research in Epidemiology and Population Health (CESP), U1018, Environmental epidemiology of cancer Team, Villejuif, France; Université Paris-Sud, UMRS 1018, Villejuif, France; Epidemiology Unit, Fondazione IRCCS Ca’ Granda—Ospedale Maggiore Policlinico, Milan, Italy; National Cancer Institute, Bethesda, MD; Roy Castle Lung Cancer Research Programme, The University of Liverpool Cancer Research Centre, Department of Molecular and Clinical Cancer Medicine, Institute of Translational Medicine, Liverpool, United Kingdom; Institut für Epidemiologie, Deutsches Forschungszentrum fur Gesundheit und Umwelt, Neuherberg, Germany; University of Montreal Hospital Research Center (CRCHUM), Montreal, Canada; INRS-Institut Armand-Frappier, Université du Québec, Laval, Québec, Canada; Institute for Medical Informatics, Biometry and Epidemiology, University of Duisburg-Essen, Essen, Germany; Leibniz Institute for Prevention Research and Epidemiology – BIPS, Bremen, Germany; The Biomedical Research Centre Network for Epidemiology and Public Health (CIBERESP), University of Oviedo, Oviedo, Spain; Russian Cancer Research Centre, Moscow, Russia; Public Health Ontario, Toronto, Canada; Occupational Cancer Research Centre, Cancer Care Ontario, Toronto, Canada; The Nofer Institute of Occupational Medicine, Lodz, Poland; The M Sklodowska-Curie Cancer Center and Institute of Oncology, Warsaw, Poland; National Centre for Public Health, Budapest, Hungary; Regional Authority of Public Health, Banska Bystrica, Slovakia; Institute of Public Health, Bucharest, Romania; Institute of Hygiene and Epidemiology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic; Masaryk Memorial Cancer Institute and Medical Faculty of Masaryk University, Department of Cancer Epidemiology & Genetics, Brno, Czech Republic; Faculty of Medicine, Palacky University, Olomouc, Czech Republic; The Tisch Cancer Institute and Institute for Translational Epidemiology, Icahn School of Medicine at Mount Sinai, New York, NY; National Institute for Public Health and the Environment (RIVM), Bilthoven, The Netherlands; and Department of Epidemiology, ASL RomaE, Rome, Italy
| | - Dario Mirabelli
- From the International Agency for Research on Cancer, Lyon, France; The Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden; Institute for Risk Assessment Sciences, Utrecht, The Netherlands; Institute for Prevention and Occupational Medicine of the German Social Accident Insurance – Institute of the Ruhr-Universität Bochum (IPA), Bochum, Germany; Occupational Respiratory Epidemiology, School of Population Health, University of Western Australia, Perth, Australia; Cancer Epidemiology Unit, Department of Medical Sciences, University of Turin and CPO Piemonte, Turin, Italy; INSERM, Centre for research in Epidemiology and Population Health (CESP), U1018, Environmental epidemiology of cancer Team, Villejuif, France; Université Paris-Sud, UMRS 1018, Villejuif, France; Epidemiology Unit, Fondazione IRCCS Ca’ Granda—Ospedale Maggiore Policlinico, Milan, Italy; National Cancer Institute, Bethesda, MD; Roy Castle Lung Cancer Research Programme, The University of Liverpool Cancer Research Centre, Department of Molecular and Clinical Cancer Medicine, Institute of Translational Medicine, Liverpool, United Kingdom; Institut für Epidemiologie, Deutsches Forschungszentrum fur Gesundheit und Umwelt, Neuherberg, Germany; University of Montreal Hospital Research Center (CRCHUM), Montreal, Canada; INRS-Institut Armand-Frappier, Université du Québec, Laval, Québec, Canada; Institute for Medical Informatics, Biometry and Epidemiology, University of Duisburg-Essen, Essen, Germany; Leibniz Institute for Prevention Research and Epidemiology – BIPS, Bremen, Germany; The Biomedical Research Centre Network for Epidemiology and Public Health (CIBERESP), University of Oviedo, Oviedo, Spain; Russian Cancer Research Centre, Moscow, Russia; Public Health Ontario, Toronto, Canada; Occupational Cancer Research Centre, Cancer Care Ontario, Toronto, Canada; The Nofer Institute of Occupational Medicine, Lodz, Poland; The M Sklodowska-Curie Cancer Center and Institute of Oncology, Warsaw, Poland; National Centre for Public Health, Budapest, Hungary; Regional Authority of Public Health, Banska Bystrica, Slovakia; Institute of Public Health, Bucharest, Romania; Institute of Hygiene and Epidemiology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic; Masaryk Memorial Cancer Institute and Medical Faculty of Masaryk University, Department of Cancer Epidemiology & Genetics, Brno, Czech Republic; Faculty of Medicine, Palacky University, Olomouc, Czech Republic; The Tisch Cancer Institute and Institute for Translational Epidemiology, Icahn School of Medicine at Mount Sinai, New York, NY; National Institute for Public Health and the Environment (RIVM), Bilthoven, The Netherlands; and Department of Epidemiology, ASL RomaE, Rome, Italy
| | - Per Gustavsson
- From the International Agency for Research on Cancer, Lyon, France; The Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden; Institute for Risk Assessment Sciences, Utrecht, The Netherlands; Institute for Prevention and Occupational Medicine of the German Social Accident Insurance – Institute of the Ruhr-Universität Bochum (IPA), Bochum, Germany; Occupational Respiratory Epidemiology, School of Population Health, University of Western Australia, Perth, Australia; Cancer Epidemiology Unit, Department of Medical Sciences, University of Turin and CPO Piemonte, Turin, Italy; INSERM, Centre for research in Epidemiology and Population Health (CESP), U1018, Environmental epidemiology of cancer Team, Villejuif, France; Université Paris-Sud, UMRS 1018, Villejuif, France; Epidemiology Unit, Fondazione IRCCS Ca’ Granda—Ospedale Maggiore Policlinico, Milan, Italy; National Cancer Institute, Bethesda, MD; Roy Castle Lung Cancer Research Programme, The University of Liverpool Cancer Research Centre, Department of Molecular and Clinical Cancer Medicine, Institute of Translational Medicine, Liverpool, United Kingdom; Institut für Epidemiologie, Deutsches Forschungszentrum fur Gesundheit und Umwelt, Neuherberg, Germany; University of Montreal Hospital Research Center (CRCHUM), Montreal, Canada; INRS-Institut Armand-Frappier, Université du Québec, Laval, Québec, Canada; Institute for Medical Informatics, Biometry and Epidemiology, University of Duisburg-Essen, Essen, Germany; Leibniz Institute for Prevention Research and Epidemiology – BIPS, Bremen, Germany; The Biomedical Research Centre Network for Epidemiology and Public Health (CIBERESP), University of Oviedo, Oviedo, Spain; Russian Cancer Research Centre, Moscow, Russia; Public Health Ontario, Toronto, Canada; Occupational Cancer Research Centre, Cancer Care Ontario, Toronto, Canada; The Nofer Institute of Occupational Medicine, Lodz, Poland; The M Sklodowska-Curie Cancer Center and Institute of Oncology, Warsaw, Poland; National Centre for Public Health, Budapest, Hungary; Regional Authority of Public Health, Banska Bystrica, Slovakia; Institute of Public Health, Bucharest, Romania; Institute of Hygiene and Epidemiology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic; Masaryk Memorial Cancer Institute and Medical Faculty of Masaryk University, Department of Cancer Epidemiology & Genetics, Brno, Czech Republic; Faculty of Medicine, Palacky University, Olomouc, Czech Republic; The Tisch Cancer Institute and Institute for Translational Epidemiology, Icahn School of Medicine at Mount Sinai, New York, NY; National Institute for Public Health and the Environment (RIVM), Bilthoven, The Netherlands; and Department of Epidemiology, ASL RomaE, Rome, Italy
| | - Benjamin Kendzia
- From the International Agency for Research on Cancer, Lyon, France; The Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden; Institute for Risk Assessment Sciences, Utrecht, The Netherlands; Institute for Prevention and Occupational Medicine of the German Social Accident Insurance – Institute of the Ruhr-Universität Bochum (IPA), Bochum, Germany; Occupational Respiratory Epidemiology, School of Population Health, University of Western Australia, Perth, Australia; Cancer Epidemiology Unit, Department of Medical Sciences, University of Turin and CPO Piemonte, Turin, Italy; INSERM, Centre for research in Epidemiology and Population Health (CESP), U1018, Environmental epidemiology of cancer Team, Villejuif, France; Université Paris-Sud, UMRS 1018, Villejuif, France; Epidemiology Unit, Fondazione IRCCS Ca’ Granda—Ospedale Maggiore Policlinico, Milan, Italy; National Cancer Institute, Bethesda, MD; Roy Castle Lung Cancer Research Programme, The University of Liverpool Cancer Research Centre, Department of Molecular and Clinical Cancer Medicine, Institute of Translational Medicine, Liverpool, United Kingdom; Institut für Epidemiologie, Deutsches Forschungszentrum fur Gesundheit und Umwelt, Neuherberg, Germany; University of Montreal Hospital Research Center (CRCHUM), Montreal, Canada; INRS-Institut Armand-Frappier, Université du Québec, Laval, Québec, Canada; Institute for Medical Informatics, Biometry and Epidemiology, University of Duisburg-Essen, Essen, Germany; Leibniz Institute for Prevention Research and Epidemiology – BIPS, Bremen, Germany; The Biomedical Research Centre Network for Epidemiology and Public Health (CIBERESP), University of Oviedo, Oviedo, Spain; Russian Cancer Research Centre, Moscow, Russia; Public Health Ontario, Toronto, Canada; Occupational Cancer Research Centre, Cancer Care Ontario, Toronto, Canada; The Nofer Institute of Occupational Medicine, Lodz, Poland; The M Sklodowska-Curie Cancer Center and Institute of Oncology, Warsaw, Poland; National Centre for Public Health, Budapest, Hungary; Regional Authority of Public Health, Banska Bystrica, Slovakia; Institute of Public Health, Bucharest, Romania; Institute of Hygiene and Epidemiology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic; Masaryk Memorial Cancer Institute and Medical Faculty of Masaryk University, Department of Cancer Epidemiology & Genetics, Brno, Czech Republic; Faculty of Medicine, Palacky University, Olomouc, Czech Republic; The Tisch Cancer Institute and Institute for Translational Epidemiology, Icahn School of Medicine at Mount Sinai, New York, NY; National Institute for Public Health and the Environment (RIVM), Bilthoven, The Netherlands; and Department of Epidemiology, ASL RomaE, Rome, Italy
| | - Josue Almansa
- From the International Agency for Research on Cancer, Lyon, France; The Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden; Institute for Risk Assessment Sciences, Utrecht, The Netherlands; Institute for Prevention and Occupational Medicine of the German Social Accident Insurance – Institute of the Ruhr-Universität Bochum (IPA), Bochum, Germany; Occupational Respiratory Epidemiology, School of Population Health, University of Western Australia, Perth, Australia; Cancer Epidemiology Unit, Department of Medical Sciences, University of Turin and CPO Piemonte, Turin, Italy; INSERM, Centre for research in Epidemiology and Population Health (CESP), U1018, Environmental epidemiology of cancer Team, Villejuif, France; Université Paris-Sud, UMRS 1018, Villejuif, France; Epidemiology Unit, Fondazione IRCCS Ca’ Granda—Ospedale Maggiore Policlinico, Milan, Italy; National Cancer Institute, Bethesda, MD; Roy Castle Lung Cancer Research Programme, The University of Liverpool Cancer Research Centre, Department of Molecular and Clinical Cancer Medicine, Institute of Translational Medicine, Liverpool, United Kingdom; Institut für Epidemiologie, Deutsches Forschungszentrum fur Gesundheit und Umwelt, Neuherberg, Germany; University of Montreal Hospital Research Center (CRCHUM), Montreal, Canada; INRS-Institut Armand-Frappier, Université du Québec, Laval, Québec, Canada; Institute for Medical Informatics, Biometry and Epidemiology, University of Duisburg-Essen, Essen, Germany; Leibniz Institute for Prevention Research and Epidemiology – BIPS, Bremen, Germany; The Biomedical Research Centre Network for Epidemiology and Public Health (CIBERESP), University of Oviedo, Oviedo, Spain; Russian Cancer Research Centre, Moscow, Russia; Public Health Ontario, Toronto, Canada; Occupational Cancer Research Centre, Cancer Care Ontario, Toronto, Canada; The Nofer Institute of Occupational Medicine, Lodz, Poland; The M Sklodowska-Curie Cancer Center and Institute of Oncology, Warsaw, Poland; National Centre for Public Health, Budapest, Hungary; Regional Authority of Public Health, Banska Bystrica, Slovakia; Institute of Public Health, Bucharest, Romania; Institute of Hygiene and Epidemiology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic; Masaryk Memorial Cancer Institute and Medical Faculty of Masaryk University, Department of Cancer Epidemiology & Genetics, Brno, Czech Republic; Faculty of Medicine, Palacky University, Olomouc, Czech Republic; The Tisch Cancer Institute and Institute for Translational Epidemiology, Icahn School of Medicine at Mount Sinai, New York, NY; National Institute for Public Health and the Environment (RIVM), Bilthoven, The Netherlands; and Department of Epidemiology, ASL RomaE, Rome, Italy
| | - Veronique Luzon
- From the International Agency for Research on Cancer, Lyon, France; The Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden; Institute for Risk Assessment Sciences, Utrecht, The Netherlands; Institute for Prevention and Occupational Medicine of the German Social Accident Insurance – Institute of the Ruhr-Universität Bochum (IPA), Bochum, Germany; Occupational Respiratory Epidemiology, School of Population Health, University of Western Australia, Perth, Australia; Cancer Epidemiology Unit, Department of Medical Sciences, University of Turin and CPO Piemonte, Turin, Italy; INSERM, Centre for research in Epidemiology and Population Health (CESP), U1018, Environmental epidemiology of cancer Team, Villejuif, France; Université Paris-Sud, UMRS 1018, Villejuif, France; Epidemiology Unit, Fondazione IRCCS Ca’ Granda—Ospedale Maggiore Policlinico, Milan, Italy; National Cancer Institute, Bethesda, MD; Roy Castle Lung Cancer Research Programme, The University of Liverpool Cancer Research Centre, Department of Molecular and Clinical Cancer Medicine, Institute of Translational Medicine, Liverpool, United Kingdom; Institut für Epidemiologie, Deutsches Forschungszentrum fur Gesundheit und Umwelt, Neuherberg, Germany; University of Montreal Hospital Research Center (CRCHUM), Montreal, Canada; INRS-Institut Armand-Frappier, Université du Québec, Laval, Québec, Canada; Institute for Medical Informatics, Biometry and Epidemiology, University of Duisburg-Essen, Essen, Germany; Leibniz Institute for Prevention Research and Epidemiology – BIPS, Bremen, Germany; The Biomedical Research Centre Network for Epidemiology and Public Health (CIBERESP), University of Oviedo, Oviedo, Spain; Russian Cancer Research Centre, Moscow, Russia; Public Health Ontario, Toronto, Canada; Occupational Cancer Research Centre, Cancer Care Ontario, Toronto, Canada; The Nofer Institute of Occupational Medicine, Lodz, Poland; The M Sklodowska-Curie Cancer Center and Institute of Oncology, Warsaw, Poland; National Centre for Public Health, Budapest, Hungary; Regional Authority of Public Health, Banska Bystrica, Slovakia; Institute of Public Health, Bucharest, Romania; Institute of Hygiene and Epidemiology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic; Masaryk Memorial Cancer Institute and Medical Faculty of Masaryk University, Department of Cancer Epidemiology & Genetics, Brno, Czech Republic; Faculty of Medicine, Palacky University, Olomouc, Czech Republic; The Tisch Cancer Institute and Institute for Translational Epidemiology, Icahn School of Medicine at Mount Sinai, New York, NY; National Institute for Public Health and the Environment (RIVM), Bilthoven, The Netherlands; and Department of Epidemiology, ASL RomaE, Rome, Italy
| | - Jelle Vlaanderen
- From the International Agency for Research on Cancer, Lyon, France; The Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden; Institute for Risk Assessment Sciences, Utrecht, The Netherlands; Institute for Prevention and Occupational Medicine of the German Social Accident Insurance – Institute of the Ruhr-Universität Bochum (IPA), Bochum, Germany; Occupational Respiratory Epidemiology, School of Population Health, University of Western Australia, Perth, Australia; Cancer Epidemiology Unit, Department of Medical Sciences, University of Turin and CPO Piemonte, Turin, Italy; INSERM, Centre for research in Epidemiology and Population Health (CESP), U1018, Environmental epidemiology of cancer Team, Villejuif, France; Université Paris-Sud, UMRS 1018, Villejuif, France; Epidemiology Unit, Fondazione IRCCS Ca’ Granda—Ospedale Maggiore Policlinico, Milan, Italy; National Cancer Institute, Bethesda, MD; Roy Castle Lung Cancer Research Programme, The University of Liverpool Cancer Research Centre, Department of Molecular and Clinical Cancer Medicine, Institute of Translational Medicine, Liverpool, United Kingdom; Institut für Epidemiologie, Deutsches Forschungszentrum fur Gesundheit und Umwelt, Neuherberg, Germany; University of Montreal Hospital Research Center (CRCHUM), Montreal, Canada; INRS-Institut Armand-Frappier, Université du Québec, Laval, Québec, Canada; Institute for Medical Informatics, Biometry and Epidemiology, University of Duisburg-Essen, Essen, Germany; Leibniz Institute for Prevention Research and Epidemiology – BIPS, Bremen, Germany; The Biomedical Research Centre Network for Epidemiology and Public Health (CIBERESP), University of Oviedo, Oviedo, Spain; Russian Cancer Research Centre, Moscow, Russia; Public Health Ontario, Toronto, Canada; Occupational Cancer Research Centre, Cancer Care Ontario, Toronto, Canada; The Nofer Institute of Occupational Medicine, Lodz, Poland; The M Sklodowska-Curie Cancer Center and Institute of Oncology, Warsaw, Poland; National Centre for Public Health, Budapest, Hungary; Regional Authority of Public Health, Banska Bystrica, Slovakia; Institute of Public Health, Bucharest, Romania; Institute of Hygiene and Epidemiology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic; Masaryk Memorial Cancer Institute and Medical Faculty of Masaryk University, Department of Cancer Epidemiology & Genetics, Brno, Czech Republic; Faculty of Medicine, Palacky University, Olomouc, Czech Republic; The Tisch Cancer Institute and Institute for Translational Epidemiology, Icahn School of Medicine at Mount Sinai, New York, NY; National Institute for Public Health and the Environment (RIVM), Bilthoven, The Netherlands; and Department of Epidemiology, ASL RomaE, Rome, Italy
| | - Isabelle Stücker
- From the International Agency for Research on Cancer, Lyon, France; The Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden; Institute for Risk Assessment Sciences, Utrecht, The Netherlands; Institute for Prevention and Occupational Medicine of the German Social Accident Insurance – Institute of the Ruhr-Universität Bochum (IPA), Bochum, Germany; Occupational Respiratory Epidemiology, School of Population Health, University of Western Australia, Perth, Australia; Cancer Epidemiology Unit, Department of Medical Sciences, University of Turin and CPO Piemonte, Turin, Italy; INSERM, Centre for research in Epidemiology and Population Health (CESP), U1018, Environmental epidemiology of cancer Team, Villejuif, France; Université Paris-Sud, UMRS 1018, Villejuif, France; Epidemiology Unit, Fondazione IRCCS Ca’ Granda—Ospedale Maggiore Policlinico, Milan, Italy; National Cancer Institute, Bethesda, MD; Roy Castle Lung Cancer Research Programme, The University of Liverpool Cancer Research Centre, Department of Molecular and Clinical Cancer Medicine, Institute of Translational Medicine, Liverpool, United Kingdom; Institut für Epidemiologie, Deutsches Forschungszentrum fur Gesundheit und Umwelt, Neuherberg, Germany; University of Montreal Hospital Research Center (CRCHUM), Montreal, Canada; INRS-Institut Armand-Frappier, Université du Québec, Laval, Québec, Canada; Institute for Medical Informatics, Biometry and Epidemiology, University of Duisburg-Essen, Essen, Germany; Leibniz Institute for Prevention Research and Epidemiology – BIPS, Bremen, Germany; The Biomedical Research Centre Network for Epidemiology and Public Health (CIBERESP), University of Oviedo, Oviedo, Spain; Russian Cancer Research Centre, Moscow, Russia; Public Health Ontario, Toronto, Canada; Occupational Cancer Research Centre, Cancer Care Ontario, Toronto, Canada; The Nofer Institute of Occupational Medicine, Lodz, Poland; The M Sklodowska-Curie Cancer Center and Institute of Oncology, Warsaw, Poland; National Centre for Public Health, Budapest, Hungary; Regional Authority of Public Health, Banska Bystrica, Slovakia; Institute of Public Health, Bucharest, Romania; Institute of Hygiene and Epidemiology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic; Masaryk Memorial Cancer Institute and Medical Faculty of Masaryk University, Department of Cancer Epidemiology & Genetics, Brno, Czech Republic; Faculty of Medicine, Palacky University, Olomouc, Czech Republic; The Tisch Cancer Institute and Institute for Translational Epidemiology, Icahn School of Medicine at Mount Sinai, New York, NY; National Institute for Public Health and the Environment (RIVM), Bilthoven, The Netherlands; and Department of Epidemiology, ASL RomaE, Rome, Italy
| | - Florence Guida
- From the International Agency for Research on Cancer, Lyon, France; The Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden; Institute for Risk Assessment Sciences, Utrecht, The Netherlands; Institute for Prevention and Occupational Medicine of the German Social Accident Insurance – Institute of the Ruhr-Universität Bochum (IPA), Bochum, Germany; Occupational Respiratory Epidemiology, School of Population Health, University of Western Australia, Perth, Australia; Cancer Epidemiology Unit, Department of Medical Sciences, University of Turin and CPO Piemonte, Turin, Italy; INSERM, Centre for research in Epidemiology and Population Health (CESP), U1018, Environmental epidemiology of cancer Team, Villejuif, France; Université Paris-Sud, UMRS 1018, Villejuif, France; Epidemiology Unit, Fondazione IRCCS Ca’ Granda—Ospedale Maggiore Policlinico, Milan, Italy; National Cancer Institute, Bethesda, MD; Roy Castle Lung Cancer Research Programme, The University of Liverpool Cancer Research Centre, Department of Molecular and Clinical Cancer Medicine, Institute of Translational Medicine, Liverpool, United Kingdom; Institut für Epidemiologie, Deutsches Forschungszentrum fur Gesundheit und Umwelt, Neuherberg, Germany; University of Montreal Hospital Research Center (CRCHUM), Montreal, Canada; INRS-Institut Armand-Frappier, Université du Québec, Laval, Québec, Canada; Institute for Medical Informatics, Biometry and Epidemiology, University of Duisburg-Essen, Essen, Germany; Leibniz Institute for Prevention Research and Epidemiology – BIPS, Bremen, Germany; The Biomedical Research Centre Network for Epidemiology and Public Health (CIBERESP), University of Oviedo, Oviedo, Spain; Russian Cancer Research Centre, Moscow, Russia; Public Health Ontario, Toronto, Canada; Occupational Cancer Research Centre, Cancer Care Ontario, Toronto, Canada; The Nofer Institute of Occupational Medicine, Lodz, Poland; The M Sklodowska-Curie Cancer Center and Institute of Oncology, Warsaw, Poland; National Centre for Public Health, Budapest, Hungary; Regional Authority of Public Health, Banska Bystrica, Slovakia; Institute of Public Health, Bucharest, Romania; Institute of Hygiene and Epidemiology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic; Masaryk Memorial Cancer Institute and Medical Faculty of Masaryk University, Department of Cancer Epidemiology & Genetics, Brno, Czech Republic; Faculty of Medicine, Palacky University, Olomouc, Czech Republic; The Tisch Cancer Institute and Institute for Translational Epidemiology, Icahn School of Medicine at Mount Sinai, New York, NY; National Institute for Public Health and the Environment (RIVM), Bilthoven, The Netherlands; and Department of Epidemiology, ASL RomaE, Rome, Italy
| | - Dario Consonni
- From the International Agency for Research on Cancer, Lyon, France; The Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden; Institute for Risk Assessment Sciences, Utrecht, The Netherlands; Institute for Prevention and Occupational Medicine of the German Social Accident Insurance – Institute of the Ruhr-Universität Bochum (IPA), Bochum, Germany; Occupational Respiratory Epidemiology, School of Population Health, University of Western Australia, Perth, Australia; Cancer Epidemiology Unit, Department of Medical Sciences, University of Turin and CPO Piemonte, Turin, Italy; INSERM, Centre for research in Epidemiology and Population Health (CESP), U1018, Environmental epidemiology of cancer Team, Villejuif, France; Université Paris-Sud, UMRS 1018, Villejuif, France; Epidemiology Unit, Fondazione IRCCS Ca’ Granda—Ospedale Maggiore Policlinico, Milan, Italy; National Cancer Institute, Bethesda, MD; Roy Castle Lung Cancer Research Programme, The University of Liverpool Cancer Research Centre, Department of Molecular and Clinical Cancer Medicine, Institute of Translational Medicine, Liverpool, United Kingdom; Institut für Epidemiologie, Deutsches Forschungszentrum fur Gesundheit und Umwelt, Neuherberg, Germany; University of Montreal Hospital Research Center (CRCHUM), Montreal, Canada; INRS-Institut Armand-Frappier, Université du Québec, Laval, Québec, Canada; Institute for Medical Informatics, Biometry and Epidemiology, University of Duisburg-Essen, Essen, Germany; Leibniz Institute for Prevention Research and Epidemiology – BIPS, Bremen, Germany; The Biomedical Research Centre Network for Epidemiology and Public Health (CIBERESP), University of Oviedo, Oviedo, Spain; Russian Cancer Research Centre, Moscow, Russia; Public Health Ontario, Toronto, Canada; Occupational Cancer Research Centre, Cancer Care Ontario, Toronto, Canada; The Nofer Institute of Occupational Medicine, Lodz, Poland; The M Sklodowska-Curie Cancer Center and Institute of Oncology, Warsaw, Poland; National Centre for Public Health, Budapest, Hungary; Regional Authority of Public Health, Banska Bystrica, Slovakia; Institute of Public Health, Bucharest, Romania; Institute of Hygiene and Epidemiology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic; Masaryk Memorial Cancer Institute and Medical Faculty of Masaryk University, Department of Cancer Epidemiology & Genetics, Brno, Czech Republic; Faculty of Medicine, Palacky University, Olomouc, Czech Republic; The Tisch Cancer Institute and Institute for Translational Epidemiology, Icahn School of Medicine at Mount Sinai, New York, NY; National Institute for Public Health and the Environment (RIVM), Bilthoven, The Netherlands; and Department of Epidemiology, ASL RomaE, Rome, Italy
| | - Neil Caporaso
- From the International Agency for Research on Cancer, Lyon, France; The Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden; Institute for Risk Assessment Sciences, Utrecht, The Netherlands; Institute for Prevention and Occupational Medicine of the German Social Accident Insurance – Institute of the Ruhr-Universität Bochum (IPA), Bochum, Germany; Occupational Respiratory Epidemiology, School of Population Health, University of Western Australia, Perth, Australia; Cancer Epidemiology Unit, Department of Medical Sciences, University of Turin and CPO Piemonte, Turin, Italy; INSERM, Centre for research in Epidemiology and Population Health (CESP), U1018, Environmental epidemiology of cancer Team, Villejuif, France; Université Paris-Sud, UMRS 1018, Villejuif, France; Epidemiology Unit, Fondazione IRCCS Ca’ Granda—Ospedale Maggiore Policlinico, Milan, Italy; National Cancer Institute, Bethesda, MD; Roy Castle Lung Cancer Research Programme, The University of Liverpool Cancer Research Centre, Department of Molecular and Clinical Cancer Medicine, Institute of Translational Medicine, Liverpool, United Kingdom; Institut für Epidemiologie, Deutsches Forschungszentrum fur Gesundheit und Umwelt, Neuherberg, Germany; University of Montreal Hospital Research Center (CRCHUM), Montreal, Canada; INRS-Institut Armand-Frappier, Université du Québec, Laval, Québec, Canada; Institute for Medical Informatics, Biometry and Epidemiology, University of Duisburg-Essen, Essen, Germany; Leibniz Institute for Prevention Research and Epidemiology – BIPS, Bremen, Germany; The Biomedical Research Centre Network for Epidemiology and Public Health (CIBERESP), University of Oviedo, Oviedo, Spain; Russian Cancer Research Centre, Moscow, Russia; Public Health Ontario, Toronto, Canada; Occupational Cancer Research Centre, Cancer Care Ontario, Toronto, Canada; The Nofer Institute of Occupational Medicine, Lodz, Poland; The M Sklodowska-Curie Cancer Center and Institute of Oncology, Warsaw, Poland; National Centre for Public Health, Budapest, Hungary; Regional Authority of Public Health, Banska Bystrica, Slovakia; Institute of Public Health, Bucharest, Romania; Institute of Hygiene and Epidemiology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic; Masaryk Memorial Cancer Institute and Medical Faculty of Masaryk University, Department of Cancer Epidemiology & Genetics, Brno, Czech Republic; Faculty of Medicine, Palacky University, Olomouc, Czech Republic; The Tisch Cancer Institute and Institute for Translational Epidemiology, Icahn School of Medicine at Mount Sinai, New York, NY; National Institute for Public Health and the Environment (RIVM), Bilthoven, The Netherlands; and Department of Epidemiology, ASL RomaE, Rome, Italy
| | - Maria Teresa Landi
- From the International Agency for Research on Cancer, Lyon, France; The Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden; Institute for Risk Assessment Sciences, Utrecht, The Netherlands; Institute for Prevention and Occupational Medicine of the German Social Accident Insurance – Institute of the Ruhr-Universität Bochum (IPA), Bochum, Germany; Occupational Respiratory Epidemiology, School of Population Health, University of Western Australia, Perth, Australia; Cancer Epidemiology Unit, Department of Medical Sciences, University of Turin and CPO Piemonte, Turin, Italy; INSERM, Centre for research in Epidemiology and Population Health (CESP), U1018, Environmental epidemiology of cancer Team, Villejuif, France; Université Paris-Sud, UMRS 1018, Villejuif, France; Epidemiology Unit, Fondazione IRCCS Ca’ Granda—Ospedale Maggiore Policlinico, Milan, Italy; National Cancer Institute, Bethesda, MD; Roy Castle Lung Cancer Research Programme, The University of Liverpool Cancer Research Centre, Department of Molecular and Clinical Cancer Medicine, Institute of Translational Medicine, Liverpool, United Kingdom; Institut für Epidemiologie, Deutsches Forschungszentrum fur Gesundheit und Umwelt, Neuherberg, Germany; University of Montreal Hospital Research Center (CRCHUM), Montreal, Canada; INRS-Institut Armand-Frappier, Université du Québec, Laval, Québec, Canada; Institute for Medical Informatics, Biometry and Epidemiology, University of Duisburg-Essen, Essen, Germany; Leibniz Institute for Prevention Research and Epidemiology – BIPS, Bremen, Germany; The Biomedical Research Centre Network for Epidemiology and Public Health (CIBERESP), University of Oviedo, Oviedo, Spain; Russian Cancer Research Centre, Moscow, Russia; Public Health Ontario, Toronto, Canada; Occupational Cancer Research Centre, Cancer Care Ontario, Toronto, Canada; The Nofer Institute of Occupational Medicine, Lodz, Poland; The M Sklodowska-Curie Cancer Center and Institute of Oncology, Warsaw, Poland; National Centre for Public Health, Budapest, Hungary; Regional Authority of Public Health, Banska Bystrica, Slovakia; Institute of Public Health, Bucharest, Romania; Institute of Hygiene and Epidemiology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic; Masaryk Memorial Cancer Institute and Medical Faculty of Masaryk University, Department of Cancer Epidemiology & Genetics, Brno, Czech Republic; Faculty of Medicine, Palacky University, Olomouc, Czech Republic; The Tisch Cancer Institute and Institute for Translational Epidemiology, Icahn School of Medicine at Mount Sinai, New York, NY; National Institute for Public Health and the Environment (RIVM), Bilthoven, The Netherlands; and Department of Epidemiology, ASL RomaE, Rome, Italy
| | - John Field
- From the International Agency for Research on Cancer, Lyon, France; The Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden; Institute for Risk Assessment Sciences, Utrecht, The Netherlands; Institute for Prevention and Occupational Medicine of the German Social Accident Insurance – Institute of the Ruhr-Universität Bochum (IPA), Bochum, Germany; Occupational Respiratory Epidemiology, School of Population Health, University of Western Australia, Perth, Australia; Cancer Epidemiology Unit, Department of Medical Sciences, University of Turin and CPO Piemonte, Turin, Italy; INSERM, Centre for research in Epidemiology and Population Health (CESP), U1018, Environmental epidemiology of cancer Team, Villejuif, France; Université Paris-Sud, UMRS 1018, Villejuif, France; Epidemiology Unit, Fondazione IRCCS Ca’ Granda—Ospedale Maggiore Policlinico, Milan, Italy; National Cancer Institute, Bethesda, MD; Roy Castle Lung Cancer Research Programme, The University of Liverpool Cancer Research Centre, Department of Molecular and Clinical Cancer Medicine, Institute of Translational Medicine, Liverpool, United Kingdom; Institut für Epidemiologie, Deutsches Forschungszentrum fur Gesundheit und Umwelt, Neuherberg, Germany; University of Montreal Hospital Research Center (CRCHUM), Montreal, Canada; INRS-Institut Armand-Frappier, Université du Québec, Laval, Québec, Canada; Institute for Medical Informatics, Biometry and Epidemiology, University of Duisburg-Essen, Essen, Germany; Leibniz Institute for Prevention Research and Epidemiology – BIPS, Bremen, Germany; The Biomedical Research Centre Network for Epidemiology and Public Health (CIBERESP), University of Oviedo, Oviedo, Spain; Russian Cancer Research Centre, Moscow, Russia; Public Health Ontario, Toronto, Canada; Occupational Cancer Research Centre, Cancer Care Ontario, Toronto, Canada; The Nofer Institute of Occupational Medicine, Lodz, Poland; The M Sklodowska-Curie Cancer Center and Institute of Oncology, Warsaw, Poland; National Centre for Public Health, Budapest, Hungary; Regional Authority of Public Health, Banska Bystrica, Slovakia; Institute of Public Health, Bucharest, Romania; Institute of Hygiene and Epidemiology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic; Masaryk Memorial Cancer Institute and Medical Faculty of Masaryk University, Department of Cancer Epidemiology & Genetics, Brno, Czech Republic; Faculty of Medicine, Palacky University, Olomouc, Czech Republic; The Tisch Cancer Institute and Institute for Translational Epidemiology, Icahn School of Medicine at Mount Sinai, New York, NY; National Institute for Public Health and the Environment (RIVM), Bilthoven, The Netherlands; and Department of Epidemiology, ASL RomaE, Rome, Italy
| | - Irene Brüske
- From the International Agency for Research on Cancer, Lyon, France; The Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden; Institute for Risk Assessment Sciences, Utrecht, The Netherlands; Institute for Prevention and Occupational Medicine of the German Social Accident Insurance – Institute of the Ruhr-Universität Bochum (IPA), Bochum, Germany; Occupational Respiratory Epidemiology, School of Population Health, University of Western Australia, Perth, Australia; Cancer Epidemiology Unit, Department of Medical Sciences, University of Turin and CPO Piemonte, Turin, Italy; INSERM, Centre for research in Epidemiology and Population Health (CESP), U1018, Environmental epidemiology of cancer Team, Villejuif, France; Université Paris-Sud, UMRS 1018, Villejuif, France; Epidemiology Unit, Fondazione IRCCS Ca’ Granda—Ospedale Maggiore Policlinico, Milan, Italy; National Cancer Institute, Bethesda, MD; Roy Castle Lung Cancer Research Programme, The University of Liverpool Cancer Research Centre, Department of Molecular and Clinical Cancer Medicine, Institute of Translational Medicine, Liverpool, United Kingdom; Institut für Epidemiologie, Deutsches Forschungszentrum fur Gesundheit und Umwelt, Neuherberg, Germany; University of Montreal Hospital Research Center (CRCHUM), Montreal, Canada; INRS-Institut Armand-Frappier, Université du Québec, Laval, Québec, Canada; Institute for Medical Informatics, Biometry and Epidemiology, University of Duisburg-Essen, Essen, Germany; Leibniz Institute for Prevention Research and Epidemiology – BIPS, Bremen, Germany; The Biomedical Research Centre Network for Epidemiology and Public Health (CIBERESP), University of Oviedo, Oviedo, Spain; Russian Cancer Research Centre, Moscow, Russia; Public Health Ontario, Toronto, Canada; Occupational Cancer Research Centre, Cancer Care Ontario, Toronto, Canada; The Nofer Institute of Occupational Medicine, Lodz, Poland; The M Sklodowska-Curie Cancer Center and Institute of Oncology, Warsaw, Poland; National Centre for Public Health, Budapest, Hungary; Regional Authority of Public Health, Banska Bystrica, Slovakia; Institute of Public Health, Bucharest, Romania; Institute of Hygiene and Epidemiology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic; Masaryk Memorial Cancer Institute and Medical Faculty of Masaryk University, Department of Cancer Epidemiology & Genetics, Brno, Czech Republic; Faculty of Medicine, Palacky University, Olomouc, Czech Republic; The Tisch Cancer Institute and Institute for Translational Epidemiology, Icahn School of Medicine at Mount Sinai, New York, NY; National Institute for Public Health and the Environment (RIVM), Bilthoven, The Netherlands; and Department of Epidemiology, ASL RomaE, Rome, Italy
| | - Heinz-Erich Wichmann
- From the International Agency for Research on Cancer, Lyon, France; The Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden; Institute for Risk Assessment Sciences, Utrecht, The Netherlands; Institute for Prevention and Occupational Medicine of the German Social Accident Insurance – Institute of the Ruhr-Universität Bochum (IPA), Bochum, Germany; Occupational Respiratory Epidemiology, School of Population Health, University of Western Australia, Perth, Australia; Cancer Epidemiology Unit, Department of Medical Sciences, University of Turin and CPO Piemonte, Turin, Italy; INSERM, Centre for research in Epidemiology and Population Health (CESP), U1018, Environmental epidemiology of cancer Team, Villejuif, France; Université Paris-Sud, UMRS 1018, Villejuif, France; Epidemiology Unit, Fondazione IRCCS Ca’ Granda—Ospedale Maggiore Policlinico, Milan, Italy; National Cancer Institute, Bethesda, MD; Roy Castle Lung Cancer Research Programme, The University of Liverpool Cancer Research Centre, Department of Molecular and Clinical Cancer Medicine, Institute of Translational Medicine, Liverpool, United Kingdom; Institut für Epidemiologie, Deutsches Forschungszentrum fur Gesundheit und Umwelt, Neuherberg, Germany; University of Montreal Hospital Research Center (CRCHUM), Montreal, Canada; INRS-Institut Armand-Frappier, Université du Québec, Laval, Québec, Canada; Institute for Medical Informatics, Biometry and Epidemiology, University of Duisburg-Essen, Essen, Germany; Leibniz Institute for Prevention Research and Epidemiology – BIPS, Bremen, Germany; The Biomedical Research Centre Network for Epidemiology and Public Health (CIBERESP), University of Oviedo, Oviedo, Spain; Russian Cancer Research Centre, Moscow, Russia; Public Health Ontario, Toronto, Canada; Occupational Cancer Research Centre, Cancer Care Ontario, Toronto, Canada; The Nofer Institute of Occupational Medicine, Lodz, Poland; The M Sklodowska-Curie Cancer Center and Institute of Oncology, Warsaw, Poland; National Centre for Public Health, Budapest, Hungary; Regional Authority of Public Health, Banska Bystrica, Slovakia; Institute of Public Health, Bucharest, Romania; Institute of Hygiene and Epidemiology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic; Masaryk Memorial Cancer Institute and Medical Faculty of Masaryk University, Department of Cancer Epidemiology & Genetics, Brno, Czech Republic; Faculty of Medicine, Palacky University, Olomouc, Czech Republic; The Tisch Cancer Institute and Institute for Translational Epidemiology, Icahn School of Medicine at Mount Sinai, New York, NY; National Institute for Public Health and the Environment (RIVM), Bilthoven, The Netherlands; and Department of Epidemiology, ASL RomaE, Rome, Italy
| | - Jack Siemiatycki
- From the International Agency for Research on Cancer, Lyon, France; The Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden; Institute for Risk Assessment Sciences, Utrecht, The Netherlands; Institute for Prevention and Occupational Medicine of the German Social Accident Insurance – Institute of the Ruhr-Universität Bochum (IPA), Bochum, Germany; Occupational Respiratory Epidemiology, School of Population Health, University of Western Australia, Perth, Australia; Cancer Epidemiology Unit, Department of Medical Sciences, University of Turin and CPO Piemonte, Turin, Italy; INSERM, Centre for research in Epidemiology and Population Health (CESP), U1018, Environmental epidemiology of cancer Team, Villejuif, France; Université Paris-Sud, UMRS 1018, Villejuif, France; Epidemiology Unit, Fondazione IRCCS Ca’ Granda—Ospedale Maggiore Policlinico, Milan, Italy; National Cancer Institute, Bethesda, MD; Roy Castle Lung Cancer Research Programme, The University of Liverpool Cancer Research Centre, Department of Molecular and Clinical Cancer Medicine, Institute of Translational Medicine, Liverpool, United Kingdom; Institut für Epidemiologie, Deutsches Forschungszentrum fur Gesundheit und Umwelt, Neuherberg, Germany; University of Montreal Hospital Research Center (CRCHUM), Montreal, Canada; INRS-Institut Armand-Frappier, Université du Québec, Laval, Québec, Canada; Institute for Medical Informatics, Biometry and Epidemiology, University of Duisburg-Essen, Essen, Germany; Leibniz Institute for Prevention Research and Epidemiology – BIPS, Bremen, Germany; The Biomedical Research Centre Network for Epidemiology and Public Health (CIBERESP), University of Oviedo, Oviedo, Spain; Russian Cancer Research Centre, Moscow, Russia; Public Health Ontario, Toronto, Canada; Occupational Cancer Research Centre, Cancer Care Ontario, Toronto, Canada; The Nofer Institute of Occupational Medicine, Lodz, Poland; The M Sklodowska-Curie Cancer Center and Institute of Oncology, Warsaw, Poland; National Centre for Public Health, Budapest, Hungary; Regional Authority of Public Health, Banska Bystrica, Slovakia; Institute of Public Health, Bucharest, Romania; Institute of Hygiene and Epidemiology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic; Masaryk Memorial Cancer Institute and Medical Faculty of Masaryk University, Department of Cancer Epidemiology & Genetics, Brno, Czech Republic; Faculty of Medicine, Palacky University, Olomouc, Czech Republic; The Tisch Cancer Institute and Institute for Translational Epidemiology, Icahn School of Medicine at Mount Sinai, New York, NY; National Institute for Public Health and the Environment (RIVM), Bilthoven, The Netherlands; and Department of Epidemiology, ASL RomaE, Rome, Italy
| | - Marie-Elise Parent
- From the International Agency for Research on Cancer, Lyon, France; The Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden; Institute for Risk Assessment Sciences, Utrecht, The Netherlands; Institute for Prevention and Occupational Medicine of the German Social Accident Insurance – Institute of the Ruhr-Universität Bochum (IPA), Bochum, Germany; Occupational Respiratory Epidemiology, School of Population Health, University of Western Australia, Perth, Australia; Cancer Epidemiology Unit, Department of Medical Sciences, University of Turin and CPO Piemonte, Turin, Italy; INSERM, Centre for research in Epidemiology and Population Health (CESP), U1018, Environmental epidemiology of cancer Team, Villejuif, France; Université Paris-Sud, UMRS 1018, Villejuif, France; Epidemiology Unit, Fondazione IRCCS Ca’ Granda—Ospedale Maggiore Policlinico, Milan, Italy; National Cancer Institute, Bethesda, MD; Roy Castle Lung Cancer Research Programme, The University of Liverpool Cancer Research Centre, Department of Molecular and Clinical Cancer Medicine, Institute of Translational Medicine, Liverpool, United Kingdom; Institut für Epidemiologie, Deutsches Forschungszentrum fur Gesundheit und Umwelt, Neuherberg, Germany; University of Montreal Hospital Research Center (CRCHUM), Montreal, Canada; INRS-Institut Armand-Frappier, Université du Québec, Laval, Québec, Canada; Institute for Medical Informatics, Biometry and Epidemiology, University of Duisburg-Essen, Essen, Germany; Leibniz Institute for Prevention Research and Epidemiology – BIPS, Bremen, Germany; The Biomedical Research Centre Network for Epidemiology and Public Health (CIBERESP), University of Oviedo, Oviedo, Spain; Russian Cancer Research Centre, Moscow, Russia; Public Health Ontario, Toronto, Canada; Occupational Cancer Research Centre, Cancer Care Ontario, Toronto, Canada; The Nofer Institute of Occupational Medicine, Lodz, Poland; The M Sklodowska-Curie Cancer Center and Institute of Oncology, Warsaw, Poland; National Centre for Public Health, Budapest, Hungary; Regional Authority of Public Health, Banska Bystrica, Slovakia; Institute of Public Health, Bucharest, Romania; Institute of Hygiene and Epidemiology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic; Masaryk Memorial Cancer Institute and Medical Faculty of Masaryk University, Department of Cancer Epidemiology & Genetics, Brno, Czech Republic; Faculty of Medicine, Palacky University, Olomouc, Czech Republic; The Tisch Cancer Institute and Institute for Translational Epidemiology, Icahn School of Medicine at Mount Sinai, New York, NY; National Institute for Public Health and the Environment (RIVM), Bilthoven, The Netherlands; and Department of Epidemiology, ASL RomaE, Rome, Italy
| | - Lorenzo Richiardi
- From the International Agency for Research on Cancer, Lyon, France; The Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden; Institute for Risk Assessment Sciences, Utrecht, The Netherlands; Institute for Prevention and Occupational Medicine of the German Social Accident Insurance – Institute of the Ruhr-Universität Bochum (IPA), Bochum, Germany; Occupational Respiratory Epidemiology, School of Population Health, University of Western Australia, Perth, Australia; Cancer Epidemiology Unit, Department of Medical Sciences, University of Turin and CPO Piemonte, Turin, Italy; INSERM, Centre for research in Epidemiology and Population Health (CESP), U1018, Environmental epidemiology of cancer Team, Villejuif, France; Université Paris-Sud, UMRS 1018, Villejuif, France; Epidemiology Unit, Fondazione IRCCS Ca’ Granda—Ospedale Maggiore Policlinico, Milan, Italy; National Cancer Institute, Bethesda, MD; Roy Castle Lung Cancer Research Programme, The University of Liverpool Cancer Research Centre, Department of Molecular and Clinical Cancer Medicine, Institute of Translational Medicine, Liverpool, United Kingdom; Institut für Epidemiologie, Deutsches Forschungszentrum fur Gesundheit und Umwelt, Neuherberg, Germany; University of Montreal Hospital Research Center (CRCHUM), Montreal, Canada; INRS-Institut Armand-Frappier, Université du Québec, Laval, Québec, Canada; Institute for Medical Informatics, Biometry and Epidemiology, University of Duisburg-Essen, Essen, Germany; Leibniz Institute for Prevention Research and Epidemiology – BIPS, Bremen, Germany; The Biomedical Research Centre Network for Epidemiology and Public Health (CIBERESP), University of Oviedo, Oviedo, Spain; Russian Cancer Research Centre, Moscow, Russia; Public Health Ontario, Toronto, Canada; Occupational Cancer Research Centre, Cancer Care Ontario, Toronto, Canada; The Nofer Institute of Occupational Medicine, Lodz, Poland; The M Sklodowska-Curie Cancer Center and Institute of Oncology, Warsaw, Poland; National Centre for Public Health, Budapest, Hungary; Regional Authority of Public Health, Banska Bystrica, Slovakia; Institute of Public Health, Bucharest, Romania; Institute of Hygiene and Epidemiology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic; Masaryk Memorial Cancer Institute and Medical Faculty of Masaryk University, Department of Cancer Epidemiology & Genetics, Brno, Czech Republic; Faculty of Medicine, Palacky University, Olomouc, Czech Republic; The Tisch Cancer Institute and Institute for Translational Epidemiology, Icahn School of Medicine at Mount Sinai, New York, NY; National Institute for Public Health and the Environment (RIVM), Bilthoven, The Netherlands; and Department of Epidemiology, ASL RomaE, Rome, Italy
| | - Franco Merletti
- From the International Agency for Research on Cancer, Lyon, France; The Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden; Institute for Risk Assessment Sciences, Utrecht, The Netherlands; Institute for Prevention and Occupational Medicine of the German Social Accident Insurance – Institute of the Ruhr-Universität Bochum (IPA), Bochum, Germany; Occupational Respiratory Epidemiology, School of Population Health, University of Western Australia, Perth, Australia; Cancer Epidemiology Unit, Department of Medical Sciences, University of Turin and CPO Piemonte, Turin, Italy; INSERM, Centre for research in Epidemiology and Population Health (CESP), U1018, Environmental epidemiology of cancer Team, Villejuif, France; Université Paris-Sud, UMRS 1018, Villejuif, France; Epidemiology Unit, Fondazione IRCCS Ca’ Granda—Ospedale Maggiore Policlinico, Milan, Italy; National Cancer Institute, Bethesda, MD; Roy Castle Lung Cancer Research Programme, The University of Liverpool Cancer Research Centre, Department of Molecular and Clinical Cancer Medicine, Institute of Translational Medicine, Liverpool, United Kingdom; Institut für Epidemiologie, Deutsches Forschungszentrum fur Gesundheit und Umwelt, Neuherberg, Germany; University of Montreal Hospital Research Center (CRCHUM), Montreal, Canada; INRS-Institut Armand-Frappier, Université du Québec, Laval, Québec, Canada; Institute for Medical Informatics, Biometry and Epidemiology, University of Duisburg-Essen, Essen, Germany; Leibniz Institute for Prevention Research and Epidemiology – BIPS, Bremen, Germany; The Biomedical Research Centre Network for Epidemiology and Public Health (CIBERESP), University of Oviedo, Oviedo, Spain; Russian Cancer Research Centre, Moscow, Russia; Public Health Ontario, Toronto, Canada; Occupational Cancer Research Centre, Cancer Care Ontario, Toronto, Canada; The Nofer Institute of Occupational Medicine, Lodz, Poland; The M Sklodowska-Curie Cancer Center and Institute of Oncology, Warsaw, Poland; National Centre for Public Health, Budapest, Hungary; Regional Authority of Public Health, Banska Bystrica, Slovakia; Institute of Public Health, Bucharest, Romania; Institute of Hygiene and Epidemiology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic; Masaryk Memorial Cancer Institute and Medical Faculty of Masaryk University, Department of Cancer Epidemiology & Genetics, Brno, Czech Republic; Faculty of Medicine, Palacky University, Olomouc, Czech Republic; The Tisch Cancer Institute and Institute for Translational Epidemiology, Icahn School of Medicine at Mount Sinai, New York, NY; National Institute for Public Health and the Environment (RIVM), Bilthoven, The Netherlands; and Department of Epidemiology, ASL RomaE, Rome, Italy
| | - Karl-Heinz Jöckel
- From the International Agency for Research on Cancer, Lyon, France; The Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden; Institute for Risk Assessment Sciences, Utrecht, The Netherlands; Institute for Prevention and Occupational Medicine of the German Social Accident Insurance – Institute of the Ruhr-Universität Bochum (IPA), Bochum, Germany; Occupational Respiratory Epidemiology, School of Population Health, University of Western Australia, Perth, Australia; Cancer Epidemiology Unit, Department of Medical Sciences, University of Turin and CPO Piemonte, Turin, Italy; INSERM, Centre for research in Epidemiology and Population Health (CESP), U1018, Environmental epidemiology of cancer Team, Villejuif, France; Université Paris-Sud, UMRS 1018, Villejuif, France; Epidemiology Unit, Fondazione IRCCS Ca’ Granda—Ospedale Maggiore Policlinico, Milan, Italy; National Cancer Institute, Bethesda, MD; Roy Castle Lung Cancer Research Programme, The University of Liverpool Cancer Research Centre, Department of Molecular and Clinical Cancer Medicine, Institute of Translational Medicine, Liverpool, United Kingdom; Institut für Epidemiologie, Deutsches Forschungszentrum fur Gesundheit und Umwelt, Neuherberg, Germany; University of Montreal Hospital Research Center (CRCHUM), Montreal, Canada; INRS-Institut Armand-Frappier, Université du Québec, Laval, Québec, Canada; Institute for Medical Informatics, Biometry and Epidemiology, University of Duisburg-Essen, Essen, Germany; Leibniz Institute for Prevention Research and Epidemiology – BIPS, Bremen, Germany; The Biomedical Research Centre Network for Epidemiology and Public Health (CIBERESP), University of Oviedo, Oviedo, Spain; Russian Cancer Research Centre, Moscow, Russia; Public Health Ontario, Toronto, Canada; Occupational Cancer Research Centre, Cancer Care Ontario, Toronto, Canada; The Nofer Institute of Occupational Medicine, Lodz, Poland; The M Sklodowska-Curie Cancer Center and Institute of Oncology, Warsaw, Poland; National Centre for Public Health, Budapest, Hungary; Regional Authority of Public Health, Banska Bystrica, Slovakia; Institute of Public Health, Bucharest, Romania; Institute of Hygiene and Epidemiology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic; Masaryk Memorial Cancer Institute and Medical Faculty of Masaryk University, Department of Cancer Epidemiology & Genetics, Brno, Czech Republic; Faculty of Medicine, Palacky University, Olomouc, Czech Republic; The Tisch Cancer Institute and Institute for Translational Epidemiology, Icahn School of Medicine at Mount Sinai, New York, NY; National Institute for Public Health and the Environment (RIVM), Bilthoven, The Netherlands; and Department of Epidemiology, ASL RomaE, Rome, Italy
| | - Wolfgang Ahrens
- From the International Agency for Research on Cancer, Lyon, France; The Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden; Institute for Risk Assessment Sciences, Utrecht, The Netherlands; Institute for Prevention and Occupational Medicine of the German Social Accident Insurance – Institute of the Ruhr-Universität Bochum (IPA), Bochum, Germany; Occupational Respiratory Epidemiology, School of Population Health, University of Western Australia, Perth, Australia; Cancer Epidemiology Unit, Department of Medical Sciences, University of Turin and CPO Piemonte, Turin, Italy; INSERM, Centre for research in Epidemiology and Population Health (CESP), U1018, Environmental epidemiology of cancer Team, Villejuif, France; Université Paris-Sud, UMRS 1018, Villejuif, France; Epidemiology Unit, Fondazione IRCCS Ca’ Granda—Ospedale Maggiore Policlinico, Milan, Italy; National Cancer Institute, Bethesda, MD; Roy Castle Lung Cancer Research Programme, The University of Liverpool Cancer Research Centre, Department of Molecular and Clinical Cancer Medicine, Institute of Translational Medicine, Liverpool, United Kingdom; Institut für Epidemiologie, Deutsches Forschungszentrum fur Gesundheit und Umwelt, Neuherberg, Germany; University of Montreal Hospital Research Center (CRCHUM), Montreal, Canada; INRS-Institut Armand-Frappier, Université du Québec, Laval, Québec, Canada; Institute for Medical Informatics, Biometry and Epidemiology, University of Duisburg-Essen, Essen, Germany; Leibniz Institute for Prevention Research and Epidemiology – BIPS, Bremen, Germany; The Biomedical Research Centre Network for Epidemiology and Public Health (CIBERESP), University of Oviedo, Oviedo, Spain; Russian Cancer Research Centre, Moscow, Russia; Public Health Ontario, Toronto, Canada; Occupational Cancer Research Centre, Cancer Care Ontario, Toronto, Canada; The Nofer Institute of Occupational Medicine, Lodz, Poland; The M Sklodowska-Curie Cancer Center and Institute of Oncology, Warsaw, Poland; National Centre for Public Health, Budapest, Hungary; Regional Authority of Public Health, Banska Bystrica, Slovakia; Institute of Public Health, Bucharest, Romania; Institute of Hygiene and Epidemiology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic; Masaryk Memorial Cancer Institute and Medical Faculty of Masaryk University, Department of Cancer Epidemiology & Genetics, Brno, Czech Republic; Faculty of Medicine, Palacky University, Olomouc, Czech Republic; The Tisch Cancer Institute and Institute for Translational Epidemiology, Icahn School of Medicine at Mount Sinai, New York, NY; National Institute for Public Health and the Environment (RIVM), Bilthoven, The Netherlands; and Department of Epidemiology, ASL RomaE, Rome, Italy
| | - Hermann Pohlabeln
- From the International Agency for Research on Cancer, Lyon, France; The Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden; Institute for Risk Assessment Sciences, Utrecht, The Netherlands; Institute for Prevention and Occupational Medicine of the German Social Accident Insurance – Institute of the Ruhr-Universität Bochum (IPA), Bochum, Germany; Occupational Respiratory Epidemiology, School of Population Health, University of Western Australia, Perth, Australia; Cancer Epidemiology Unit, Department of Medical Sciences, University of Turin and CPO Piemonte, Turin, Italy; INSERM, Centre for research in Epidemiology and Population Health (CESP), U1018, Environmental epidemiology of cancer Team, Villejuif, France; Université Paris-Sud, UMRS 1018, Villejuif, France; Epidemiology Unit, Fondazione IRCCS Ca’ Granda—Ospedale Maggiore Policlinico, Milan, Italy; National Cancer Institute, Bethesda, MD; Roy Castle Lung Cancer Research Programme, The University of Liverpool Cancer Research Centre, Department of Molecular and Clinical Cancer Medicine, Institute of Translational Medicine, Liverpool, United Kingdom; Institut für Epidemiologie, Deutsches Forschungszentrum fur Gesundheit und Umwelt, Neuherberg, Germany; University of Montreal Hospital Research Center (CRCHUM), Montreal, Canada; INRS-Institut Armand-Frappier, Université du Québec, Laval, Québec, Canada; Institute for Medical Informatics, Biometry and Epidemiology, University of Duisburg-Essen, Essen, Germany; Leibniz Institute for Prevention Research and Epidemiology – BIPS, Bremen, Germany; The Biomedical Research Centre Network for Epidemiology and Public Health (CIBERESP), University of Oviedo, Oviedo, Spain; Russian Cancer Research Centre, Moscow, Russia; Public Health Ontario, Toronto, Canada; Occupational Cancer Research Centre, Cancer Care Ontario, Toronto, Canada; The Nofer Institute of Occupational Medicine, Lodz, Poland; The M Sklodowska-Curie Cancer Center and Institute of Oncology, Warsaw, Poland; National Centre for Public Health, Budapest, Hungary; Regional Authority of Public Health, Banska Bystrica, Slovakia; Institute of Public Health, Bucharest, Romania; Institute of Hygiene and Epidemiology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic; Masaryk Memorial Cancer Institute and Medical Faculty of Masaryk University, Department of Cancer Epidemiology & Genetics, Brno, Czech Republic; Faculty of Medicine, Palacky University, Olomouc, Czech Republic; The Tisch Cancer Institute and Institute for Translational Epidemiology, Icahn School of Medicine at Mount Sinai, New York, NY; National Institute for Public Health and the Environment (RIVM), Bilthoven, The Netherlands; and Department of Epidemiology, ASL RomaE, Rome, Italy
| | - Nils Plato
- From the International Agency for Research on Cancer, Lyon, France; The Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden; Institute for Risk Assessment Sciences, Utrecht, The Netherlands; Institute for Prevention and Occupational Medicine of the German Social Accident Insurance – Institute of the Ruhr-Universität Bochum (IPA), Bochum, Germany; Occupational Respiratory Epidemiology, School of Population Health, University of Western Australia, Perth, Australia; Cancer Epidemiology Unit, Department of Medical Sciences, University of Turin and CPO Piemonte, Turin, Italy; INSERM, Centre for research in Epidemiology and Population Health (CESP), U1018, Environmental epidemiology of cancer Team, Villejuif, France; Université Paris-Sud, UMRS 1018, Villejuif, France; Epidemiology Unit, Fondazione IRCCS Ca’ Granda—Ospedale Maggiore Policlinico, Milan, Italy; National Cancer Institute, Bethesda, MD; Roy Castle Lung Cancer Research Programme, The University of Liverpool Cancer Research Centre, Department of Molecular and Clinical Cancer Medicine, Institute of Translational Medicine, Liverpool, United Kingdom; Institut für Epidemiologie, Deutsches Forschungszentrum fur Gesundheit und Umwelt, Neuherberg, Germany; University of Montreal Hospital Research Center (CRCHUM), Montreal, Canada; INRS-Institut Armand-Frappier, Université du Québec, Laval, Québec, Canada; Institute for Medical Informatics, Biometry and Epidemiology, University of Duisburg-Essen, Essen, Germany; Leibniz Institute for Prevention Research and Epidemiology – BIPS, Bremen, Germany; The Biomedical Research Centre Network for Epidemiology and Public Health (CIBERESP), University of Oviedo, Oviedo, Spain; Russian Cancer Research Centre, Moscow, Russia; Public Health Ontario, Toronto, Canada; Occupational Cancer Research Centre, Cancer Care Ontario, Toronto, Canada; The Nofer Institute of Occupational Medicine, Lodz, Poland; The M Sklodowska-Curie Cancer Center and Institute of Oncology, Warsaw, Poland; National Centre for Public Health, Budapest, Hungary; Regional Authority of Public Health, Banska Bystrica, Slovakia; Institute of Public Health, Bucharest, Romania; Institute of Hygiene and Epidemiology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic; Masaryk Memorial Cancer Institute and Medical Faculty of Masaryk University, Department of Cancer Epidemiology & Genetics, Brno, Czech Republic; Faculty of Medicine, Palacky University, Olomouc, Czech Republic; The Tisch Cancer Institute and Institute for Translational Epidemiology, Icahn School of Medicine at Mount Sinai, New York, NY; National Institute for Public Health and the Environment (RIVM), Bilthoven, The Netherlands; and Department of Epidemiology, ASL RomaE, Rome, Italy
| | - Adonina Tardón
- From the International Agency for Research on Cancer, Lyon, France; The Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden; Institute for Risk Assessment Sciences, Utrecht, The Netherlands; Institute for Prevention and Occupational Medicine of the German Social Accident Insurance – Institute of the Ruhr-Universität Bochum (IPA), Bochum, Germany; Occupational Respiratory Epidemiology, School of Population Health, University of Western Australia, Perth, Australia; Cancer Epidemiology Unit, Department of Medical Sciences, University of Turin and CPO Piemonte, Turin, Italy; INSERM, Centre for research in Epidemiology and Population Health (CESP), U1018, Environmental epidemiology of cancer Team, Villejuif, France; Université Paris-Sud, UMRS 1018, Villejuif, France; Epidemiology Unit, Fondazione IRCCS Ca’ Granda—Ospedale Maggiore Policlinico, Milan, Italy; National Cancer Institute, Bethesda, MD; Roy Castle Lung Cancer Research Programme, The University of Liverpool Cancer Research Centre, Department of Molecular and Clinical Cancer Medicine, Institute of Translational Medicine, Liverpool, United Kingdom; Institut für Epidemiologie, Deutsches Forschungszentrum fur Gesundheit und Umwelt, Neuherberg, Germany; University of Montreal Hospital Research Center (CRCHUM), Montreal, Canada; INRS-Institut Armand-Frappier, Université du Québec, Laval, Québec, Canada; Institute for Medical Informatics, Biometry and Epidemiology, University of Duisburg-Essen, Essen, Germany; Leibniz Institute for Prevention Research and Epidemiology – BIPS, Bremen, Germany; The Biomedical Research Centre Network for Epidemiology and Public Health (CIBERESP), University of Oviedo, Oviedo, Spain; Russian Cancer Research Centre, Moscow, Russia; Public Health Ontario, Toronto, Canada; Occupational Cancer Research Centre, Cancer Care Ontario, Toronto, Canada; The Nofer Institute of Occupational Medicine, Lodz, Poland; The M Sklodowska-Curie Cancer Center and Institute of Oncology, Warsaw, Poland; National Centre for Public Health, Budapest, Hungary; Regional Authority of Public Health, Banska Bystrica, Slovakia; Institute of Public Health, Bucharest, Romania; Institute of Hygiene and Epidemiology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic; Masaryk Memorial Cancer Institute and Medical Faculty of Masaryk University, Department of Cancer Epidemiology & Genetics, Brno, Czech Republic; Faculty of Medicine, Palacky University, Olomouc, Czech Republic; The Tisch Cancer Institute and Institute for Translational Epidemiology, Icahn School of Medicine at Mount Sinai, New York, NY; National Institute for Public Health and the Environment (RIVM), Bilthoven, The Netherlands; and Department of Epidemiology, ASL RomaE, Rome, Italy
| | - David Zaridze
- From the International Agency for Research on Cancer, Lyon, France; The Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden; Institute for Risk Assessment Sciences, Utrecht, The Netherlands; Institute for Prevention and Occupational Medicine of the German Social Accident Insurance – Institute of the Ruhr-Universität Bochum (IPA), Bochum, Germany; Occupational Respiratory Epidemiology, School of Population Health, University of Western Australia, Perth, Australia; Cancer Epidemiology Unit, Department of Medical Sciences, University of Turin and CPO Piemonte, Turin, Italy; INSERM, Centre for research in Epidemiology and Population Health (CESP), U1018, Environmental epidemiology of cancer Team, Villejuif, France; Université Paris-Sud, UMRS 1018, Villejuif, France; Epidemiology Unit, Fondazione IRCCS Ca’ Granda—Ospedale Maggiore Policlinico, Milan, Italy; National Cancer Institute, Bethesda, MD; Roy Castle Lung Cancer Research Programme, The University of Liverpool Cancer Research Centre, Department of Molecular and Clinical Cancer Medicine, Institute of Translational Medicine, Liverpool, United Kingdom; Institut für Epidemiologie, Deutsches Forschungszentrum fur Gesundheit und Umwelt, Neuherberg, Germany; University of Montreal Hospital Research Center (CRCHUM), Montreal, Canada; INRS-Institut Armand-Frappier, Université du Québec, Laval, Québec, Canada; Institute for Medical Informatics, Biometry and Epidemiology, University of Duisburg-Essen, Essen, Germany; Leibniz Institute for Prevention Research and Epidemiology – BIPS, Bremen, Germany; The Biomedical Research Centre Network for Epidemiology and Public Health (CIBERESP), University of Oviedo, Oviedo, Spain; Russian Cancer Research Centre, Moscow, Russia; Public Health Ontario, Toronto, Canada; Occupational Cancer Research Centre, Cancer Care Ontario, Toronto, Canada; The Nofer Institute of Occupational Medicine, Lodz, Poland; The M Sklodowska-Curie Cancer Center and Institute of Oncology, Warsaw, Poland; National Centre for Public Health, Budapest, Hungary; Regional Authority of Public Health, Banska Bystrica, Slovakia; Institute of Public Health, Bucharest, Romania; Institute of Hygiene and Epidemiology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic; Masaryk Memorial Cancer Institute and Medical Faculty of Masaryk University, Department of Cancer Epidemiology & Genetics, Brno, Czech Republic; Faculty of Medicine, Palacky University, Olomouc, Czech Republic; The Tisch Cancer Institute and Institute for Translational Epidemiology, Icahn School of Medicine at Mount Sinai, New York, NY; National Institute for Public Health and the Environment (RIVM), Bilthoven, The Netherlands; and Department of Epidemiology, ASL RomaE, Rome, Italy
| | - John McLaughlin
- From the International Agency for Research on Cancer, Lyon, France; The Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden; Institute for Risk Assessment Sciences, Utrecht, The Netherlands; Institute for Prevention and Occupational Medicine of the German Social Accident Insurance – Institute of the Ruhr-Universität Bochum (IPA), Bochum, Germany; Occupational Respiratory Epidemiology, School of Population Health, University of Western Australia, Perth, Australia; Cancer Epidemiology Unit, Department of Medical Sciences, University of Turin and CPO Piemonte, Turin, Italy; INSERM, Centre for research in Epidemiology and Population Health (CESP), U1018, Environmental epidemiology of cancer Team, Villejuif, France; Université Paris-Sud, UMRS 1018, Villejuif, France; Epidemiology Unit, Fondazione IRCCS Ca’ Granda—Ospedale Maggiore Policlinico, Milan, Italy; National Cancer Institute, Bethesda, MD; Roy Castle Lung Cancer Research Programme, The University of Liverpool Cancer Research Centre, Department of Molecular and Clinical Cancer Medicine, Institute of Translational Medicine, Liverpool, United Kingdom; Institut für Epidemiologie, Deutsches Forschungszentrum fur Gesundheit und Umwelt, Neuherberg, Germany; University of Montreal Hospital Research Center (CRCHUM), Montreal, Canada; INRS-Institut Armand-Frappier, Université du Québec, Laval, Québec, Canada; Institute for Medical Informatics, Biometry and Epidemiology, University of Duisburg-Essen, Essen, Germany; Leibniz Institute for Prevention Research and Epidemiology – BIPS, Bremen, Germany; The Biomedical Research Centre Network for Epidemiology and Public Health (CIBERESP), University of Oviedo, Oviedo, Spain; Russian Cancer Research Centre, Moscow, Russia; Public Health Ontario, Toronto, Canada; Occupational Cancer Research Centre, Cancer Care Ontario, Toronto, Canada; The Nofer Institute of Occupational Medicine, Lodz, Poland; The M Sklodowska-Curie Cancer Center and Institute of Oncology, Warsaw, Poland; National Centre for Public Health, Budapest, Hungary; Regional Authority of Public Health, Banska Bystrica, Slovakia; Institute of Public Health, Bucharest, Romania; Institute of Hygiene and Epidemiology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic; Masaryk Memorial Cancer Institute and Medical Faculty of Masaryk University, Department of Cancer Epidemiology & Genetics, Brno, Czech Republic; Faculty of Medicine, Palacky University, Olomouc, Czech Republic; The Tisch Cancer Institute and Institute for Translational Epidemiology, Icahn School of Medicine at Mount Sinai, New York, NY; National Institute for Public Health and the Environment (RIVM), Bilthoven, The Netherlands; and Department of Epidemiology, ASL RomaE, Rome, Italy
| | - Paul Demers
- From the International Agency for Research on Cancer, Lyon, France; The Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden; Institute for Risk Assessment Sciences, Utrecht, The Netherlands; Institute for Prevention and Occupational Medicine of the German Social Accident Insurance – Institute of the Ruhr-Universität Bochum (IPA), Bochum, Germany; Occupational Respiratory Epidemiology, School of Population Health, University of Western Australia, Perth, Australia; Cancer Epidemiology Unit, Department of Medical Sciences, University of Turin and CPO Piemonte, Turin, Italy; INSERM, Centre for research in Epidemiology and Population Health (CESP), U1018, Environmental epidemiology of cancer Team, Villejuif, France; Université Paris-Sud, UMRS 1018, Villejuif, France; Epidemiology Unit, Fondazione IRCCS Ca’ Granda—Ospedale Maggiore Policlinico, Milan, Italy; National Cancer Institute, Bethesda, MD; Roy Castle Lung Cancer Research Programme, The University of Liverpool Cancer Research Centre, Department of Molecular and Clinical Cancer Medicine, Institute of Translational Medicine, Liverpool, United Kingdom; Institut für Epidemiologie, Deutsches Forschungszentrum fur Gesundheit und Umwelt, Neuherberg, Germany; University of Montreal Hospital Research Center (CRCHUM), Montreal, Canada; INRS-Institut Armand-Frappier, Université du Québec, Laval, Québec, Canada; Institute for Medical Informatics, Biometry and Epidemiology, University of Duisburg-Essen, Essen, Germany; Leibniz Institute for Prevention Research and Epidemiology – BIPS, Bremen, Germany; The Biomedical Research Centre Network for Epidemiology and Public Health (CIBERESP), University of Oviedo, Oviedo, Spain; Russian Cancer Research Centre, Moscow, Russia; Public Health Ontario, Toronto, Canada; Occupational Cancer Research Centre, Cancer Care Ontario, Toronto, Canada; The Nofer Institute of Occupational Medicine, Lodz, Poland; The M Sklodowska-Curie Cancer Center and Institute of Oncology, Warsaw, Poland; National Centre for Public Health, Budapest, Hungary; Regional Authority of Public Health, Banska Bystrica, Slovakia; Institute of Public Health, Bucharest, Romania; Institute of Hygiene and Epidemiology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic; Masaryk Memorial Cancer Institute and Medical Faculty of Masaryk University, Department of Cancer Epidemiology & Genetics, Brno, Czech Republic; Faculty of Medicine, Palacky University, Olomouc, Czech Republic; The Tisch Cancer Institute and Institute for Translational Epidemiology, Icahn School of Medicine at Mount Sinai, New York, NY; National Institute for Public Health and the Environment (RIVM), Bilthoven, The Netherlands; and Department of Epidemiology, ASL RomaE, Rome, Italy
| | - Neonila Szeszenia-Dabrowska
- From the International Agency for Research on Cancer, Lyon, France; The Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden; Institute for Risk Assessment Sciences, Utrecht, The Netherlands; Institute for Prevention and Occupational Medicine of the German Social Accident Insurance – Institute of the Ruhr-Universität Bochum (IPA), Bochum, Germany; Occupational Respiratory Epidemiology, School of Population Health, University of Western Australia, Perth, Australia; Cancer Epidemiology Unit, Department of Medical Sciences, University of Turin and CPO Piemonte, Turin, Italy; INSERM, Centre for research in Epidemiology and Population Health (CESP), U1018, Environmental epidemiology of cancer Team, Villejuif, France; Université Paris-Sud, UMRS 1018, Villejuif, France; Epidemiology Unit, Fondazione IRCCS Ca’ Granda—Ospedale Maggiore Policlinico, Milan, Italy; National Cancer Institute, Bethesda, MD; Roy Castle Lung Cancer Research Programme, The University of Liverpool Cancer Research Centre, Department of Molecular and Clinical Cancer Medicine, Institute of Translational Medicine, Liverpool, United Kingdom; Institut für Epidemiologie, Deutsches Forschungszentrum fur Gesundheit und Umwelt, Neuherberg, Germany; University of Montreal Hospital Research Center (CRCHUM), Montreal, Canada; INRS-Institut Armand-Frappier, Université du Québec, Laval, Québec, Canada; Institute for Medical Informatics, Biometry and Epidemiology, University of Duisburg-Essen, Essen, Germany; Leibniz Institute for Prevention Research and Epidemiology – BIPS, Bremen, Germany; The Biomedical Research Centre Network for Epidemiology and Public Health (CIBERESP), University of Oviedo, Oviedo, Spain; Russian Cancer Research Centre, Moscow, Russia; Public Health Ontario, Toronto, Canada; Occupational Cancer Research Centre, Cancer Care Ontario, Toronto, Canada; The Nofer Institute of Occupational Medicine, Lodz, Poland; The M Sklodowska-Curie Cancer Center and Institute of Oncology, Warsaw, Poland; National Centre for Public Health, Budapest, Hungary; Regional Authority of Public Health, Banska Bystrica, Slovakia; Institute of Public Health, Bucharest, Romania; Institute of Hygiene and Epidemiology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic; Masaryk Memorial Cancer Institute and Medical Faculty of Masaryk University, Department of Cancer Epidemiology & Genetics, Brno, Czech Republic; Faculty of Medicine, Palacky University, Olomouc, Czech Republic; The Tisch Cancer Institute and Institute for Translational Epidemiology, Icahn School of Medicine at Mount Sinai, New York, NY; National Institute for Public Health and the Environment (RIVM), Bilthoven, The Netherlands; and Department of Epidemiology, ASL RomaE, Rome, Italy
| | - Jolanta Lissowska
- From the International Agency for Research on Cancer, Lyon, France; The Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden; Institute for Risk Assessment Sciences, Utrecht, The Netherlands; Institute for Prevention and Occupational Medicine of the German Social Accident Insurance – Institute of the Ruhr-Universität Bochum (IPA), Bochum, Germany; Occupational Respiratory Epidemiology, School of Population Health, University of Western Australia, Perth, Australia; Cancer Epidemiology Unit, Department of Medical Sciences, University of Turin and CPO Piemonte, Turin, Italy; INSERM, Centre for research in Epidemiology and Population Health (CESP), U1018, Environmental epidemiology of cancer Team, Villejuif, France; Université Paris-Sud, UMRS 1018, Villejuif, France; Epidemiology Unit, Fondazione IRCCS Ca’ Granda—Ospedale Maggiore Policlinico, Milan, Italy; National Cancer Institute, Bethesda, MD; Roy Castle Lung Cancer Research Programme, The University of Liverpool Cancer Research Centre, Department of Molecular and Clinical Cancer Medicine, Institute of Translational Medicine, Liverpool, United Kingdom; Institut für Epidemiologie, Deutsches Forschungszentrum fur Gesundheit und Umwelt, Neuherberg, Germany; University of Montreal Hospital Research Center (CRCHUM), Montreal, Canada; INRS-Institut Armand-Frappier, Université du Québec, Laval, Québec, Canada; Institute for Medical Informatics, Biometry and Epidemiology, University of Duisburg-Essen, Essen, Germany; Leibniz Institute for Prevention Research and Epidemiology – BIPS, Bremen, Germany; The Biomedical Research Centre Network for Epidemiology and Public Health (CIBERESP), University of Oviedo, Oviedo, Spain; Russian Cancer Research Centre, Moscow, Russia; Public Health Ontario, Toronto, Canada; Occupational Cancer Research Centre, Cancer Care Ontario, Toronto, Canada; The Nofer Institute of Occupational Medicine, Lodz, Poland; The M Sklodowska-Curie Cancer Center and Institute of Oncology, Warsaw, Poland; National Centre for Public Health, Budapest, Hungary; Regional Authority of Public Health, Banska Bystrica, Slovakia; Institute of Public Health, Bucharest, Romania; Institute of Hygiene and Epidemiology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic; Masaryk Memorial Cancer Institute and Medical Faculty of Masaryk University, Department of Cancer Epidemiology & Genetics, Brno, Czech Republic; Faculty of Medicine, Palacky University, Olomouc, Czech Republic; The Tisch Cancer Institute and Institute for Translational Epidemiology, Icahn School of Medicine at Mount Sinai, New York, NY; National Institute for Public Health and the Environment (RIVM), Bilthoven, The Netherlands; and Department of Epidemiology, ASL RomaE, Rome, Italy
| | - Peter Rudnai
- From the International Agency for Research on Cancer, Lyon, France; The Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden; Institute for Risk Assessment Sciences, Utrecht, The Netherlands; Institute for Prevention and Occupational Medicine of the German Social Accident Insurance – Institute of the Ruhr-Universität Bochum (IPA), Bochum, Germany; Occupational Respiratory Epidemiology, School of Population Health, University of Western Australia, Perth, Australia; Cancer Epidemiology Unit, Department of Medical Sciences, University of Turin and CPO Piemonte, Turin, Italy; INSERM, Centre for research in Epidemiology and Population Health (CESP), U1018, Environmental epidemiology of cancer Team, Villejuif, France; Université Paris-Sud, UMRS 1018, Villejuif, France; Epidemiology Unit, Fondazione IRCCS Ca’ Granda—Ospedale Maggiore Policlinico, Milan, Italy; National Cancer Institute, Bethesda, MD; Roy Castle Lung Cancer Research Programme, The University of Liverpool Cancer Research Centre, Department of Molecular and Clinical Cancer Medicine, Institute of Translational Medicine, Liverpool, United Kingdom; Institut für Epidemiologie, Deutsches Forschungszentrum fur Gesundheit und Umwelt, Neuherberg, Germany; University of Montreal Hospital Research Center (CRCHUM), Montreal, Canada; INRS-Institut Armand-Frappier, Université du Québec, Laval, Québec, Canada; Institute for Medical Informatics, Biometry and Epidemiology, University of Duisburg-Essen, Essen, Germany; Leibniz Institute for Prevention Research and Epidemiology – BIPS, Bremen, Germany; The Biomedical Research Centre Network for Epidemiology and Public Health (CIBERESP), University of Oviedo, Oviedo, Spain; Russian Cancer Research Centre, Moscow, Russia; Public Health Ontario, Toronto, Canada; Occupational Cancer Research Centre, Cancer Care Ontario, Toronto, Canada; The Nofer Institute of Occupational Medicine, Lodz, Poland; The M Sklodowska-Curie Cancer Center and Institute of Oncology, Warsaw, Poland; National Centre for Public Health, Budapest, Hungary; Regional Authority of Public Health, Banska Bystrica, Slovakia; Institute of Public Health, Bucharest, Romania; Institute of Hygiene and Epidemiology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic; Masaryk Memorial Cancer Institute and Medical Faculty of Masaryk University, Department of Cancer Epidemiology & Genetics, Brno, Czech Republic; Faculty of Medicine, Palacky University, Olomouc, Czech Republic; The Tisch Cancer Institute and Institute for Translational Epidemiology, Icahn School of Medicine at Mount Sinai, New York, NY; National Institute for Public Health and the Environment (RIVM), Bilthoven, The Netherlands; and Department of Epidemiology, ASL RomaE, Rome, Italy
| | - Eleonora Fabianova
- From the International Agency for Research on Cancer, Lyon, France; The Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden; Institute for Risk Assessment Sciences, Utrecht, The Netherlands; Institute for Prevention and Occupational Medicine of the German Social Accident Insurance – Institute of the Ruhr-Universität Bochum (IPA), Bochum, Germany; Occupational Respiratory Epidemiology, School of Population Health, University of Western Australia, Perth, Australia; Cancer Epidemiology Unit, Department of Medical Sciences, University of Turin and CPO Piemonte, Turin, Italy; INSERM, Centre for research in Epidemiology and Population Health (CESP), U1018, Environmental epidemiology of cancer Team, Villejuif, France; Université Paris-Sud, UMRS 1018, Villejuif, France; Epidemiology Unit, Fondazione IRCCS Ca’ Granda—Ospedale Maggiore Policlinico, Milan, Italy; National Cancer Institute, Bethesda, MD; Roy Castle Lung Cancer Research Programme, The University of Liverpool Cancer Research Centre, Department of Molecular and Clinical Cancer Medicine, Institute of Translational Medicine, Liverpool, United Kingdom; Institut für Epidemiologie, Deutsches Forschungszentrum fur Gesundheit und Umwelt, Neuherberg, Germany; University of Montreal Hospital Research Center (CRCHUM), Montreal, Canada; INRS-Institut Armand-Frappier, Université du Québec, Laval, Québec, Canada; Institute for Medical Informatics, Biometry and Epidemiology, University of Duisburg-Essen, Essen, Germany; Leibniz Institute for Prevention Research and Epidemiology – BIPS, Bremen, Germany; The Biomedical Research Centre Network for Epidemiology and Public Health (CIBERESP), University of Oviedo, Oviedo, Spain; Russian Cancer Research Centre, Moscow, Russia; Public Health Ontario, Toronto, Canada; Occupational Cancer Research Centre, Cancer Care Ontario, Toronto, Canada; The Nofer Institute of Occupational Medicine, Lodz, Poland; The M Sklodowska-Curie Cancer Center and Institute of Oncology, Warsaw, Poland; National Centre for Public Health, Budapest, Hungary; Regional Authority of Public Health, Banska Bystrica, Slovakia; Institute of Public Health, Bucharest, Romania; Institute of Hygiene and Epidemiology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic; Masaryk Memorial Cancer Institute and Medical Faculty of Masaryk University, Department of Cancer Epidemiology & Genetics, Brno, Czech Republic; Faculty of Medicine, Palacky University, Olomouc, Czech Republic; The Tisch Cancer Institute and Institute for Translational Epidemiology, Icahn School of Medicine at Mount Sinai, New York, NY; National Institute for Public Health and the Environment (RIVM), Bilthoven, The Netherlands; and Department of Epidemiology, ASL RomaE, Rome, Italy
| | - Rodica Stanescu Dumitru
- From the International Agency for Research on Cancer, Lyon, France; The Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden; Institute for Risk Assessment Sciences, Utrecht, The Netherlands; Institute for Prevention and Occupational Medicine of the German Social Accident Insurance – Institute of the Ruhr-Universität Bochum (IPA), Bochum, Germany; Occupational Respiratory Epidemiology, School of Population Health, University of Western Australia, Perth, Australia; Cancer Epidemiology Unit, Department of Medical Sciences, University of Turin and CPO Piemonte, Turin, Italy; INSERM, Centre for research in Epidemiology and Population Health (CESP), U1018, Environmental epidemiology of cancer Team, Villejuif, France; Université Paris-Sud, UMRS 1018, Villejuif, France; Epidemiology Unit, Fondazione IRCCS Ca’ Granda—Ospedale Maggiore Policlinico, Milan, Italy; National Cancer Institute, Bethesda, MD; Roy Castle Lung Cancer Research Programme, The University of Liverpool Cancer Research Centre, Department of Molecular and Clinical Cancer Medicine, Institute of Translational Medicine, Liverpool, United Kingdom; Institut für Epidemiologie, Deutsches Forschungszentrum fur Gesundheit und Umwelt, Neuherberg, Germany; University of Montreal Hospital Research Center (CRCHUM), Montreal, Canada; INRS-Institut Armand-Frappier, Université du Québec, Laval, Québec, Canada; Institute for Medical Informatics, Biometry and Epidemiology, University of Duisburg-Essen, Essen, Germany; Leibniz Institute for Prevention Research and Epidemiology – BIPS, Bremen, Germany; The Biomedical Research Centre Network for Epidemiology and Public Health (CIBERESP), University of Oviedo, Oviedo, Spain; Russian Cancer Research Centre, Moscow, Russia; Public Health Ontario, Toronto, Canada; Occupational Cancer Research Centre, Cancer Care Ontario, Toronto, Canada; The Nofer Institute of Occupational Medicine, Lodz, Poland; The M Sklodowska-Curie Cancer Center and Institute of Oncology, Warsaw, Poland; National Centre for Public Health, Budapest, Hungary; Regional Authority of Public Health, Banska Bystrica, Slovakia; Institute of Public Health, Bucharest, Romania; Institute of Hygiene and Epidemiology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic; Masaryk Memorial Cancer Institute and Medical Faculty of Masaryk University, Department of Cancer Epidemiology & Genetics, Brno, Czech Republic; Faculty of Medicine, Palacky University, Olomouc, Czech Republic; The Tisch Cancer Institute and Institute for Translational Epidemiology, Icahn School of Medicine at Mount Sinai, New York, NY; National Institute for Public Health and the Environment (RIVM), Bilthoven, The Netherlands; and Department of Epidemiology, ASL RomaE, Rome, Italy
| | - Vladimir Bencko
- From the International Agency for Research on Cancer, Lyon, France; The Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden; Institute for Risk Assessment Sciences, Utrecht, The Netherlands; Institute for Prevention and Occupational Medicine of the German Social Accident Insurance – Institute of the Ruhr-Universität Bochum (IPA), Bochum, Germany; Occupational Respiratory Epidemiology, School of Population Health, University of Western Australia, Perth, Australia; Cancer Epidemiology Unit, Department of Medical Sciences, University of Turin and CPO Piemonte, Turin, Italy; INSERM, Centre for research in Epidemiology and Population Health (CESP), U1018, Environmental epidemiology of cancer Team, Villejuif, France; Université Paris-Sud, UMRS 1018, Villejuif, France; Epidemiology Unit, Fondazione IRCCS Ca’ Granda—Ospedale Maggiore Policlinico, Milan, Italy; National Cancer Institute, Bethesda, MD; Roy Castle Lung Cancer Research Programme, The University of Liverpool Cancer Research Centre, Department of Molecular and Clinical Cancer Medicine, Institute of Translational Medicine, Liverpool, United Kingdom; Institut für Epidemiologie, Deutsches Forschungszentrum fur Gesundheit und Umwelt, Neuherberg, Germany; University of Montreal Hospital Research Center (CRCHUM), Montreal, Canada; INRS-Institut Armand-Frappier, Université du Québec, Laval, Québec, Canada; Institute for Medical Informatics, Biometry and Epidemiology, University of Duisburg-Essen, Essen, Germany; Leibniz Institute for Prevention Research and Epidemiology – BIPS, Bremen, Germany; The Biomedical Research Centre Network for Epidemiology and Public Health (CIBERESP), University of Oviedo, Oviedo, Spain; Russian Cancer Research Centre, Moscow, Russia; Public Health Ontario, Toronto, Canada; Occupational Cancer Research Centre, Cancer Care Ontario, Toronto, Canada; The Nofer Institute of Occupational Medicine, Lodz, Poland; The M Sklodowska-Curie Cancer Center and Institute of Oncology, Warsaw, Poland; National Centre for Public Health, Budapest, Hungary; Regional Authority of Public Health, Banska Bystrica, Slovakia; Institute of Public Health, Bucharest, Romania; Institute of Hygiene and Epidemiology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic; Masaryk Memorial Cancer Institute and Medical Faculty of Masaryk University, Department of Cancer Epidemiology & Genetics, Brno, Czech Republic; Faculty of Medicine, Palacky University, Olomouc, Czech Republic; The Tisch Cancer Institute and Institute for Translational Epidemiology, Icahn School of Medicine at Mount Sinai, New York, NY; National Institute for Public Health and the Environment (RIVM), Bilthoven, The Netherlands; and Department of Epidemiology, ASL RomaE, Rome, Italy
| | - Lenka Foretova
- From the International Agency for Research on Cancer, Lyon, France; The Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden; Institute for Risk Assessment Sciences, Utrecht, The Netherlands; Institute for Prevention and Occupational Medicine of the German Social Accident Insurance – Institute of the Ruhr-Universität Bochum (IPA), Bochum, Germany; Occupational Respiratory Epidemiology, School of Population Health, University of Western Australia, Perth, Australia; Cancer Epidemiology Unit, Department of Medical Sciences, University of Turin and CPO Piemonte, Turin, Italy; INSERM, Centre for research in Epidemiology and Population Health (CESP), U1018, Environmental epidemiology of cancer Team, Villejuif, France; Université Paris-Sud, UMRS 1018, Villejuif, France; Epidemiology Unit, Fondazione IRCCS Ca’ Granda—Ospedale Maggiore Policlinico, Milan, Italy; National Cancer Institute, Bethesda, MD; Roy Castle Lung Cancer Research Programme, The University of Liverpool Cancer Research Centre, Department of Molecular and Clinical Cancer Medicine, Institute of Translational Medicine, Liverpool, United Kingdom; Institut für Epidemiologie, Deutsches Forschungszentrum fur Gesundheit und Umwelt, Neuherberg, Germany; University of Montreal Hospital Research Center (CRCHUM), Montreal, Canada; INRS-Institut Armand-Frappier, Université du Québec, Laval, Québec, Canada; Institute for Medical Informatics, Biometry and Epidemiology, University of Duisburg-Essen, Essen, Germany; Leibniz Institute for Prevention Research and Epidemiology – BIPS, Bremen, Germany; The Biomedical Research Centre Network for Epidemiology and Public Health (CIBERESP), University of Oviedo, Oviedo, Spain; Russian Cancer Research Centre, Moscow, Russia; Public Health Ontario, Toronto, Canada; Occupational Cancer Research Centre, Cancer Care Ontario, Toronto, Canada; The Nofer Institute of Occupational Medicine, Lodz, Poland; The M Sklodowska-Curie Cancer Center and Institute of Oncology, Warsaw, Poland; National Centre for Public Health, Budapest, Hungary; Regional Authority of Public Health, Banska Bystrica, Slovakia; Institute of Public Health, Bucharest, Romania; Institute of Hygiene and Epidemiology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic; Masaryk Memorial Cancer Institute and Medical Faculty of Masaryk University, Department of Cancer Epidemiology & Genetics, Brno, Czech Republic; Faculty of Medicine, Palacky University, Olomouc, Czech Republic; The Tisch Cancer Institute and Institute for Translational Epidemiology, Icahn School of Medicine at Mount Sinai, New York, NY; National Institute for Public Health and the Environment (RIVM), Bilthoven, The Netherlands; and Department of Epidemiology, ASL RomaE, Rome, Italy
| | - Vladimir Janout
- From the International Agency for Research on Cancer, Lyon, France; The Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden; Institute for Risk Assessment Sciences, Utrecht, The Netherlands; Institute for Prevention and Occupational Medicine of the German Social Accident Insurance – Institute of the Ruhr-Universität Bochum (IPA), Bochum, Germany; Occupational Respiratory Epidemiology, School of Population Health, University of Western Australia, Perth, Australia; Cancer Epidemiology Unit, Department of Medical Sciences, University of Turin and CPO Piemonte, Turin, Italy; INSERM, Centre for research in Epidemiology and Population Health (CESP), U1018, Environmental epidemiology of cancer Team, Villejuif, France; Université Paris-Sud, UMRS 1018, Villejuif, France; Epidemiology Unit, Fondazione IRCCS Ca’ Granda—Ospedale Maggiore Policlinico, Milan, Italy; National Cancer Institute, Bethesda, MD; Roy Castle Lung Cancer Research Programme, The University of Liverpool Cancer Research Centre, Department of Molecular and Clinical Cancer Medicine, Institute of Translational Medicine, Liverpool, United Kingdom; Institut für Epidemiologie, Deutsches Forschungszentrum fur Gesundheit und Umwelt, Neuherberg, Germany; University of Montreal Hospital Research Center (CRCHUM), Montreal, Canada; INRS-Institut Armand-Frappier, Université du Québec, Laval, Québec, Canada; Institute for Medical Informatics, Biometry and Epidemiology, University of Duisburg-Essen, Essen, Germany; Leibniz Institute for Prevention Research and Epidemiology – BIPS, Bremen, Germany; The Biomedical Research Centre Network for Epidemiology and Public Health (CIBERESP), University of Oviedo, Oviedo, Spain; Russian Cancer Research Centre, Moscow, Russia; Public Health Ontario, Toronto, Canada; Occupational Cancer Research Centre, Cancer Care Ontario, Toronto, Canada; The Nofer Institute of Occupational Medicine, Lodz, Poland; The M Sklodowska-Curie Cancer Center and Institute of Oncology, Warsaw, Poland; National Centre for Public Health, Budapest, Hungary; Regional Authority of Public Health, Banska Bystrica, Slovakia; Institute of Public Health, Bucharest, Romania; Institute of Hygiene and Epidemiology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic; Masaryk Memorial Cancer Institute and Medical Faculty of Masaryk University, Department of Cancer Epidemiology & Genetics, Brno, Czech Republic; Faculty of Medicine, Palacky University, Olomouc, Czech Republic; The Tisch Cancer Institute and Institute for Translational Epidemiology, Icahn School of Medicine at Mount Sinai, New York, NY; National Institute for Public Health and the Environment (RIVM), Bilthoven, The Netherlands; and Department of Epidemiology, ASL RomaE, Rome, Italy
| | - Paolo Boffetta
- From the International Agency for Research on Cancer, Lyon, France; The Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden; Institute for Risk Assessment Sciences, Utrecht, The Netherlands; Institute for Prevention and Occupational Medicine of the German Social Accident Insurance – Institute of the Ruhr-Universität Bochum (IPA), Bochum, Germany; Occupational Respiratory Epidemiology, School of Population Health, University of Western Australia, Perth, Australia; Cancer Epidemiology Unit, Department of Medical Sciences, University of Turin and CPO Piemonte, Turin, Italy; INSERM, Centre for research in Epidemiology and Population Health (CESP), U1018, Environmental epidemiology of cancer Team, Villejuif, France; Université Paris-Sud, UMRS 1018, Villejuif, France; Epidemiology Unit, Fondazione IRCCS Ca’ Granda—Ospedale Maggiore Policlinico, Milan, Italy; National Cancer Institute, Bethesda, MD; Roy Castle Lung Cancer Research Programme, The University of Liverpool Cancer Research Centre, Department of Molecular and Clinical Cancer Medicine, Institute of Translational Medicine, Liverpool, United Kingdom; Institut für Epidemiologie, Deutsches Forschungszentrum fur Gesundheit und Umwelt, Neuherberg, Germany; University of Montreal Hospital Research Center (CRCHUM), Montreal, Canada; INRS-Institut Armand-Frappier, Université du Québec, Laval, Québec, Canada; Institute for Medical Informatics, Biometry and Epidemiology, University of Duisburg-Essen, Essen, Germany; Leibniz Institute for Prevention Research and Epidemiology – BIPS, Bremen, Germany; The Biomedical Research Centre Network for Epidemiology and Public Health (CIBERESP), University of Oviedo, Oviedo, Spain; Russian Cancer Research Centre, Moscow, Russia; Public Health Ontario, Toronto, Canada; Occupational Cancer Research Centre, Cancer Care Ontario, Toronto, Canada; The Nofer Institute of Occupational Medicine, Lodz, Poland; The M Sklodowska-Curie Cancer Center and Institute of Oncology, Warsaw, Poland; National Centre for Public Health, Budapest, Hungary; Regional Authority of Public Health, Banska Bystrica, Slovakia; Institute of Public Health, Bucharest, Romania; Institute of Hygiene and Epidemiology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic; Masaryk Memorial Cancer Institute and Medical Faculty of Masaryk University, Department of Cancer Epidemiology & Genetics, Brno, Czech Republic; Faculty of Medicine, Palacky University, Olomouc, Czech Republic; The Tisch Cancer Institute and Institute for Translational Epidemiology, Icahn School of Medicine at Mount Sinai, New York, NY; National Institute for Public Health and the Environment (RIVM), Bilthoven, The Netherlands; and Department of Epidemiology, ASL RomaE, Rome, Italy
| | - Bas Bueno-de-Mesquita
- From the International Agency for Research on Cancer, Lyon, France; The Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden; Institute for Risk Assessment Sciences, Utrecht, The Netherlands; Institute for Prevention and Occupational Medicine of the German Social Accident Insurance – Institute of the Ruhr-Universität Bochum (IPA), Bochum, Germany; Occupational Respiratory Epidemiology, School of Population Health, University of Western Australia, Perth, Australia; Cancer Epidemiology Unit, Department of Medical Sciences, University of Turin and CPO Piemonte, Turin, Italy; INSERM, Centre for research in Epidemiology and Population Health (CESP), U1018, Environmental epidemiology of cancer Team, Villejuif, France; Université Paris-Sud, UMRS 1018, Villejuif, France; Epidemiology Unit, Fondazione IRCCS Ca’ Granda—Ospedale Maggiore Policlinico, Milan, Italy; National Cancer Institute, Bethesda, MD; Roy Castle Lung Cancer Research Programme, The University of Liverpool Cancer Research Centre, Department of Molecular and Clinical Cancer Medicine, Institute of Translational Medicine, Liverpool, United Kingdom; Institut für Epidemiologie, Deutsches Forschungszentrum fur Gesundheit und Umwelt, Neuherberg, Germany; University of Montreal Hospital Research Center (CRCHUM), Montreal, Canada; INRS-Institut Armand-Frappier, Université du Québec, Laval, Québec, Canada; Institute for Medical Informatics, Biometry and Epidemiology, University of Duisburg-Essen, Essen, Germany; Leibniz Institute for Prevention Research and Epidemiology – BIPS, Bremen, Germany; The Biomedical Research Centre Network for Epidemiology and Public Health (CIBERESP), University of Oviedo, Oviedo, Spain; Russian Cancer Research Centre, Moscow, Russia; Public Health Ontario, Toronto, Canada; Occupational Cancer Research Centre, Cancer Care Ontario, Toronto, Canada; The Nofer Institute of Occupational Medicine, Lodz, Poland; The M Sklodowska-Curie Cancer Center and Institute of Oncology, Warsaw, Poland; National Centre for Public Health, Budapest, Hungary; Regional Authority of Public Health, Banska Bystrica, Slovakia; Institute of Public Health, Bucharest, Romania; Institute of Hygiene and Epidemiology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic; Masaryk Memorial Cancer Institute and Medical Faculty of Masaryk University, Department of Cancer Epidemiology & Genetics, Brno, Czech Republic; Faculty of Medicine, Palacky University, Olomouc, Czech Republic; The Tisch Cancer Institute and Institute for Translational Epidemiology, Icahn School of Medicine at Mount Sinai, New York, NY; National Institute for Public Health and the Environment (RIVM), Bilthoven, The Netherlands; and Department of Epidemiology, ASL RomaE, Rome, Italy
| | - Francesco Forastiere
- From the International Agency for Research on Cancer, Lyon, France; The Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden; Institute for Risk Assessment Sciences, Utrecht, The Netherlands; Institute for Prevention and Occupational Medicine of the German Social Accident Insurance – Institute of the Ruhr-Universität Bochum (IPA), Bochum, Germany; Occupational Respiratory Epidemiology, School of Population Health, University of Western Australia, Perth, Australia; Cancer Epidemiology Unit, Department of Medical Sciences, University of Turin and CPO Piemonte, Turin, Italy; INSERM, Centre for research in Epidemiology and Population Health (CESP), U1018, Environmental epidemiology of cancer Team, Villejuif, France; Université Paris-Sud, UMRS 1018, Villejuif, France; Epidemiology Unit, Fondazione IRCCS Ca’ Granda—Ospedale Maggiore Policlinico, Milan, Italy; National Cancer Institute, Bethesda, MD; Roy Castle Lung Cancer Research Programme, The University of Liverpool Cancer Research Centre, Department of Molecular and Clinical Cancer Medicine, Institute of Translational Medicine, Liverpool, United Kingdom; Institut für Epidemiologie, Deutsches Forschungszentrum fur Gesundheit und Umwelt, Neuherberg, Germany; University of Montreal Hospital Research Center (CRCHUM), Montreal, Canada; INRS-Institut Armand-Frappier, Université du Québec, Laval, Québec, Canada; Institute for Medical Informatics, Biometry and Epidemiology, University of Duisburg-Essen, Essen, Germany; Leibniz Institute for Prevention Research and Epidemiology – BIPS, Bremen, Germany; The Biomedical Research Centre Network for Epidemiology and Public Health (CIBERESP), University of Oviedo, Oviedo, Spain; Russian Cancer Research Centre, Moscow, Russia; Public Health Ontario, Toronto, Canada; Occupational Cancer Research Centre, Cancer Care Ontario, Toronto, Canada; The Nofer Institute of Occupational Medicine, Lodz, Poland; The M Sklodowska-Curie Cancer Center and Institute of Oncology, Warsaw, Poland; National Centre for Public Health, Budapest, Hungary; Regional Authority of Public Health, Banska Bystrica, Slovakia; Institute of Public Health, Bucharest, Romania; Institute of Hygiene and Epidemiology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic; Masaryk Memorial Cancer Institute and Medical Faculty of Masaryk University, Department of Cancer Epidemiology & Genetics, Brno, Czech Republic; Faculty of Medicine, Palacky University, Olomouc, Czech Republic; The Tisch Cancer Institute and Institute for Translational Epidemiology, Icahn School of Medicine at Mount Sinai, New York, NY; National Institute for Public Health and the Environment (RIVM), Bilthoven, The Netherlands; and Department of Epidemiology, ASL RomaE, Rome, Italy
| | - Thomas Brüning
- From the International Agency for Research on Cancer, Lyon, France; The Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden; Institute for Risk Assessment Sciences, Utrecht, The Netherlands; Institute for Prevention and Occupational Medicine of the German Social Accident Insurance – Institute of the Ruhr-Universität Bochum (IPA), Bochum, Germany; Occupational Respiratory Epidemiology, School of Population Health, University of Western Australia, Perth, Australia; Cancer Epidemiology Unit, Department of Medical Sciences, University of Turin and CPO Piemonte, Turin, Italy; INSERM, Centre for research in Epidemiology and Population Health (CESP), U1018, Environmental epidemiology of cancer Team, Villejuif, France; Université Paris-Sud, UMRS 1018, Villejuif, France; Epidemiology Unit, Fondazione IRCCS Ca’ Granda—Ospedale Maggiore Policlinico, Milan, Italy; National Cancer Institute, Bethesda, MD; Roy Castle Lung Cancer Research Programme, The University of Liverpool Cancer Research Centre, Department of Molecular and Clinical Cancer Medicine, Institute of Translational Medicine, Liverpool, United Kingdom; Institut für Epidemiologie, Deutsches Forschungszentrum fur Gesundheit und Umwelt, Neuherberg, Germany; University of Montreal Hospital Research Center (CRCHUM), Montreal, Canada; INRS-Institut Armand-Frappier, Université du Québec, Laval, Québec, Canada; Institute for Medical Informatics, Biometry and Epidemiology, University of Duisburg-Essen, Essen, Germany; Leibniz Institute for Prevention Research and Epidemiology – BIPS, Bremen, Germany; The Biomedical Research Centre Network for Epidemiology and Public Health (CIBERESP), University of Oviedo, Oviedo, Spain; Russian Cancer Research Centre, Moscow, Russia; Public Health Ontario, Toronto, Canada; Occupational Cancer Research Centre, Cancer Care Ontario, Toronto, Canada; The Nofer Institute of Occupational Medicine, Lodz, Poland; The M Sklodowska-Curie Cancer Center and Institute of Oncology, Warsaw, Poland; National Centre for Public Health, Budapest, Hungary; Regional Authority of Public Health, Banska Bystrica, Slovakia; Institute of Public Health, Bucharest, Romania; Institute of Hygiene and Epidemiology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic; Masaryk Memorial Cancer Institute and Medical Faculty of Masaryk University, Department of Cancer Epidemiology & Genetics, Brno, Czech Republic; Faculty of Medicine, Palacky University, Olomouc, Czech Republic; The Tisch Cancer Institute and Institute for Translational Epidemiology, Icahn School of Medicine at Mount Sinai, New York, NY; National Institute for Public Health and the Environment (RIVM), Bilthoven, The Netherlands; and Department of Epidemiology, ASL RomaE, Rome, Italy
| | - Kurt Straif
- From the International Agency for Research on Cancer, Lyon, France; The Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden; Institute for Risk Assessment Sciences, Utrecht, The Netherlands; Institute for Prevention and Occupational Medicine of the German Social Accident Insurance – Institute of the Ruhr-Universität Bochum (IPA), Bochum, Germany; Occupational Respiratory Epidemiology, School of Population Health, University of Western Australia, Perth, Australia; Cancer Epidemiology Unit, Department of Medical Sciences, University of Turin and CPO Piemonte, Turin, Italy; INSERM, Centre for research in Epidemiology and Population Health (CESP), U1018, Environmental epidemiology of cancer Team, Villejuif, France; Université Paris-Sud, UMRS 1018, Villejuif, France; Epidemiology Unit, Fondazione IRCCS Ca’ Granda—Ospedale Maggiore Policlinico, Milan, Italy; National Cancer Institute, Bethesda, MD; Roy Castle Lung Cancer Research Programme, The University of Liverpool Cancer Research Centre, Department of Molecular and Clinical Cancer Medicine, Institute of Translational Medicine, Liverpool, United Kingdom; Institut für Epidemiologie, Deutsches Forschungszentrum fur Gesundheit und Umwelt, Neuherberg, Germany; University of Montreal Hospital Research Center (CRCHUM), Montreal, Canada; INRS-Institut Armand-Frappier, Université du Québec, Laval, Québec, Canada; Institute for Medical Informatics, Biometry and Epidemiology, University of Duisburg-Essen, Essen, Germany; Leibniz Institute for Prevention Research and Epidemiology – BIPS, Bremen, Germany; The Biomedical Research Centre Network for Epidemiology and Public Health (CIBERESP), University of Oviedo, Oviedo, Spain; Russian Cancer Research Centre, Moscow, Russia; Public Health Ontario, Toronto, Canada; Occupational Cancer Research Centre, Cancer Care Ontario, Toronto, Canada; The Nofer Institute of Occupational Medicine, Lodz, Poland; The M Sklodowska-Curie Cancer Center and Institute of Oncology, Warsaw, Poland; National Centre for Public Health, Budapest, Hungary; Regional Authority of Public Health, Banska Bystrica, Slovakia; Institute of Public Health, Bucharest, Romania; Institute of Hygiene and Epidemiology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic; Masaryk Memorial Cancer Institute and Medical Faculty of Masaryk University, Department of Cancer Epidemiology & Genetics, Brno, Czech Republic; Faculty of Medicine, Palacky University, Olomouc, Czech Republic; The Tisch Cancer Institute and Institute for Translational Epidemiology, Icahn School of Medicine at Mount Sinai, New York, NY; National Institute for Public Health and the Environment (RIVM), Bilthoven, The Netherlands; and Department of Epidemiology, ASL RomaE, Rome, Italy
| |
Collapse
|
45
|
Baglietto L, Ponzi E, Haycock P, Hodge A, Bianca Assumma M, Jung C, Chung J, Fasanelli F, Guida F, Campanella G, Chadeau‐Hyam M, Grankvist K, Johansson M, Ala U, Provero P, Wong EM, Joo J, English DR, Kazmi N, Lund E, Faltus C, Kaaks R, Risch A, Barrdahl M, Sandanger TM, Southey MC, Giles GG, Johansson M, Vineis P, Polidoro S, Relton CL, Severi G. DNA methylation changes measured in pre-diagnostic peripheral blood samples are associated with smoking and lung cancer risk. Int J Cancer 2017; 140:50-61. [PMID: 27632354 PMCID: PMC5731426 DOI: 10.1002/ijc.30431] [Citation(s) in RCA: 93] [Impact Index Per Article: 13.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/11/2016] [Accepted: 07/20/2016] [Indexed: 12/26/2022]
Abstract
DNA methylation changes are associated with cigarette smoking. We used the Illumina Infinium HumanMethylation450 array to determine whether methylation in DNA from pre-diagnostic, peripheral blood samples is associated with lung cancer risk. We used a case-control study nested within the EPIC-Italy cohort and a study within the MCCS cohort as discovery sets (a total of 552 case-control pairs). We validated the top signals in 429 case-control pairs from another 3 studies. We identified six CpGs for which hypomethylation was associated with lung cancer risk: cg05575921 in the AHRR gene (p-valuepooled = 4 × 10-17 ), cg03636183 in the F2RL3 gene (p-valuepooled = 2 × 10 - 13 ), cg21566642 and cg05951221 in 2q37.1 (p-valuepooled = 7 × 10-16 and 1 × 10-11 respectively), cg06126421 in 6p21.33 (p-valuepooled = 2 × 10-15 ) and cg23387569 in 12q14.1 (p-valuepooled = 5 × 10-7 ). For cg05951221 and cg23387569 the strength of association was virtually identical in never and current smokers. For all these CpGs except for cg23387569, the methylation levels were different across smoking categories in controls (p-valuesheterogeneity ≤ 1.8 x10 - 7 ), were lowest for current smokers and increased with time since quitting for former smokers. We observed a gain in discrimination between cases and controls measured by the area under the ROC curve of at least 8% (p-values ≥ 0.003) in former smokers by adding methylation at the 6 CpGs into risk prediction models including smoking status and number of pack-years. Our findings provide convincing evidence that smoking and possibly other factors lead to DNA methylation changes measurable in peripheral blood that may improve prediction of lung cancer risk.
Collapse
Affiliation(s)
- Laura Baglietto
- Université Paris‐Saclay, Univ. Paris‐Sud, UVSQ, CESP, INSERMVillejuifFrance
- Gustave RoussyVillejuifF‐94805France
- Cancer Epidemiology CentreCancer Council VictoriaMelbourneAustralia
- Centre for Epidemiology and Biostatistics, Melbourne School of Population & Global HealthThe University of MelbourneAustralia
| | - Erica Ponzi
- Department of Evolutionary Biology and Environmental StudiesUniversity of ZurichSwitzerland
- Epidemiology, Biostatistics and Prevention Institute, University of ZurichSwitzerland
| | - Philip Haycock
- MRC Integrative Epidemiology Unit, School of Social & Community MedicineUniversity of BristolBS8 2BNUK
| | - Allison Hodge
- Centre for Epidemiology and Biostatistics, Melbourne School of Population & Global HealthThe University of MelbourneAustralia
| | | | - Chol‐Hee Jung
- Victorian Life Sciences Computation InitiativeThe University of MelbourneVictoria3010Australia
| | - Jessica Chung
- Victorian Life Sciences Computation InitiativeThe University of MelbourneVictoria3010Australia
| | - Francesca Fasanelli
- HuGeF, Human Genetics FoundationTorino10126Italy
- Unit of Cancer Epidemiology, Citta' della Salute e della Scienza Hospital‐University of Turin and Center for Cancer Prevention (CPO)10126Torino
| | - Florence Guida
- MRC‐PHE Centre for Environment and Health, Department of Epidemiology and Biostatistics, School of Public HealthImperial College LondonNorfolk PlaceLondonW2 1PGUK
| | - Gianluca Campanella
- MRC‐PHE Centre for Environment and Health, Department of Epidemiology and Biostatistics, School of Public HealthImperial College LondonNorfolk PlaceLondonW2 1PGUK
| | - Marc Chadeau‐Hyam
- MRC‐PHE Centre for Environment and Health, Department of Epidemiology and Biostatistics, School of Public HealthImperial College LondonNorfolk PlaceLondonW2 1PGUK
| | | | | | - Ugo Ala
- Department of Molecular Biotechnology and Health SciencesUniversità di Torino10126Italy
| | - Paolo Provero
- Department of Molecular Biotechnology and Health SciencesUniversità di Torino10126Italy
- Center for Translational Genomics and Bioinformatics, San Raffaele Scientific InstituteMilanItaly
| | - Ee Ming Wong
- Genetic Epidemiology Laboratory, Department of PathologyThe University of MelbourneAustralia
| | - Jihoon Joo
- Genetic Epidemiology Laboratory, Department of PathologyThe University of MelbourneAustralia
| | - Dallas R. English
- Cancer Epidemiology CentreCancer Council VictoriaMelbourneAustralia
- Centre for Epidemiology and Biostatistics, Melbourne School of Population & Global HealthThe University of MelbourneAustralia
| | - Nabila Kazmi
- MRC Integrative Epidemiology Unit, School of Social & Community MedicineUniversity of BristolBS8 2BNUK
| | - Eiliv Lund
- Department of Community MedicineUiT‐ The Arctic University of NorwayTromsoNorway
| | - Christian Faltus
- Division of Cancer Research and Epigenetics, Department of Molecular BiologyUniversity of SalzburgSalzburgAustria
- Division of Epigenomics and Cancer Risk FactorsDKFZ – German Cancer Research CenterHeidelbergGermany
| | - Rudolf Kaaks
- Division of Cancer EpidemiologyDKFZ ‐ German Cancer Research CenterHeidelbergGermany
- Translational Lung Research Center Heidelberg (TLRC‐H), Member of the German Center for Lung Research (DZL)HeidelbergGermany
| | - Angela Risch
- Division of Cancer Research and Epigenetics, Department of Molecular BiologyUniversity of SalzburgSalzburgAustria
- Division of Epigenomics and Cancer Risk FactorsDKFZ – German Cancer Research CenterHeidelbergGermany
- Translational Lung Research Center Heidelberg (TLRC‐H), Member of the German Center for Lung Research (DZL)HeidelbergGermany
| | - Myrto Barrdahl
- Division of Cancer EpidemiologyDKFZ ‐ German Cancer Research CenterHeidelbergGermany
| | - Torkjel M. Sandanger
- Department of Community MedicineUiT‐ The Arctic University of NorwayTromsoNorway
| | - Melissa C. Southey
- Genetic Epidemiology Laboratory, Department of PathologyThe University of MelbourneAustralia
| | - Graham G. Giles
- Cancer Epidemiology CentreCancer Council VictoriaMelbourneAustralia
- Centre for Epidemiology and Biostatistics, Melbourne School of Population & Global HealthThe University of MelbourneAustralia
| | | | - Paolo Vineis
- HuGeF, Human Genetics FoundationTorino10126Italy
- MRC‐PHE Centre for Environment and Health, Department of Epidemiology and Biostatistics, School of Public HealthImperial College LondonNorfolk PlaceLondonW2 1PGUK
| | | | - Caroline L. Relton
- MRC Integrative Epidemiology Unit, School of Social & Community MedicineUniversity of BristolBS8 2BNUK
| | - Gianluca Severi
- Université Paris‐Saclay, Univ. Paris‐Sud, UVSQ, CESP, INSERMVillejuifFrance
- Gustave RoussyVillejuifF‐94805France
- Cancer Epidemiology CentreCancer Council VictoriaMelbourneAustralia
- Centre for Epidemiology and Biostatistics, Melbourne School of Population & Global HealthThe University of MelbourneAustralia
- HuGeF, Human Genetics FoundationTorino10126Italy
| |
Collapse
|
46
|
Castagné R, Kelly-Irving M, Campanella G, Guida F, Krogh V, Palli D, Panico S, Sacerdote C, Tumino R, Kleinjans J, de Kok T, Kyrtopoulos SA, Lang T, Stringhini S, Vermeulen R, Vineis P, Delpierre C, Chadeau-Hyam M. Biological marks of early-life socioeconomic experience is detected in the adult inflammatory transcriptome. Sci Rep 2016; 6:38705. [PMID: 27934951 PMCID: PMC5146729 DOI: 10.1038/srep38705] [Citation(s) in RCA: 36] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/21/2016] [Accepted: 11/10/2016] [Indexed: 12/12/2022] Open
Abstract
Consistent evidence is accumulating to link lower socioeconomic position (SEP) and poorer health, and the inflammatory system stands out as a potential pathway through which socioeconomic environment is biologically embedded. Using bloodderived genome-wide transcriptional profiles from 268 Italian participants of the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort, we evaluated the association between early life, young and later adulthood SEP and the expression of 845 genes involved in human inflammatory responses. These were examined individually and jointly using several inflammatory scores. Our results consistently show that participants whose father had a manual (as compared to nonmanual) occupation exhibit, later in life, a higher inflammatory score, hence indicating an overall increased level of expression for the selected inflammatory-related genes. Adopting a life course approach, these associations remained statistically significant upon adjustment for later-in-life socioeconomic experiences. Sensitivity analyses indicated that our findings were not affected by the way the inflammatory score was calculated, and were replicated in an independent study. Our study provides additional evidence that childhood SEP is associated with a sustainable upregulation of the inflammatory transcriptome, independently of subsequent socioeconomic experiences. Our results support the hypothesis that early social inequalities impacts adult physiology.
Collapse
Affiliation(s)
- Raphaële Castagné
- Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London, Norfolk Place, W2 1PG London, UK
- INSERM, UMR1027, Toulouse F-31000, France
- Université Toulouse III Paul-Sabatier, UMR1027, Toulouse F-31000, France
| | - Michelle Kelly-Irving
- INSERM, UMR1027, Toulouse F-31000, France
- Université Toulouse III Paul-Sabatier, UMR1027, Toulouse F-31000, France
| | - Gianluca Campanella
- Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London, Norfolk Place, W2 1PG London, UK
| | - Florence Guida
- Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London, Norfolk Place, W2 1PG London, UK
| | - Vittorio Krogh
- Epidemiology and Prevention Unit, Fondazione IRCCS- Istituto Nazionale dei Tumori, Via Venezian 1, 20133 Milan, Italy
| | - Domenico Palli
- Molecular and Nutritional Epidemiology Unit, Istituto per lo Studio e la Prevenzione Oncologica (ISPO Toscana), Via delle Oblate 2, 50141, Florence, Italy
| | - Salvatore Panico
- Department of Clinical Medicine and Surgery, University of Naples Federico II, Via Pansini 5, 80131 Naples, Italy
| | - Carlotta Sacerdote
- Piedmont Reference Centre for Epidemiology and Cancer Prevention (CPO Piemonte), Viale Settimio Severo nr. 65, 10133 Turin, Italy
| | - Rosario Tumino
- Cancer registry and Histopathology Unit, Azienda Ospedaliera ‘Civile –M.P.Arezzo’, Via Dante N 109, 97100 Ragusa, Italy
| | - Jos Kleinjans
- Department of Toxicogenomics, Maastricht University, 6211 LK Maastricht, The Netherlands
| | - Theo de Kok
- Department of Toxicogenomics, Maastricht University, 6211 LK Maastricht, The Netherlands
| | - Soterios A. Kyrtopoulos
- National Hellenic Research Foundation, Institute of Biology, Pharmaceutical Chemistry and Biotechnology, Vas. Constantinou 48, 11635 Athens, Greece
| | - Thierry Lang
- INSERM, UMR1027, Toulouse F-31000, France
- Université Toulouse III Paul-Sabatier, UMR1027, Toulouse F-31000, France
| | - Silvia Stringhini
- Institute of Social and Preventive Medicine, Lausanne University Hospital, Route de la Corniche 10, 1010 Lausanne, Switzerland
| | - Roel Vermeulen
- Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London, Norfolk Place, W2 1PG London, UK
- Institute for Risk Assessment Sciences (IRAS), Utrecht University, PO Box 80178, 3508 TD, Utrecht, The Netherlands
| | - Paolo Vineis
- Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London, Norfolk Place, W2 1PG London, UK
- HuGeF, Human Genetics Foundation, Via Nizza 52, 10126 Torino, Italy
- MRC-PHE Centre for Environment and Health, Imperial College, Praed Street Wing, St Mary’s Campus, W2 1PG London, UK
| | - Cyrille Delpierre
- INSERM, UMR1027, Toulouse F-31000, France
- Université Toulouse III Paul-Sabatier, UMR1027, Toulouse F-31000, France
| | - Marc Chadeau-Hyam
- Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London, Norfolk Place, W2 1PG London, UK
- MRC-PHE Centre for Environment and Health, Imperial College, Praed Street Wing, St Mary’s Campus, W2 1PG London, UK
| |
Collapse
|
47
|
Bigert C, Gustavsson P, Straif K, Taeger D, Pesch B, Kendzia B, Schüz J, Stücker I, Guida F, Brüske I, Wichmann HE, Pesatori AC, Landi MT, Caporaso N, Tse LA, Yu ITS, Siemiatycki J, Lavoué J, Richardi L, Mirabelli D, Simonato L, Jöckel KH, Ahrens W, Pohlabeln H, Tardón A, Zaridze D, Field JK, Mannetje A, Pearce N, McLaughlin J, Demers P, Szeszenia-Dabrowska N, Lissowska J, Rudnai P, Fabianova E, Dumitru RS, Bencko V, Foretova L, Janout V, Boffetta P, Peters S, Vermeulen R, Kromhout H, Brüning T, Olsson AC. P025 Lung cancer risk among firefighters when accounting for tobacco smoking – preliminary results from a pooled analysis of case-control studies from europe, canada, new zealand and china. Cancer 2016. [DOI: 10.1136/oemed-2016-103951.350] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
48
|
Behrens T, Groß I, Siemiatycki J, Conway DI, Olsson A, Stücker I, Guida F, Jöckel KH, Pohlabeln H, Ahrens W, Brüske I, Wichmann HE, Gustavsson P, Consonni D, Merletti F, Richiardi L, Simonato L, Fortes C, Parent ME, McLaughlin J, Demers P, Landi MT, Caporaso N, Zaridze D, Szeszenia-Dabrowska N, Rudnai P, Lissowska J, Fabianova E, Tardón A, Field JK, Dumitru RS, Bencko V, Foretova L, Janout V, Kromhout H, Vermeulen R, Boffetta P, Straif K, Schüz J, Hovanec J, Kendzia B, Pesch B, Brüning T. Occupational prestige, social mobility and the association with lung cancer in men. BMC Cancer 2016; 16:395. [PMID: 27388894 PMCID: PMC4936282 DOI: 10.1186/s12885-016-2432-9] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/27/2015] [Accepted: 06/10/2016] [Indexed: 12/29/2022] Open
Abstract
BACKGROUND The nature of the association between occupational social prestige, social mobility, and risk of lung cancer remains uncertain. Using data from the international pooled SYNERGY case-control study, we studied the association between lung cancer and the level of time-weighted average occupational social prestige as well as its lifetime trajectory. METHODS We included 11,433 male cases and 14,147 male control subjects. Each job was translated into an occupational social prestige score by applying Treiman's Standard International Occupational Prestige Scale (SIOPS). SIOPS scores were categorized as low, medium, and high prestige (reference). We calculated odds ratios (OR) with 95 % confidence intervals (CI), adjusting for study center, age, smoking, ever employment in a job with known lung carcinogen exposure, and education. Trajectories in SIOPS categories from first to last and first to longest job were defined as consistent, downward, or upward. We conducted several subgroup and sensitivity analyses to assess the robustness of our results. RESULTS We observed increased lung cancer risk estimates for men with medium (OR = 1.23; 95 % CI 1.13-1.33) and low occupational prestige (OR = 1.44; 95 % CI 1.32-1.57). Although adjustment for smoking and education reduced the associations between occupational prestige and lung cancer, they did not explain the association entirely. Traditional occupational exposures reduced the associations only slightly. We observed small associations with downward prestige trajectories, with ORs of 1.13, 95 % CI 0.88-1.46 for high to low, and 1.24; 95 % CI 1.08-1.41 for medium to low trajectories. CONCLUSIONS Our results indicate that occupational prestige is independently associated with lung cancer among men.
Collapse
Affiliation(s)
- Thomas Behrens
- />Institute for Prevention and Occupational Medicine of the German Social Accident Insurance (IPA), Institute of the Ruhr-Universität Bochum, Bürkle-de-la-Camp-Platz 1, 44789 Bochum, Germany
| | - Isabelle Groß
- />Institute for Prevention and Occupational Medicine of the German Social Accident Insurance (IPA), Institute of the Ruhr-Universität Bochum, Bürkle-de-la-Camp-Platz 1, 44789 Bochum, Germany
| | - Jack Siemiatycki
- />Hospital Research Center (CRCHUM) and School of Public Health, University of Montreal, Montreal, Canada
| | - David I. Conway
- />Dental School, College of Medicine Veterinary and Life Sciences, University of Glasgow, Glasgow, G2 3JZ UK
| | - Ann Olsson
- />International Agency for Research on Cancer (IARC), Lyon, France
- />Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden
| | - Isabelle Stücker
- />Inserm, Centre for Research in Epidemiology and Population Health (CESP), U1018, Environmental Epidemiology of Cancer Team, F-94807 Villejuif, France
- />University Paris-Sud, UMRS 1018, F-94807 Villejuif, France
| | - Florence Guida
- />Inserm, Centre for Research in Epidemiology and Population Health (CESP), U1018, Environmental Epidemiology of Cancer Team, F-94807 Villejuif, France
- />University Paris-Sud, UMRS 1018, F-94807 Villejuif, France
| | - Karl-Heinz Jöckel
- />Institute for Medical Informatics, Biometry and Epidemiology, University Hospital Essen, Essen, Germany
| | - Hermann Pohlabeln
- />Leibniz-Institute for Prevention Research and Epidemiology -BIPS GmbH, Bremen, Germany
| | - Wolfgang Ahrens
- />Leibniz-Institute for Prevention Research and Epidemiology -BIPS GmbH, Bremen, Germany
- />Institute for Statistics, University Bremen, Bremen, Germany
| | - Irene Brüske
- />Institute of Epidemiology I, Helmholtz Zentrum München, Neuherberg, Germany
| | - Heinz-Erich Wichmann
- />Institute of Epidemiology I, Helmholtz Zentrum München, Neuherberg, Germany
- />Institute of Medical Statistics and Epidemiology, Technical University Munich, Munich, Germany
| | - Per Gustavsson
- />Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden
| | - Dario Consonni
- />Unit of Epidemiology, Fondazione IRCCS Ca’ Granda-Ospedale Maggiore Policlinico, Milan, Italy
| | - Franco Merletti
- />Department of Medical Sciences, Unit of Cancer Epidemiology, University of Turin, Turin, Italy
| | - Lorenzo Richiardi
- />Department of Medical Sciences, Unit of Cancer Epidemiology, University of Turin, Turin, Italy
| | - Lorenzo Simonato
- />Department of Molecular Medicine, Laboratory of Public Health and Population Studies, University of Padova, Padova, Italy
| | - Cristina Fortes
- />Epidemiology Unit, Istituto Dermopatico dell’Immacolata, Rome, Italy
| | - Marie-Elise Parent
- />INRS-Institut Armand-Frappier, Université du Québec, Laval, Québec Canada
| | - John McLaughlin
- />Cancer Care Ontario, Occupational Cancer Research Centre, Toronto, Canada
| | - Paul Demers
- />Cancer Care Ontario, Occupational Cancer Research Centre, Toronto, Canada
| | - Maria Teresa Landi
- />National Cancer Institute, Division of Cancer Epidemiology and Genetics, Bethesda, USA
| | - Neil Caporaso
- />National Cancer Institute, Division of Cancer Epidemiology and Genetics, Bethesda, USA
| | - David Zaridze
- />Institute of Carcinogenesis, Russian Cancer Research Centre, Moscow, Russia
| | | | - Peter Rudnai
- />National Centre for Public Health, Budapest, Hungary
| | - Jolanta Lissowska
- />The M Sklodowska-Curie Cancer Center and Institute of Oncology, Warsaw, Poland
| | - Eleonora Fabianova
- />Regional Authority of Public Health, Preventive Occupational Medicine, Banska Bystrica, Slovakia
| | - Adonina Tardón
- />Molecular Epidemiology of Cancer Unit, University of Oviedo-Ciber de Epidemiologia, CIBERESP, Oviedo, Spain
| | - John K. Field
- />Roy Castle Lung Cancer Research Programme, The University of Liverpool Cancer Research Centre, Liverpool, UK
- />Department of Molecular and Clinical Cancer Medicine, Institute of Translational Medicine, University of Liverpool, Liverpool, UK
| | | | - Vladimir Bencko
- />Institute of Hygiene and Epidemiology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic
| | - Lenka Foretova
- />Department of Cancer Epidemiology & Genetics, Masaryk Memorial Cancer Institute and Medical Faculty of Masaryk University, Brno, Czech Republic
| | - Vladimir Janout
- />Faculty of Medicine, Palacky University, Olomouc, Czech Republic
- />Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic
| | - Hans Kromhout
- />Environmental Epidemiology Division, Institute for Risk Assessment Sciences, Utrecht University, Utrecht, The Netherlands
| | - Roel Vermeulen
- />Environmental Epidemiology Division, Institute for Risk Assessment Sciences, Utrecht University, Utrecht, The Netherlands
| | - Paolo Boffetta
- />The Tisch Cancer Institute and Institute for Translational Epidemiology, Icahn School of Medicine at Mount Sinai, New York, USA
| | - Kurt Straif
- />International Agency for Research on Cancer (IARC), Lyon, France
| | - Joachim Schüz
- />International Agency for Research on Cancer (IARC), Lyon, France
| | - Jan Hovanec
- />Institute for Prevention and Occupational Medicine of the German Social Accident Insurance (IPA), Institute of the Ruhr-Universität Bochum, Bürkle-de-la-Camp-Platz 1, 44789 Bochum, Germany
| | - Benjamin Kendzia
- />Institute for Prevention and Occupational Medicine of the German Social Accident Insurance (IPA), Institute of the Ruhr-Universität Bochum, Bürkle-de-la-Camp-Platz 1, 44789 Bochum, Germany
| | - Beate Pesch
- />Institute for Prevention and Occupational Medicine of the German Social Accident Insurance (IPA), Institute of the Ruhr-Universität Bochum, Bürkle-de-la-Camp-Platz 1, 44789 Bochum, Germany
| | - Thomas Brüning
- />Institute for Prevention and Occupational Medicine of the German Social Accident Insurance (IPA), Institute of the Ruhr-Universität Bochum, Bürkle-de-la-Camp-Platz 1, 44789 Bochum, Germany
| |
Collapse
|
49
|
Guida F, Monaco L, Schettino M, Porfidia R, Iapicca G. Predictive factors of difficult procedure in octogenarians undergoing elective laparoscopic cholecystectomy: a single center experience. G Chir 2016; 37:68-70. [PMID: 27381691 DOI: 10.11138/gchir/2016.37.2.068] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
AIM To assess the feasibility and safety of laparoscopic cholecystectomy (LC) in very elderly patients with particular attention to the predicitive factors of difficulty. PATIENTS AND METHODS All patients aged ≥ 80 undergoing elective LC for lithiasis at our institution since 1st January 2015 to 31st December 2015 were included in the study. Exclusion criteria were: a) acute cholecystitis; b) biliary pancreatitis; c) biliary tract neoplasms; d) urgent procedure. Pre-, intra- and postoperative data were recorded. RESULTS During the study period, we performed 72 LC and we enrolled 17 patients aged ≥ 80 with a M:F = 5:12. Of these, 10 patients had a "difficult" cholecystectomy. In seven cases an intraoperative cholangiography (IOC) was performed. Postoperative course was regular but in two patients we had an Oddian spasm in 1st postoperative day. Female sex (p=0.03) and preoperative high level of serum amylase (p= 0.02) were significantly associated to difficult cholecystectomy in elderly patients. CONCLUSION LC in octogenarians is feasible and safe. However, sex and serum amylase can help the surgeon to predict a more difficult procedure in elective LC. In this group of patients an approach based on the individual risk is desirable and the patient could be referred to a multidisciplinary approach.
Collapse
|
50
|
Mattei F, Liverani S, Guida F, Matrat M, Cenée S, Azizi L, Menvielle G, Sanchez M, Pilorget C, Lapôtre-Ledoux B, Luce D, Richardson S, Stücker I. Multidimensional analysis of the effect of occupational exposure to organic solvents on lung cancer risk: the ICARE study. Occup Environ Med 2016; 73:368-77. [PMID: 26911986 PMCID: PMC4893113 DOI: 10.1136/oemed-2015-103177] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/09/2015] [Revised: 01/22/2016] [Accepted: 02/05/2016] [Indexed: 11/03/2022]
Abstract
BACKGROUND The association between lung cancer and occupational exposure to organic solvents is discussed. Since different solvents are often used simultaneously, it is difficult to assess the role of individual substances. OBJECTIVES The present study is focused on an in-depth investigation of the potential association between lung cancer risk and occupational exposure to a large group of organic solvents, taking into account the well-known risk factors for lung cancer, tobacco smoking and occupational exposure to asbestos. METHODS We analysed data from the Investigation of occupational and environmental causes of respiratory cancers (ICARE) study, a large French population-based case-control study, set up between 2001 and 2007. A total of 2276 male cases and 2780 male controls were interviewed, and long-life occupational history was collected. In order to overcome the analytical difficulties created by multiple correlated exposures, we carried out a novel type of analysis based on Bayesian profile regression. RESULTS After analysis with conventional logistic regression methods, none of the 11 solvents examined were associated with lung cancer risk. Through a profile regression approach, we did not observe any significant association between solvent exposure and lung cancer. However, we identified clusters at high risk that are related to occupations known to be at risk of developing lung cancer, such as painters. CONCLUSIONS Organic solvents do not appear to be substantial contributors to the occupational risk of lung cancer for the occupations known to be at risk.
Collapse
Affiliation(s)
- Francesca Mattei
- Université Paris Saclay, Univ. Paris-Sud, UVSQ, CESP, INSERM, Villejuif, France
| | - Silvia Liverani
- Department of Mathematics, Brunel University London, Uxbridge, UK
- MRC Biostatistics Unit, Cambridge Institute of Public Health, Cambridge Biomedical Campus, Cambridge, UK
| | - Florence Guida
- Department of Epidemiology and Biostatistics, Imperial College London, MRC-PHE Centre for Environment and Health, School of Public Health, London, UK
| | - Mireille Matrat
- Université Paris Saclay, Univ. Paris-Sud, UVSQ, CESP, INSERM, Villejuif, France
- Faculty of Medicine IFR 10, University Paris Est-Créteil, Créteil, France
| | - Sylvie Cenée
- Université Paris Saclay, Univ. Paris-Sud, UVSQ, CESP, INSERM, Villejuif, France
| | - Lamiae Azizi
- University of Sydney, Sydney School of Public Health, Screening an Evaluation Test Program, Sydney, New South Wales, Australia
| | - Gwenn Menvielle
- Department of social epidemiology, INSERM, UMR_S 1136, Pierre Louis Institute of Epidemiology and Public Health, Villejuif, France
- Department of social epidemiology, Sorbonne University, UPMC University of Paris 06, UMR_S 1136, Pierre Louis Institute of Epidemiology and Public Health, Villejuif, France
| | - Marie Sanchez
- Université Paris Saclay, Univ. Paris-Sud, UVSQ, CESP, INSERM, Villejuif, France
| | - Corinne Pilorget
- French Institute for Public Health Surveillance, Saint-Maurice, France
- Epidemiological research and surveillance unit in transport, occupation and environment, Claude Bernard Lyon1 University, Lyon, France
| | | | - Danièle Luce
- INSERM, U 1085_IRSET, Pointe-à-Pitre, France
- University of Rennes 1, Rennes, France
| | - Sylvia Richardson
- MRC Biostatistics Unit, Cambridge Institute of Public Health, Cambridge Biomedical Campus, Cambridge, UK
| | - Isabelle Stücker
- Université Paris Saclay, Univ. Paris-Sud, UVSQ, CESP, INSERM, Villejuif, France
| | | |
Collapse
|